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Abstract 
VAPOR TRANSPORT AND AEROSOL DYNAMICS IN THE RESPIRATORY 
AIRWAYS 
By Geng Tian 
A dissertation submitted in partial fulfillment of the requirements for the degree 
of Doctor of Philosophy at Virginia Commonwealth University. 
Virginia Commonwealth University, 2011 
Director: Dr. P. Worth Longest 
Associate Professor, Department of Mechanical Engineering and  
Department of Pharmaceutics 
 Predicting vapor transport and aerosol dynamics in the respiratory airways 
is important for analyzing both environmental exposure and respiratory drug 
delivery. A large number of analytical models, computational studies, and 
experiments on vapor and aerosol transport in the respiratory tract have been 
conducted previously. However, a number of critical questions remain 
unanswered. In this study, computational fluid dynamics (CFD) is primarily 
employed with frequent comparisons to existing and new experimental data sets 
to address previously unanswered issues related to the transport of vapors and 
aerosol in the respiratory tract. The three objectives of this study are further 
described below. 
 Objective 1: A CFD model was developed to predict the transient 
absorption of inhaled vapors in the respiratory tract. Results indicated that 
 xxi 
transient absorption can significantly influence the transport and uptake of vapors 
in the walls of the conducting airways. 
Objective 2: The concept of enhanced condensational growth (ECG) 
applied to respiratory drug delivery was tested in a representative airway model 
extending from the oral cavity to the end of the tracheobronchial (TB) airways. 
Results indicated that ECG is an effective method to provide near full lung 
retention of the aerosol. The CFD results also indicated that the ECG delivery 
approach under transient inhalation conditions increased aerosol deposition in the 
TB airways by only a small amount, as compared with steady state conditions. 
 Objective 3: The effect of transient waveforms on the transport and 
deposition of pharmaceutical aerosols from inhalers in the upper airways was 
considered. Results indicated that the CFD model predictions matched the in vitro 
experiments to a high degree. The CFD results also indicated that it was critical to 
consider transient inhalation effects when assessing aerosol deposition. The 
stochastic individual path (SIP) modeling approach was then introduced and 
implemented to evaluate the transport and deposition of pharmaceutical aerosols 
from inhalers in medium and small TB airways. Results indicated that steady state 
inhalation could be used to predict deposition efficiencies in the TB airways 
between the 4th branch (B4) and the bronchioles (B15). 
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Chapter 1. Specific Aims 
The overall goal of this project is to investigate under-explored areas of 
vapor transport and aerosol dynamics in the respiratory tract. Computational fluid 
dynamics (CFD) is primarily employed with frequent comparisons to existing and 
new experimental data sets. New experimental data related to this project was 
developed in collaboration with the VCU Department of Pharmaceutics (Dr. 
Michael Hindle) as part of an active NIH R21 grant and FDA contract. 
Applications of this research include developing a better understanding of the 
dosimetry of gaseous pollutants in the respiratory tract and the development of 
new therapeutic techniques for treating lung diseases and systemic conditions. 
Specifically, this work will develop dosimetry models for inhaled gaseous species, 
optimize the use of the enhanced condensational growth approach to improve the 
delivery of therapeutic aerosols to the lungs, and predict local and regional 
deposition of pharmaceutically relevant polydisperse aerosols from pressurized 
metered dose inhalers (MDIs) and dry powder inhalers (DPIs) throughout the 
tracheobronchial (TB) airways. These applications are further described below in 
the form of objectives. 
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Objective 1: Transient Absorption of Inhaled Vapors. 
Current models of vapor absorption in the respiratory airways assume that 
transport into the walls is a steady state process. However, simple non-
dimensional analysis reveals that airway wall resistance makes absorption a 
transient process over the course of an inhalation cycle. As a result, current 
models of vapor absorption may significantly over- or under predict uptake and 
dose by an order of magnitude or more. The objective of this study is to develop a 
CFD model to predict the transient absorption of inhaled vapors in the respiratory 
tract. This objective is divided into the following three tasks. 
Task 1.1. Determine if transient absorption is significant over the course of 
an inhalation cycle in a simple mucus-tissue-blood representation of the airway 
wall. 
Task 1.2. Develop a CFD boundary condition for predicting transient wall 
absorption and uptake in a complex respiratory geometry. 
Task 1.3. Apply the transient CFD boundary condition to evaluate the 
effects of both transient inhalation and transient absorption on regional and local 
uptake in a model upper airway geometry. 
To determine if transient absorption is important, both numerical and 
analytical solutions of absorption will be considered in a multilayer 
approximation of the respiratory wall. The absorption of highly and moderately 
soluble compounds will be considered over the time cycle of one inhalation (~ 2 
seconds). Provided transient effects are important, the analytical solution will be 
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extended to allow for implementation as a CFD boundary condition. This will 
require the addition of an air-phase and a variable air-mucus concentration value. 
The CFD boundary condition will then be applied in a mouth-throat upper airway 
geometry. Comparison will be made between absorption predictions based on the 
standard steady state model and the new transient boundary condition. The effects 
of steady state vs. transient flow will also be evaluated. These results will provide 
a new, more accurate method to predict vapor absorption in the respiratory tract. 
It is expected that the transient model will ultimately improve upon the steady 
state predictions by a factor of 10X or more. 
 
Objective 2: The Concept of Enhanced Condensational Growth. 
 Our group has recently proposed the concept of enhanced condensational 
growth (ECG) for improved respiratory drug delivery. In this approach, a 
nanoaerosol containing at active agent (drug or marker) is initially generated and 
inhaled past the mouth-throat (MT) resulting in low deposition and loss. The 
nanoaerosol is delivered with sufficient water vapor to cause supersaturation and 
aerosol growth to micrometer size in the tracheobronchial (TB) and/or alveolar 
airways, which facilitates pulmonary retention. As a result, negligible MT and 
near 100% lung deposition is possible. Furthermore, regional TB or alveolar 
deposition can be engineered allowing for drug targeting by controlling the rate of 
size increase. Factors affecting the rate of growth include the initial aerosol size, 
drug hygroscopicity, and the gas phase conditions of the humidity and aerosol 
delivery streams (i.e., temperature, relative humidity, and flow rate). 
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The prediction of aerosol growth in the ECG approach requires accurate 
knowledge of the relative humidity (RH) field surrounding the nanoaerosol. To 
extend this concept, the following tasks are proposed. 
Task 2.1. Determine the size increase of aerosols in a single path model 
from the MT region through the TB geometry (~ generation G16). 
Task 2.2. Consider the effects of transient inhalation waveforms on the 
ECG process in the upper TB airways. 
Previous studies have indicated that ECG increases aerosol size from the 
submicrometer range to approximately 2 - 3 µm. However, transient inhalation 
will affect both aerosol inertia and RH conditions. Furthermore, only delivery in 
the upper airways has been explored. Relative humidity and growth conditions 
need to be investigated throughout the TB region. Finally, the ECG approach can 
potentially be tailored for targeted respiratory drug delivery. Conditions for lung 
deposition in the upper, mid, and lower regions of the respiratory tract should be 
explored. 
 
Objective 3: Local and Regional Deposition of Pharmaceutical Aerosols. 
 Previous whole-lung particle deposition models have been used to assess 
branch-averaged deposition. However, inaccurate predictions of absorption 
associated with using idealized aerosols and neglecting interactions at the patient-
device interface remain significant shortcomings of these models. In contrast, 
fully resolved three-dimensional (3-D) models with pharmaceutical delivery 
devices can predict local and regional deposition in the TB airways. Furthermore, 
local and regional deposition can be extended to predict dissolution and 
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absorption into the airways and bloodstream. Therefore, the objective of this 
study is to develop a CFD model of orally inhaled drug products that can account 
for inhaler attributes (spray or jet momentum), physicochemical properties 
(aerodynamic size distribution and dissolution), and physiological parameters 
(breathing pattern and airway geometry) in determining local and regional 
deposition throughout the TB airways. Specifically, this objective is divided into 
the following two tasks. 
Task 3.1. Develop a CFD model to evaluate aerosol deposition in a 
realistic MT and upper TB model and validate the developed model using new in 
vitro results in the geometries considered for specific inhaler devices. 
Task 3.2. Characterize deposition within the right lower lung lobe using 
the stochastic individual path (SIP) model approach. 
For accurate delivery predictions, MDI and DPI inhaler types have been 
considered based on (i) the exceedingly large drug losses in the upper airways, 
and (ii) the effect of reduced drug aerosol fractions and induced turbulence on 
deposition in the lower airways. 
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Chapter 2. Background 
Predicting vapor transport and aerosol dynamics in the respiratory airways is 
important for analyzing both environmental exposure and respiratory drug 
delivery. A large number of analytical models, computational studies, and 
experiments on vapor and aerosol transport in the respiratory tract have been 
conducted previously. However, a number of critical questions remain 
unanswered. For example, the effects of transient vapor absorption into the walls 
of the conducting airways have not previously been considered. The delivery of 
inhaled medicines to the lungs is known to be highly inefficient due to large 
depositional losses in the delivery device and extrathoracic region. In this study, 
computational fluid dynamics (CFD) is primarily employed with frequent 
comparisons to existing and new experimental data sets to address previously 
unanswered issues related to the transport of vapors and aerosol in the respiratory 
tract. Background information further motivating the objectives of this study is 
provided in this chapter. 
2.1 Objective 1: Transient Absorption of Inhaled Vapors. 
Determining the transport and absorption of inhaled vapors in the 
respiratory tract is an important step in predicting the biological responses and 
health effects of exposures (Jarabek 1995). Sources of inhaled vapors may include 
potentially toxic environmental pollutants, noxious compounds released in a 
chemical terrorist attack, combustion byproducts resulting from fires, and medical 
gases.  The dosimetry of these chemical species in the respiratory tract is 
controlled by both gas-phase motion in the airways and mass transport through 
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the respiratory liquid and tissue layers and into the bloodstream.  A number of 
studies have considered the gas-phase transport and surface absorption of inhaled 
chemical species (Frederick et al. 1998; Kimbell and Subramaniam 2001; Shi et al. 
2006; Zhang and Kleinstreuer 2006; Zhang et al. 2006b).  Other studies have 
more directly focused on the mass transport process through the walls of the 
respiratory tract (Aharonson et al. 1974; Anderson et al. 2003; Chang et al. 1983; 
Cohen Hubal et al. 1996a; Morris and Blanchard 1992; Morris and Cavanagh 
1986; Morris and Cavanagh 1987). 
The mass transport of chemical species within the lining of the respiratory 
tract is controlled by solubility, diffusion, and wall structure.  Motion of the liquid 
lining and blood can also create convective transport.  Highly and moderately 
soluble compounds are largely absorbed in the upper respiratory tract (URT), 
which effectively protects the more sensitive alveolar airways.  Some highly 
soluble compounds like formaldehyde are almost completely absorbed in the 
extrathoracic airways during nasal inhalation (Chang et al. 1983; Cohen Hubal et 
al. 1997; Kimbell et al. 2001b).  Even relatively insoluble compounds like ozone 
are largely absorbed in the lower tracheobronchial airways as surface area 
increases, thereby significantly reducing the amount reaching the alveolar region.  
For species absorbed in the URT, the mucus layer serves as a barrier that reduces 
absorption in the tissue and blood components of the wall structure.  Therefore, an 
accurate view of absorption into the mucus is essential to determine doses 
received in the lower layers.  Doses of inhaled vapors that reach the respiratory 
tract tissue may be associated with a local response such as bronchoconstriction 
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and injury in the case of inhaled pollutants.  Compounds that reach the blood may 
result in systemic uptake and related toxicological effects.  Furthermore, an 
accurate prediction of absorption in the URT is important to determine 
penetration depth of inhaled vapors traveling down the respiratory tract and into 
the highly sensitive alveolar region. 
Mass transport through the walls of the URT has been modeled using a 
variety of approaches.  Cohen Hubal et al. (1996a) summarized previous models 
of URT absorption and categorized the existing models as early, lumped 
parameter, and distributed parameter approaches.  Early models were used to gain 
qualitative physical insight regarding the absorption process (LaBelle et al. 1955).  
Lumped parameter models assume well-mixed compartments and consider only 
time-dependent concentration variables (Chang et al. 1983; Morris and Blanchard 
1992; Morris and Cavanagh 1986; Morris and Cavanagh 1987).  Distributed 
parameter models consider both spatial and temporal concentrations (Aharonson 
et al. 1974; Kimbell et al. 1993).  The first distributed parameter model was 
reported by Aharonson et al. (1974) to examine the effects of airflow rate on the 
uptake of soluble vapors in the nose.  In this model, a transient expression for 
total uptake was developed based on a local mass transfer coefficient.  As with 
Aharonson et al. (1974) most of the lumped parameter and distributed parameter 
models reviewed by Cohen Hubal et al. (1996a) considered the effect of 
absorption time on uptake into the mucus and tissue.  However, these models 
assumed that a steady state diffusion flux through the respiratory airway wall was 
reached instantaneously. This assumption neglects the effects of transient 
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diffusion on the absorption and uptake of vapors. To gain a better understanding 
of the time scale for absorption in a multilayer system consisting of air, mucus, 
tissue, and blood, transient flux boundary conditions were implemented in a 
multilayer CFD model of the transport in the upper airways. 
Computational fluid dynamics (CFD) modeling provides a distributed 
parameter approach that has been used to simulate the transport and uptake of 
vapors in the respiratory tract.  This approach uses CFD to simulate airflow 
dynamics and applies an analytically determined boundary condition to model 
absorption in either a mucus or a mucus-tissue representation of the wall.  Some 
studies assume high reactivity of the inhaled vapor and apply a zero concentration 
boundary condition at the wall surface (Shi et al. 2006; Taylor et al. 2007; Zhang 
and Kleinstreuer 2003).  Studies considering solubility and potential reactions in a 
mucus layer include Keyhani et al. (1997), Zhang et al. (2006), and Zhao et al. 
(2004).  Other studies have considered solubility and reactivity in a mucus-tissue 
representation of the URT (Cohen Hubal et al. 1996b; Cohen Hubal et al. 1997; 
Frederick et al. 1998; Kimbell et al. 2001a).  However, as with previous studies, 
all computational models assume that steady state diffusion through the mucus or 
mucus and tissue layers is reached instantaneously.  That is, the concentration 
profiles are immediately linear and a constant flux is assumed through the mucus 
and tissue walls into the blood. 
In previous mass transport models, the assumption of steady state diffusion 
through the mucus and tissue of the URT was based on the observation that these 
layers are thin compared with the airway lumen.  However, this assumption 
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neglects the fact that diffusion is much slower in liquids than in air.  To gain a 
better understanding of the time scale for absorption, the mass transfer Fourier 
number (Fom) should be considered, which is defined as 
 2m
DFo t
H
=        (2.1) 
In this expression, D is the diffusivity of the chemical species in mucus or tissue, 
H is the height of the layer, and t is the absorption time.  Values of Fom less than 
10 typically indicate that transient effects are significant in the diffusion process.  
Considering the mucus layer (Hm ~ 10 μm and Dm ~ 5×10-6 cm2/s) (ICRP 1994) 
for a characteristic inhalation time scale of 1 second, the Fourier number is 5.  For 
a combined mucus and tissue layer (Hmt ~ 60 μm and Dmt ~ 5×10-6 cm2/s) (ICRP 
1994), the Fourier number is approximately 0.14.  As a result, transient effects in 
the diffusion process may significantly influence the uptake of chemical species 
through a mucus or mucus-tissue barrier.  For example, flux into the mucus may 
be faster than predicted with a steady state assumption due to higher initial 
concentration differences.  In contrast, flux into the blood may be slower than 
predicted with steady state conditions based on transient resistance in the higher 
layers.  However, a more detailed analysis is needed to determine the quantitative 
effects of transient diffusion on the absorption and uptake of vapors over a 
characteristic time in a multilayer model of the respiratory walls. 
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2.2 Objective 2: The Concept of Enhanced Condensational Growth. 
Enhanced Condensational Growth (ECG) Concept 
 
Enhanced condensational growth (ECG) applied to respiratory drug delivery 
is a recently proposed concept that seeks to combine the advantages of both 
submicrometer and micrometer aerosols.  In this approach, a submicrometer 
aerosol is delivered to the respiratory airways in conjunction with an airstream 
that is saturated or supersaturated with water vapor and above body temperature.  
The initially submicrometer particles or droplets, in the approximate size range of 
100 – 900 nm, have very low deposition values in the mouth-throat (MT) and 
upper tracheobronchial regions (Cheng 2003; Cohen et al. 1990; Xi and Longest 
2008a; Xi and Longest 2008b).  As a result, aerosol loss in the MT can be largely 
eliminated.  The inhaled water vapor is used to create supersaturation conditions 
within the respiratory airways.  Submicrometer droplets in this supersaturated 
environment will increase in size at a controlled rate due to condensation.  Size 
increases to within the range of 2 – 3 μm can be used to ensure full lung retention 
of the aerosol.  Furthermore, engineering the rate of size increase can be used to 
target deposition within specific regions of the lung.  Factors influencing the 
amount and rate of size increase with the ECG approach include the degree of 
supersaturation, temperature, particle or droplet hygroscopicity, initial size, and 
aerosol number concentration.  However, the effects of these variables on aerosol 
size growth have only been investigated on a very limited basis. 
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Hygroscopic Aerosol Growth in the Lungs 
 
The relative humidity (RH) of the tracheobronchial airways beyond the first 
several bronchi is generally expected to be 99.5% (Ferron 1977).  Furthermore, 
many inhaled environmental and pharmaceutical aerosols are soluble.  As a result, 
hygroscopic effects are known to influence the deposition of these inhaled 
respiratory aerosols (Ferron 1977; Ferron et al. 1988; Finlay and Stapleton 1995; 
Li and Hopke 1993; Martonen et al. 1982; Zhang et al. 2006b).  Hygroscopic 
particle growth has been investigated experimentally for NaCl particles (Cinkotai 
1971), pharmaceutical aerosols (Peng et al. 2000), and combustion droplets (Li 
and Hopke 1993).  A number of mathematical models have also been formulated 
for the hygroscopic growth of respiratory aerosols at RH values below 100% 
(Broday and Georgopoulous 2001; Ferron 1977; Ferron et al. 1988; Ferron et al. 
1989; Finlay and Stapleton 1995; Robinson and Yu 1998; Varghese and 
Gangamma 2009).  These studies typically indicate a maximum size increase of 
approximately 400% for NaCl particles.  The hygroscopic growth of most other 
salts and most pharmaceutical aerosols result in size increases less than 100% at 
RH values of 99.5% and below (Ferron et al. 1988; Ferron et al. 1989).  Recently, 
Zhang et al. (2006a) developed a CFD model of hygroscopic growth in the upper 
respiratory tract.  It was found that saline concentrations of 10% and higher were 
required for hygroscopic growth to have a significant impact on deposition.  
Finlay and Stapleton (1995) applied a numerical model to show that mass 
coupling between aerosol droplets and the continuous phase was significant for 
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droplet concentrations above 25,000 part/cm3.  However, all of these previous 
studies have only considered RH conditions up to 100%. 
 
Supersaturation in the Respiratory Airways 
 
Very little work has been done to evaluate the effects of RH conditions 
above 100% (i.e., supersaturated conditions) on the condensational growth of 
respiratory aerosols.  However, supersaturated conditions can be achieved in the 
respiratory tract through the inhalation of warm (T > Tbody) saturated air.  Ferron 
et al. (1984) has shown that RH above 100% is possible in the upper respiratory 
tract under some inhalation conditions.  Significant growth of NaCl particles was 
observed for very localized supersaturation in the nasal cavity (Ferron et al. 1984).  
Longest and Xi (2008) considered the inhalation of warm humidified air during 
smoking.  Computational fluid dynamics simulations indicated that the inhalation 
of warm saturated air approximately 3 oC above body temperature could result in 
supersaturation conditions (RH > 100%) through approximately the 6th respiratory 
bifurcation.  Moreover, submicrometer aerosols exposed to RH conditions in the 
range of 101% experienced a large and rapid increase in size. 
 
2.3 Objective 3: Local and Regional Deposition of Pharmaceutical  
  Aerosols. 
 Inhalation of aerosol drugs is widely used in the treatment of asthma and 
chronic obstructive pulmonary disease (COPD). Predicting the regional and 
highly localized deposition of pharmaceutically aerosols from oral drug delivery 
devices is a critical component in determining the dose received and the resulting 
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local and systemic responses (Isaacs et al. 2005; Martonen et al. 2005a; Martonen 
et al. 2005b). Whole-lung and regional models as well as experiments in 
respiratory casts have been employed to investigate aerosol dynamics and 
deposition in the lung (Balashazy et al. 2003; Comer et al. 2000; Darquenne 2002; 
Darquenne and Paiva 1996; Hofmann et al. 2003; Karl et al. 2004; Kimbell and 
Subramaniam 2001; Liu et al. 2002; Martonen et al. 2003; Martonen et al. 2001; 
Schroeter et al. 2001; Zhang and Kleinstreuer 2002; Zhang et al. 2005; Zhang et 
al. 2004). Whole-lung deposition models can predict deposition based on the 
branch-averaged correlations (Asgharian et al. 2001; ICRP 1994; Martonen 1993; 
NCRP 1997). Additionally, CFD models have been used to determine branch-
averaged deposition in whole-lung modeling (Balashazy et al. 2003; Hofmann et 
al. 2003; Zhang et al. 2005). These models considered the effects of multiple 
physiological, geometric, and particle characteristics on deposition patterns. A 
number of these studies have quantitatively validated the resulting aerosol 
deposition rates with in vitro data (Liu et al. 2002; Longest and Vinchurkar 
2007b; Martonen et al. 2001; Oldham et al. 2000; Zhang and Kleinstreuer 2002). 
However, these models neglected the importance of the interface between device 
and patient in achieving efficient aerosol drug delivery to the lungs. For this 
reason, a validated CFD model is needed which can account for inhaler 
characteristics (spray or jet momentum), drug physiochemical properties 
(aerodynamic size distribution, dissolution) and physiological parameters 
(breathing pattern, geometry) in determining local and regional deposition in the 
TB airways. Specifically, pressurized metered dose inhalers (MDIs) and dry 
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power inhalers (DPIs) deliver drug while target inflammation control and airway 
dilation (Ibsen and Bratton 1999), are considered in this study. These two 
representative classes of inhalers are the most common devices for administering 
drugs for inhalation. Pharmaceutical aerosols from MDIs are delivered as a spray 
droplet by actuation of the canister contains a pressurized propellant drug 
formulation, in contrast, DPIs are breath actuated and deliver a power aerosol. 
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Chapter 3. Transient Absorption of Inhaled Vapors into a Multilayer 
Mucus-Tissue-Blood System 
3.1 Introduction 
Individual multilayer models are considered that represent the wall 
dimensions of the nasal extrathoracic, upper, and lower tracheobronchial airways.  
A constant concentration of vapor species is assumed at the air-mucus interface 
and zero concentration is assumed in the blood.  The sample vapors considered 
are highly or moderately soluble in mucus and tissue.  To determine absorption, 
mass transport is calculated based on an existing analytical steady state solution, a 
new analytical transient solution,  and a numerical transient solution.  
Comparisons of results from multiple approaches are used to assess solution 
quality.  Differences between steady and transient solutions are used to evaluate 
the importance of transient effects on the diffusion and uptake process.  The 
effects of chemical reactions in the mucus and tissue over time are also explored 
for a range of first-order reaction rate constants using the numerical model.  These 
results can be implemented to (i) expand previous estimates of steady state 
diffusion to more realistic transient conditions and (ii) lay the foundation for an 
analytic boundary condition that accounts for transient diffusion in a CFD model 
of respiratory tract absorption and uptake.  Furthermore, the solution techniques 
developed in this study can be applied to analyze the transport of chemicals in 
other multilayer systems such as absorption through mucus in the gastrointestinal 
tract and dermal uptake. 
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 The objective of this study was to evaluate the mass transport of sample 
chemical species through a simple multilayer system composed of mucus, tissue, 
and blood components on a transient basis and compare with steady state results. 
 
3.2 Methods 
In this study, vapor absorption and transport are considered through the 
walls of the conducting airways, which are responsible for delivering air to the 
alveolar region.  Using the notation of Weibel (1963),  the conducting airways 
originate at the nose or mouth and extend to approximately generation 16.  The 
walls of the conducting airways are lined with a thin layer of protective mucus 
(Yeates et al. 1997).  The mucus layer is typically considered to keep the surfaces 
of the airways moist, condition incoming air, and trap inhaled particles and 
microorganisms.  In addition, mucus also serves as a barrier that controls the 
absorption of gases and drugs into the walls of the conducting airways.  Clearance 
of soluble and insoluble compounds trapped in the mucus is accomplished by 
ciliary motion, which propels the mucus up the respiratory tract to be expelled or 
swallowed (Yeates et al. 1997).  The cilia move in a watery substance that lies 
under the mucus and is referred to as sol, which also helps lubricate the motion of 
the more viscous mucus layer.  Cilia are present throughout the conducting 
airways and are secured to an epithelial layer, which is mostly composed of 
ciliated, basal, and goblet cells.  The epithelial layer is attached to a basement 
membrane, which is then followed by a sub-epithelium layer that is highly 
vascularized (ICRP 1994). 
  18
To approximate transport within the walls of the conducting airways in this 
study, a model system was considered that consists of mucus, tissue, and blood 
layers (Fig. 3.1).  The liquid mucus and sol regions, which contain the cilia, were 
considered to form a single mucus layer.  As described below, convection due to 
ciliary motion and clearance were neglected in this study.  The epithelial region 
was approximated as a generalized tissue layer.  Finally, the highly vascularized 
sub-epithelium region was assumed to form a blood layer.  The resulting 
multilayer model is identical to the mucus-tissue-blood airway approximation 
considered by Cohen Hubal et al. (1996b; 1997) and adds tissue and blood layers 
to the previous approximations considered by Keyhani et al. (1997), Zhang et al. 
(2006), and Zhao et al. (2004). 
In this study, convection due to mucus motion was neglected and transport 
through the multilayer system was assumed to result from pure diffusion.  This 
assumption was based on the relative rates of convective transport due to mucus 
motion compared with diffusive transport through the thin mucus layer.  For 
example, the average rate of mucus motion in the trachea, which has the fastest 
clearance in the tracheobronchial region, is 9.2 × 10-2 mm/s (Foster et al. 1980).  
For approximate tracheal conditions (Hm ~ 1×10-3 cm and Dm ~ 5×10-6 cm2/s), the 
timescale for diffusive transport through the mucus (Hm2/Dm) is 0.2 s.  Based on 
mucus velocity, the mucus moves approximately 0.02 mm over the timescale 
required for diffusive transport across the boundary.  Considering the length of 
the trachea is approximately 9 cm (ICRP 1994), it is concluded that convective 
mucus motion can be neglected compared with diffusive transport across the 
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barrier and into the tissue.  Similar results are found for lower lung generations, 
arising from the fact that mucus velocity decreases with depth into the lungs 
(Foster et al. 1980). 
The purpose of this study is to evaluate the time dependent transport of 
vapors across a multilayer airway wall system.  To facilitate this evaluation, 
constant concentrations of vapor species were assumed at the air-mucus and 
tissue-blood interfaces (Fig. 3.1).  During inhalation in vivo, concentrations of 
vapors in the air, mucus, tissue, and blood are all interconnected.  For example, 
decreasing the solubility of a species in the tissue layer will increase 
concentrations in the air and mucus phases.  However, it is not necessary to 
consider variable air phase concentrations in order to determine the transient 
behavior of transport across the airway wall.  As a result, to assess transient 
effects on diffusional wall uptake in this study, the air phase concentration is 
assumed constant and known a priori.  At the tissue-blood interface, zero 
concentration of the vapor species is assumed.  This approximation is justified for 
vapors absorbed in small quantities compared with blood volumes, compounds 
with high solubility in blood, or materials that are metabolized in downstream 
tissues and organs, such as the liver. 
To approximate wall dimension for the conducting airways, multiple regions 
were considered.  The conducting airways were divided based on the ICRP (1994) 
dosimetry model convention into extrathoracic (ET2), bronchial (BB), and 
bronchiolar (bb) regions.  The ET2 region includes the nasal passages distal to the 
nasal valve, pharynx, and larynx.  The BB region consists of the trachea 
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(generation 0), main bronchi, and distal bronchi ending with approximately 
generation 8.  Finally, the conducting airways conclude with the bb region, which 
extends from generation 9 to approximately generation 16.  Dimensions of each 
region are reported in Table 3.1, based on ICRP (1994) estimates.  Considering 
the relative thicknesses of each layer, diffusive transport in the ET2 and BB 
regions is expected to be similar.  In contrast, the thin layers of the bb region will 
likely result in much faster absorption compared with the other models. 
 
Vapor Species and Properties 
 
Representative environmental pollutants considered in this study are 
acetaldehyde and benzene, which are highly soluble and moderately soluble in 
mucus, respectively.  Substances with relatively low solubilities were neglected 
because they are already considered to be dependent on transient effects during 
the absorption process.  Benzene is a known human carcinogen that may also 
cause nervous system disorders, immune system suppression, and anemia 
(ATSDR 2007b).  Benzene is considered a hazardous air pollutant by the United 
States Environmental Protection Agency (US EPA) (1999) and is also found in 
mainstream and sidestream cigarette smoke (Sakuma et al. 1984).  Acetaldehyde 
is also classified as a hazardous air pollutant (EPA 1999) that is a potential 
carcinogen in humans and may cause respiratory tract irritation and lesion 
formation at sufficient concentrations (ATSDR 2007a). Recently, acetaldehyde in 
cigarette smoke was linked to the formation of MAO-inhibitors, which may play a 
role in reinforcing tobacco smoke dependence and addiction (Talhout et al. 2007). 
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Transport through the airway wall is controlled by absorption into the mucus, 
diffusion across the mucus barrier, partitioning into the tissue, diffusion within the 
tissue, and partitioning into the blood.  Therefore, two diffusional coefficients and 
three partition coefficients are needed to describe uptake in the multilayer system.  
Considering diffusion, the transport of a vapor species in mucus was assumed to 
be equivalent to diffusion in water at the same temperature (Cohen Hubal et al. 
1996a).  The diffusivity of a species in tissue was assumed to be approximately 
one-third of the value in water (George et al. 1996; Hlastala and Robertson 1998).  
The resulting diffusivities in mucus (Dm) and in tissue (Dt) are reported in Table 
3.2 for a body temperature of 37 oC. 
The mucus-air partition coefficient is defined in nondimensional form as 
 mma
a
C
C
λ =         (3.1) 
where the concentration of a species on the mucus side of the mucus-air interface, 
Cm (g/cm3), is in equilibrium with the concentration on the air side Ca (g/cm3).  
Considering that mucus is primarily composed of water (Yeates et al. 1997), the 
mucus-air partition coefficients were assumed to be equal to well known water-air 
coefficients.  Species with λma >> 1 are considered to be highly soluble in mucus, 
and coefficients in the range of 1 are assumed to be moderately soluble.  Specific 
values of mucus-air partition coefficients are reported in Table 3.2 for 
acetaldehyde and benzene. 
For most vapor species, the blood-tissue partition coefficient, λbt, is assumed 
to be equal to one (Anderson et al. 2003).  The tissue-mucus partition coefficient, 
λtm, can be approximated as (Anderson et al. 2003) 
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where λba is the frequently reported blood-air partition coefficient.  Values of both 
λba and λtm are reported in Table 3.2 for the compounds of interest. 
 
Governing Equations and Boundary Conditions 
 
The transient diffusion equations governing absorption into the mucus and 
tissue can be expressed as 
2
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m
C y t C y tD
t y
∂ ∂=∂ ∂ , [0, ]my H∈     (3.3a) 
2
2
( , ) ( , )t t
t
C y t C y tD
t y
∂ ∂=∂ ∂ , [ , ]m m ty H H H∈ +    (3.3b) 
where y is the spatial coordinate defining the depth into the mucus and tissue.  
Heights of the mucus and tissue layers are denoted Hm and Ht, respectively. 
Concentrations Cm(y,t) and Ct(y,t) are the bulk densities of chemical species in 
mucus and tissue with units of g/cm3. These concentrations are spatially and time 
dependent in each material.  In the equations above, the left-hand-side accounts 
for temporal variations in concentration at a fixed location and the right-hand-side 
accounts for net diffusive transport through a control volume. Initially, zero 
concentration is assumed in the mucus and tissue.  The boundary conditions of the 
multilayer system are 
0( , ) |m y ma airC y t Cλ= = ,       (3.4a) 
( , ) | ( , ) |
m mt y H tm m y H
C y t C y tλ= == ,     (3.4b) 
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where Cair is the concentration on the air side of the mucus-air interface (assumed 
to be constant). Equations (3.4a and 3.4b) imply that equilibrium occurs on each 
side of the thin mucus-air and mucus-tissue interfaces. Equation (3.4c) implies 
that the vapor species mass flux (mass flow rate of a compound per unit area with 
units of g/s-cm2) leaving the mucus is equal to the flux entering the tissue.  As 
indicated above, zero concentration of the vapor species was assumed in the blood.  
A summary of the multilayer system considered with the appropriate governing 
equations and boundary conditions is shown in Fig. 3.2. 
Constant air-phase boundary conditions of acetaldehyde and benzene are 
taken to be 100 ppm (1.83×10-7 g/cm3) and 1 ppm (3.19×10-9 g/cm3), respectively, 
which are below OSHA short term exposure limits.  Breathing frequencies for 
sedentary, light, and heavy activity conditions are 14, 21, and 33 breaths per 
minute, respectively (ICRP 1994).  Assuming that inhalation occurs for one-half 
of the breathing cycle, the associated inhalation times are 2.2, 1.4, and 0.9 s.  As a 
result, inhalation can be characterized as occurring for a period of approximately 
1 to 2 s.  Based on these estimates, transient effects that are significantly less than 
1 s can be considered negligible.  However, transient effects on the order of 1 s 
may significantly affect absorption over the inhalation period.  In this study, 
transient absorption is considered for periods of 2 s and beyond to evaluate a 
range of potential breathing conditions and the time required to reach steady state.  
Furthermore, some simulations are conducted in which a 2 s inhalation period is 
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followed by a 2 s exhalation period with zero air phase concentration to evaluate 
the potential for species buildup in the mucus over multiple breath cycles. 
 
Solution Techniques 
 
In this study, the governing equations were solved using three different 
solution approaches with the goals of (i) evaluating the influence of transient 
effects on absorption and (ii) developing the form of an analytic solution that can 
be used as a boundary condition in a CFD model.  First, a common steady state 
analytical solution was performed for comparison with transient solutions over 
time.  An analytical transient solution was then developed by splitting the steady 
and time-dependent components of the governing equations and performing a 
Fourier series solution.  To verify the transient analytical results, a numerical 
solution of the equations was then conducted with the Transient Absorption of 
Chemical Species (TAOCS) 1.0 program.  Each of these solution techniques is 
described in more detail below. 
 
Analytical Steady State Solution 
 
For steady state conditions, the time derivative is not present in Equations 
(3.3a and b), and the resulting coupled ordinary differential equations have the 
solution 
( ) |
( ) mma air m y Hm ma air
m
C C y
C y C y
H
λλ =−= −
%% , [0, ]my H∈   (3.5a) 
( ) | ( ) |
( ) ( )m mtm m y H tm m y Ht m t
t t
C y C y
C y H H y
H H
λ λ= == + −
% %% , [ , ]m m ty H H H∈ +  
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         (3.5b) 
In the expressions above, mC%  and tC%  represent concentrations in the mucus and 
tissue at steady state.  The concentration on the mucus side at the mucus-tissue 
interface is obtained by substituting Equations (3.5a and 3.5b) into the flux 
condition provided by Equation (3.4c), resulting in 
 ( ) |
m
t m ma air
m y H
m tm t t m
H D CC y
H D H D
λ
λ= = +
%      (3.5c) 
 
Analytical Transient Solution 
 
An analytical solution to the coupled transient set of partial differential 
equations is presented in Appendix A.  Briefly, the transient ( ˆmC ) and steady state 
( mC% ) components of the solution can be separated.  A substitution approach can 
then be used to evaluate the transient components of the equations.  The resulting 
combined Fourier series and linear solution is expressed 
2
2
1
ˆ( , ) ( , ) ( )
( ) |
sin( )sin( ) ,
m
n
mm
m m m
D t
ma air m y HHm t n
n n ma air
n t m m m
C y t C y t C y
C C yD H yW e C y
D H H H
μ λμμ λ∞ − =
=
= +
−= + −∑
%
%
          (3.6a) 
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In these equations, the eigenvalues μn were determined by solving a 
transcendental equation using Brent’s method (Brent 1973), as described in 
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Appendix A.  The Fourier series coefficients were determined by utilizing the 
orthogonal relation and zero concentration initial conditions.  Compared with the 
steady solution (Eqs. 3.5a and 3.5b), the transient solution is observed to include a 
series expression, that decreases exponentially as a function of the transient mass 
Fourier number presented as Eq. (2.1).  
 
Numerical Transient Solution 
 
Equations (3.3a and 3.3b) and (3.4a-d) were also solved as a coupled set 
using the TAOCS 1.0 program.  Zero initial concentration was assumed in the 
mucus and tissue layers as with the analytical solution.  A finite volume method 
was used for the spatial discretization of the well-posed set of equations.  Time 
integration was performed with a stiff implicit multi-step solver.  The relative 
tolerance for numerically evaluating the equations was set to 1×10-12.  Decreasing 
the relative tolerance by an order of magnitude had a minimal impact (less than 
1% difference) on concentration and uptake values throughout the system. 
 
3.3 Results 
Concentration Values 
 
Concentration values for acetaldehyde and benzene within the model 
systems considered are shown in Fig. 3.3 based on the analytical transient and 
steady state solutions.  In each case, the transient results are shown to approach 
the steady state solution over time.  In the ET2 region (Fig. 3.3a), significant 
differences between the transient and steady state solutions are observed at both 1 
and 2 s.  Again, a typical inhalation period is expected to last for approximately 2 
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s or less.  These differences in concentration values over time will result in a 
variable flux and rate of absorption into the multilayer system.  Temporal 
differences from steady state conditions appear more significant for benzene, 
which is less soluble in mucus but more soluble in tissue compared with 
acetaldehyde.  for both compounds, the transient solution is shown to agree with 
the steady state conditions after 10 s. 
Considering the BB region (Fig. 3.3b), concentrations over time are nearly 
identical to those found in the ET2 region.  This similarity is expected because 
there is little difference in layer heights between the ET2 and BB models (Table 
3.1).  As a result, transient effects are also shown to be highly significant in the 
BB region over a timescale of approximately 2 seconds. 
In the bb region (Fig. 3.3c), concentrations evolve approximately one order 
of magnitude faster in time compared with the upper airway models.  Significant 
differences in mucus and tissue concentrations are observed to remain at 0.2 s.  
However, the analytical steady state and transient solutions are nearly identical at 
1 s. 
A comparison of analytical and numerical transient solutions of 
concentration over time is provided in Fig. 3.4 for acetaldehyde and benzene.  
Concentrations are only reported in the BB region to illustrate the close match 
between the analytical and numerical results.  In each case, a point by point 
comparison of concentration values indicates that the analytical and transient 
solutions were on average within 0.1%.  Similar results were found for the ET2 
and bb regions.  Agreement between the approaches considered provides 
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confidence that the analytical solution includes a sufficient number of terms in the 
series summation (cf. Eqs. 3.6a and 3.6b) and is correct.  The close match also 
indicates that numerical errors are small and controlled in the simulations. 
Concentration values of acetaldehyde and benzene at the mucus-tissue 
interface are displayed in Fig. 3.5 over time.  These results indicate the timeframe 
for establishing steady state transport through the mucus.  The relative values of 
concentrations on the mucus and tissue sides of the interface also illustrate the 
effects of the mucus-tissue partition coefficients.  For example, benzene is more 
soluble in tissue than in mucus (λtm > 1).  Therefore, concentrations of benzene 
are higher in the tissue compared with the mucus.  In each case, the concentration 
curves become flat over time as steady state conditions are approached.  
Considering the BB region (Fig. 3.5a), temporal effects for acetaldehyde and 
benzene appear relatively small after approximately 2 and 4 s, respectively.  
Results are similar for the ET2 region (not shown).  In the bb region, where the 
individual layers are significantly thinner, temporal effects for acetaldehyde and 
benzene are diminished after approximately 0.2 and 0.4 s, respectively (Fig. 3.5b). 
 
Flux and Uptake 
 
Flux values (g/s-cm2) into the tissue and blood phases are reported in Fig. 
3.6 for acetaldehyde and benzene in the BB and bb regions.  Under steady state 
conditions, the fluxes into the tissue and blood are equal and are constant over 
time.  However, results in Fig. 3.6 indicate that the transient flux values are highly 
variable over time.  Flux into the tissue spikes just after t = 0 due to zero initial 
concentrations and the thin mucus layer.  In contrast, flux into the blood 
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experiences a gradual increase as concentrations cross the thick tissue region and 
reach the lower boundary.  In the BB region, fluxes of acetaldehyde and benzene 
reach constant steady state conditions in approximately 6 and 8 s, respectively 
(Fig. 3.6a).  In contrast, fluxes of acetaldehyde and benzene in the bb region reach 
steady state conditions approximately one order of magnitude faster (Fig. 3.6b).  
However, transient effects appear potentially significant compared to an 
inhalation period of 1 s for all cases considered. 
Uptake of chemical species in each layer is calculated as the time integral of 
the difference between the inlet and outlet fluxes, i.e.,  
 ( ), ,0= −∫ ti i in i outUptake Flux Flux dt      (3.7) 
In the expression above, uptake is calculated for layer i in units of g/cm2 based on 
the flux values presented in Fig. 3.6.  No outlet flux is assumed for the blood, so 
the blood uptake is simply the time integral of the inlet flux.  Under steady state 
conditions, fluxes into and out of the mucus and tissue are equal at all times.  
Therefore, steady state uptake in these layers is zero.  The resulting uptake values 
in the BB and bb regions for acetaldehyde and benzene are presented in Fig. 3.7.  
For steady state conditions, the constant flux values in the blood result in a liner 
estimate of uptake.  In contrast, transient flux values produce non-linear uptake 
profiles, as shown in Fig. 3.7.  Uptake differences between transient and steady 
state conditions are highly significant in the BB region (Fig. 3.7a).  Again, steady 
state predictions of tissue uptake are zero compared with the nonzero transient 
tissue uptake values.  At 1 s, the transient blood uptake of acetaldehyde and 
benzene is lower than steady state conditions by a factor of approximately 30 in 
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the BB model.  In contrast, differences between transient and steady state blood 
uptake values are significantly less in the bb region (Fig. 3.7b).  Specifically, 
transient and steady state predictions of blood uptake differ by factors ranging 
from 1.2 to 1.3 at 1 s. 
Comparisons of steady state and transient uptake in the BB and bb regions 
over time are presented in Fig. 3.8 as percent differences.  The percent difference 
values are calculated as the absolute difference between steady and transient 
results divided by the transient value.  As shown in Fig. 3.8, percent differences in 
tissue uptake are 100% for all times considered because the steady state tissue 
uptake value is zero.  In the BB region, percent differences for blood uptake of 
acetaldehyde and benzene range from approximately 1×105  % to 100% through 4 
s (Fig. 3.8a).  At 1 s, the percent differences in BB blood uptake for acetaldehyde 
and benzene are 2,900% and 2,500%, respectively.  In the bb region, differences 
in steady vs. transient blood uptake range from approximately 100% to below 
10% (Fig. 3.8b).  After 1 s, the bb percent differences for acetaldehyde and 
benzene are 23% and 27%, respectively.  These percent differences between 
steady and transient uptake values are also presented in Tables 3.3 and 3.4. 
 
Multiple Breath Cycles 
 
The previous results considered zero initial vapor concentrations in the 
mucus and tissue and a single inhalation period.  However, vapor concentrations 
may build up over time in the mucus and tissue regions during multiple inhalation 
and exhalation cycles.  Transient effects may be dimensioned if the concentrations 
of vapor in the mucus and tissue are near steady state conditions at the start of an 
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inhalation cycle.  To test for the buildup of vapor species, a case was considered 
in which the system was exposed to a constant concentration for 2 s (inhalation 
period).  The concentration was then removed for 2 s (exhalation period).  This 
model assumes that the vapor species is completely absorbed into the blood and 
removed in the deeper alveolar region, which is reasonable for highly and 
moderately soluble components.  As a result, zero concentrations are applied 
during the exhalation phase. 
Concentrations at the mucus-tissue interface over 2 breathing cycles in the 
BB region are illustrated in Fig. 3.9.  Minimum differences are observed in the 
quantitative concentration values between cycles 1 and 2 at the end of inhalation 
and exhalation (< 10% difference).  Subsequent breathing cycles resulted in 
negligible differences of concentration values (< 1%).  Based on these 
observations, it is concluded that the effects of transient absorption are not 
diminished by multiple breaths, provided that full downstream blood absorption 
can be assumed. 
 
Effects of Chemical Reactions 
 
Chemical reactions of some absorbed species are known to occur in the 
mucus and tissue layers of the upper respiratory tract (Cohen Hubal et al. 1996a).  
For reactive species, these conversions may significantly alter the transient uptake 
characteristics.  However, reactivity levels that may influence transient absorption 
have not been previously considered.  To better evaluate the effects of chemical 
reactions on mucus and tissue uptake, acetaldehyde and benzene were considered 
over a range of first order reaction rate constants extending from 0.01 – 1×104 
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min-1 (1.67×10-4 – 167 s-1).  First order reaction rate constants are presented in 
Table 3.5 for a range of compounds considered to be non-reactive through highly 
reactive in mucus and tissue.  As shown in the table, benzene was reported as 
non-reactive and a representative first-order reaction rate constant of 0.01 min-1 
was assumed.  Acetaldehyde may be reactive with a first order reaction rate 
constant in tissue of approximately 0.1 min-1, which is approximately equal to that 
of S02.  In comparison, formaldehyde and ozone are typically considered to be 
highly reactive with first order reaction rate coefficients ranging from 1 – 300,000 
min-1. 
Evaluation of chemical reactions requires that the governing diffusional 
equation in mucus, Equation (4a), be written as 
( )2 2( , ) ( , ) ,∂ ∂= −∂ ∂m mm m m
C y t C y tD K C y t
t y
, [0, ]my H∈   (3.8) 
where Km is the first-order reaction rate coefficient in mucus.  The governing 
equation for diffusion in tissue contains a similar reaction term for Kt. The 
boundary conditions expressed as Equations (3.4a-d) remain unchanged for the 
reactive case.  Solutions to the coupled reaction equations were obtained using the 
TAOCS 1.0 program in a manner identical to the non-reactive equations.  The 
resulting transient uptake values in tissue and blood are shown in Figures. 3.10 
and 3.11, respectively, for acetaldehyde and benzene across a range of K values.  
In the numerical simulations, K values were assumed equal in mucus and tissue to 
maximize the effects of reactivity. 
Considering transport in the tissue (Fig. 3.10), reactivity appears to only 
begin influencing uptake for K values greater than 100 min-1 in both the BB and 
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bb regions.  This reaction rate coefficient is three orders of magnitude greater than 
the reported value of 0.1 min-1 for acetaldehyde and four orders of magnitude 
greater than the value assumed for benzene.  Therefore, it can be concluded that 
reactions do not influence the transient uptake of acetaldehyde and benzene at the 
concentrations considered in this study.  Moreover, a K value of 100 min-1 is two 
orders of magnitude greater than the reaction rate coefficient reported for 
formaldehyde (Table 3.5).  In contrast, K values of approximately 10,000 min-1 
eliminate nearly all of the acetaldehyde in the BB tissue region and reduce 
concentrations in the bb model by an order of magnitude, resulting in greatly 
reduced uptake values (Fig. 3.10).  While not shown in Fig. 3.10, it is clear that 
the K value of ozone (K ≈ 300,000 min-1) will result in nearly 100% removal in 
both the BB and bb regions.  Results are similar for uptake in the blood (Fig. 
3.11), with K values of 100 min-1 and below having a minimal impact on transient 
uptake.  As a result, it can be concluded that chemical reactions have a negligible 
impact on the transient uptake of both benzene and acetaldehyde.  Moreover, of 
the species shown in Table 3.5 only ozone has a sufficiently large K value to 
influence the transient uptake values. 
 
3.4 Discussion 
This study considered the transient absorption and uptake of representative 
vapor species in a model multilayer system representing the walls of the 
conducting airways.  Three models of the wall were evaluated based on 
dimensions for the ET2, BB, and bb regions (ICRP 1994).  No previous study of 
which the authors are aware has considered the effects of time-dependence on the 
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transport and absorption of vapors into the walls of the respiratory tract.  Results 
indicated that concentrations within the mucus and tissue layers were highly time 
dependent in the ET2 and BB regions and moderately time dependent in the bb 
model over the timescale of an inhalation cycle, which is approximately 1 – 2 s.  
Fluxes of vapors into the tissue and blood varied with time for approximately 6 – 
8 seconds in the BB region and 0.6 – 0.8 s in the bb model.  The associated 
transient blood uptake of acetaldehyde and benzene in the upper ET2 and BB 
regions varied from steady state values by a factor of approximately 30 after 1 s.  
Under similar conditions, transient blood uptake in the bb model varied from 
steady state conditions by a factor of approximately 1.3 after 1 s.  For all cases 
considered, transient uptake in the tissue was greater and transient uptake in the 
blood was less than predicted under steady state conditions.  As a result, it was 
concluded that the absorption and uptake of moderately and highly soluble vapors 
in the conducting airways are time-dependent over a period consistent with one 
inhalation cycle.  This time dependence is highly significant for the ET2 and BB 
regions, which extend through respiratory generation 8, and less significant for 
the remainder of the conducting airways. 
A primary implication of this study is that transient absorption effects 
should be considered when evaluating the uptake of moderately and highly 
soluble compounds in the upper respiratory tract.  Based on this analysis, both 
mucus and lung tissue serve as effective “temporal” barriers that prevent the entry 
of inhaled vapors into the blood stream.  Studies that ignore this temporal effect 
over predict blood uptake by a factor of approximately 30 in the ET2 and BB 
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regions.  As described, differences are significantly less in the bb region, due to 
the thinner mucus and tissue layers.  These results can be used to improve 
absorption and uptake predictions made in previous studies.  Furthermore, future 
studies of vapor absorption and uptake should consider transient absorption 
effects or at least correct estimates made for steady state flux conditions based on 
the results of this study. 
Both analytical and numerical transient solutions were considered in this 
study.  This approach provided the advantage of ensuring correctness of the 
analytical solution and accuracy of the numerical simulation.  In addition, an 
analytical solution of wall conditions is needed to formulate a transient absorption 
boundary condition for CFD simulations of gas phase transport and uptake.  To 
derive the appropriate CFD boundary condition, the existing analytical solution 
needs to be extended to account for air phase resistance and a variable air phase 
vapor concentration.  The resulting air-mucus-tissue-blood analytical expression 
can then be used to develop a transient flux boundary condition at the air-mucus 
interface. 
Chemical reactions are typically considered to influence the mucus and 
tissue absorption of some vapor species (Cohen Hubal et al. 1996a; ICRP 1994).  
Mucus contains enzymes to break down foreign substances (Yeates et al. 1997).  
Tissue reactions are also frequent for inhaled vapors (Cohen Hubal et al. 1997; 
Miller et al. 1985).  Benzene is generally considered to have a low reactivity once 
absorbed.  In contrast, acetaldehyde is typically expected to have some reactivity 
in the tissue under steady state conditions (Morris and Blanchard 1992).  
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Interestingly, results of this study showed that chemical reactions had a negligible 
effect on the transient absorption of both acetaldehyde and benzene.  A reaction 
rate constant of approximately 100 min-1 was required for chemical reactions to 
influence transient absorption at 2 s, which is three orders of magnitude greater 
than the reported K value of acetaldehyde.  Furthermore, the K value of 
formaldehyde did not result in significant reactions through 2 s.  Based on steady 
state analysis, chemical reactions in the upper airways for SO2, acetaldehyde, 
formaldehyde, and ozone are generally thought to be significant (Cohen Hubal et 
al. 1997; Franks 2005; ICRP 1994; Morris and Blanchard 1992).  In comparison, 
the results of this study imply that transient effects may diminish the influence of 
chemical reactions.  When transient absorption is considered, initial flux values 
into the mucus and tissue are higher and concentrations are lower compared with 
steady state.  Both of these factors serve to reduce the relative contribution of 
chemical reactivity.  As time proceeds, transient effects decrease and reactivity 
contributions increase to a steady state level.  Increases in reactivity effects over 
time are observed in Fig 10a as the curve for K = 100 min-1 increasingly separates 
from the other cases.  This separation eventually reaches a steady state, as shown 
in Fig. 3.10b for the bb region.  As a result, it appears critical to consider transient 
absorption effects when evaluating the influence of reaction on vapor uptake.  
Moreover, including transient absorption may practically eliminate the effect of 
chemical reactions for many compounds over the timescale of one inhalation 
cycle.  These estimates of reactivity may be a function of air phase concentration 
values.  However, significant increases in air phase concentration will be required 
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to overcome the observed three order of magnitude deficit in the K value required 
for reactivity to become important.  Future studies are needed to further explore 
the effects of reaction coefficients and air phase concentrations on transient 
absorption. 
Limitations of the current study include the assumptions of a constant air 
phase concentration, isothermal conditions, thermodynamic equilibrium at the 
interfaces, and a lack of data for some material properties.  A constant air phase 
concentration was assumed to simplify the evaluation of transient absorption in 
the mucus, tissue, and blood layers.  In the body, air phase concentrations vary 
with both space and time.  However, spatial and temporal variations of air phase 
concentrations are expected to enhance temporal variations in the wall layers.  
Future analyses are required to extend the analytical solution of this study to 
variable air phase concentrations.  Nevertheless, modifying the constant air phase 
concentration does not alter the reported uptake differences between the transient 
and steady state solutions shown in Fig. 3.8.  Similarly, the assumption of zero 
concentration during exhalation is only a first order approximation for species that 
are fully absorbed in the deeper lung.  Considering isothermal conditions, 
inhalation and exhalation may result in significant changes in the mucus and 
tissue temperatures, as a function of environmental conditions.  These temperature 
variations will influence the species vapor pressures on the mucus surface, the 
partition coefficients, and the diffusion coefficients.  Thermodynamic equilibrium 
was assumed at each interface to allow for the implementation of standard 
partition coefficients.  This assumption requires that the interfaces are infinitely 
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thin and that the mass transfer coefficients are not too high, which is typically the 
case in biological systems (Bird et al. 1960).  Transient effects are then controlled 
by diffusion in the much thicker mucus, tissue, and blood layers.  Finally, the 
transport properties in mucus, tissue, and blood are not fully known.  For example, 
the diffusion coefficients of the chemical species in tissue were set to be one-third 
their values in water, as reported by George et al (George et al. 1996).  Additional 
simulations (not shown) indicated that setting the diffusion coefficients in tissue 
equal to the corresponding water values decreased the time to steady state 
conditions by a factor of approximately two. 
In conclusion, this study has demonstrated that transient absorption can 
significantly influence the transport and uptake of vapors in the walls of the 
conducting airways.  The importance of transient effects was observed for 
multiple regional models, moderately and highly soluble compounds, and over 
multiple breathing cycles.  The quantitative results presented in this study can be 
used to improve previous estimates of vapor absorption and uptake in the mucus, 
tissue, and blood layers.  Furthermore, the analytical solution developed in this 
study provides the basis for a boundary condition in future CFD simulations of 
coupled air-phase transport and wall absorption.  Future studies are needed to 
evaluation the effects of air-phase resistance, variable air-phase concentrations, 
chemical reactions at multiple concentrations, and non-zero blood concentration 
levels. 
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Table 3.1. Thickness of mucus and tissue in each region. 
Region Mucus (μm) Tissue (μm) 
Nasal-extrathoracic region (ET2) 15 50 
Bronchial region (BB) G0 – G8 11 55 
Bronchiolar region (bb) G9 – G16 6 15 
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Table 3.2. Values of transport parameters. 
Model parameter Acetaldehyde Benzene 
Air   
Da (cm2/s) 8×10-2 a 8.8×10-2 a 
Mucus     
Dm (cm2/s) 8×10-6 a 9.8×10-6 a 
λma 3.2×102 b 4.4 b 
Tissue   
Dt (cm2/s) 2.64×10-6 c 3.23×10-6 c 
λtm 5.9×10-1 d 4.1 d 
Blood   
Db (cm2/s) 2.31×10-6  e 2.84×10-6  e 
λbt 1 d 1 d 
λba 1.9×102  f 1.8×101  g 
a  US Department of Environmental Quality (1994) 
b NIST Chemistry WebBook (2008) 
c Calculated as one-third value of mucus  
 (George et al. 1996; Hlastala and Robertson 1998) 
d Anderson et al. (2003) 
e Estimated using the Stokes–Einstein–Sutherland equation 
f  Karch and Peat (2007) 
g McClellan and Henderson (1995) 
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Table 3.3. Blood uptake difference (%) between steady state and transient 
conditions for acetaldehyde. 
Time ET2 BB bb 
t=0.5 s 6.1×104 1.1×105 5.8×101 
t=0.75 s 6.6×103 1.0×104 3.3×101 
t=1 s 2.1×103 2.9×103 2.3×101 
t=2 s 3.1×102 3.9×102 1.0×101 
t=3 s 1.4×102 1.7×102 6.0×100 
t=4 s 8.4×101 1.0×102 4.9×100 
 
 
Table 3.4. Blood uptake difference (%) between steady state and transient 
conditions for benzene. 
Time ET2 BB bb 
t=0.5 s 3.3×104 5.8×104 7.0×101 
t=0.75 s 5.1×103 7.5×103 3.9×101 
t=1 s 1.9×103 2.5×103 2.7×101 
t=2 s 3.4×102 4.0×102 1.2×101 
t=3 s 1.6×102 1.8×102 7.6×100 
t=4 s 9.8×101 1.1×102 5.6×100 
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Table 3.5. Reactivity constants of common chemicals in mucus and tissue. 
a Assumed to be a non-reactive baseline value. 
b Reactivity was set equal in the mucus and tissue to estimate a maximum possible 
effect. 
c Hlastala and Robertson (1998) 
d Goswami and Banerji (1970) 
e Franks (2005) 
f Miller et al. (1985) 
Compound K in mucus (min-1) K in tissue (min-1) 
Reported values Non-reactivec Non-reactivec Benzene 
This study 0.01a 0.01 
SO2 
Reported values 0.1020c 0.1020c 
Reported values Non-reactive d 0.0921d Acetaldehyde 
This study 0.1b 0.1  
Formaldehyde 
Reported values Non-reactive e 1.08 e 
Ozone 
Reported values 71,880 f 300,000 f 
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Figure 3.1. Multilayer system representing the absorption and transport of 
respiratory vapors into the walls of the conducting  airways. 
Adapted from ICRP. 
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Figure 3.2. Approximate wall model consisting of mucus, tissue, and blood 
regions with governing equations and boundary conditions. 
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Figure 3.3. Concentrations of acetaldehyde and benzene over time compared 
with steady state results in the (a) ET2, (b) BB, and (c) bb regions. 
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Figure 3.4. Comparison of analytical and numerical transient solutions for 
acetaldehyde and benzene concentrations in the BB region. 
  47
 
Time (s)A
ce
ta
ld
eh
yd
e
co
nc
en
tra
tio
n
at
th
e
m
uc
us
-ti
ss
ue
in
te
rfa
ce
(g
/c
m
3 )
0 0.2 0.4 0.6 0.8 1
0
1E-05
2E-05
3E-05
4E-05
5E-05
6E-05
7E-05
Mucus side
Tissue side
Time (s)
B
en
ze
ne
co
nc
en
tra
tio
n
at
th
e
m
uc
us
-ti
ss
ue
in
te
rfa
ce
(g
/c
m
3 )
0 0.2 0.4 0.6 0.8 1
0
1E-08
2E-08
3E-08
4E-08
5E-08
Mucus side
Tissue side
Time (s)
Be
nz
en
e
co
nc
en
tra
tio
n
at
th
e
m
uc
us
-ti
ss
ue
in
te
rfa
ce
(g
/c
m
3 )
0 1 2 3 4
0
1E-08
2E-08
3E-08
4E-08
5E-08
Mucus side
Tissue side
Time (s)A
ce
ta
ld
eh
yd
e
co
nc
en
tra
tio
n
at
th
e
m
uc
us
-ti
ss
ue
in
te
rfa
ce
(g
/c
m
3 )
0 1 2 3 4
0
1E-05
2E-05
3E-05
4E-05
5E-05
6E-05
7E-05
Mucus side
Tissue side
(a) BB region
(b) bb region
 
 
Figure 3.5. Acetaldehyde and benzene concentrations at the mucus-tissue 
interface in the (a) BB and (b) bb regions. 
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Figure 3.6. Flux of acetaldehyde and benzene into the tissue and blood for the 
(a) BB and (b) bb regions. 
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Figure 3.7. Uptake of acetaldehyde and benzene for transient and steady state 
conditions in the (a) BB and (b) bb regions. 
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Figure 3.8. Percent differences between steady state vs. transient predictions 
of uptake for acetaldehyde and benzene in the (a) BB and (b) bb 
regions. 
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Figure 3.9. Concentrations of acetaldehyde and benzene at the mucus-tissue 
interface during inhalation (0 – 2 s) and exhalation (2 – 4 s) 
periods over two breathing cycles. 
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Figure 3.10. Tissue uptake of acetaldehyde and benzene for transient conditions 
including reactivity in the (a) BB and (b) bb regions. 
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Figure 3.11. Blood uptake of acetaldehyde and benzene for transient conditions 
including reactivity in the (a) BB and (b) bb regions. 
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Chapter 4. Development of a CFD Boundary Condition to Model 
Transient Vapor Absorption in the Respiratory Airways 
4.1 Introduction 
We employ both numerical methods and analytical methods to investigate 
transport and absorption of acetaldehyde and benzene over time in an air-mucus-
tissue-blood (AMTB) system. Air phase resistance is considered, and the model 
allows air phase concentration to change with time. Both analytical and numerical 
solutions are considered and compared in a simple multilayer AMTB system. The 
transient analytical solutions of the partial differential equations describing 
diffusion result a complicated task involving calculation of Fourier series, 
eigenvalues, and orthogonal eigenfunctions. We also develop a boundary 
condition at the air-mucus interface that includes the effects of solubility, 
diffusivity, medium thickness, and duration of exposure. This boundary condition 
was then used to calculate transient absorption in a realistic nasal-laryngeal model. 
To our knowledge, no other study has reported the solution of this multiphase 
system on a transient basis. 
 
4.2 Methods 
Models of the Conducting Airway Walls and Nasal-Laryngeal Airway 
 
To approximate transport within the walls of the conducing airway in this 
study, a multilayer system was considered. As Fig. 4.1a shows, the model is 
divided into four compartments: i) the air layer, ii) the mucus layer, iii) the tissue 
layer, and iv) the blood layer. Ha, Hm, and Ht are the thicknesses of the air, mucus, 
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and tissue in specific regions of the respiratory tract, respectively. In this study, 
the extrathoracic nasal  region was considered, which includes the posterior nasal 
passages, larynx, pharynx, and mouth. Evaluation of this region is critical 
considering that it serves as a primary conduit for all vapors entering the lungs. In 
this region, Hm and Ht are commonly reported to be approximately 1.5×10-3 cm 
and 5×10-3 cm, respectively (ICRP 1994). As shown in Fig. 4.1b, the nasal-
laryngeal airway model consists of four parts: the nasal cavity, including the 
vestibule, valve region (VR), turbinate region (TR), and olfactory region (OR); 
nasopharynx, pharynx, and larynx. Xi and Longest (2009) constructed the airway 
model, and generated a computational mesh composed of approximately two 
million unstructured tetrahedral elements and a very fine near-wall pentahedral 
grid, which was employed in this study.  
 
Governing Equations in the Mucus and Tissue with Boundary Conditions 
 
We assume that there are no chemical reactions or convection (caused by an 
imposed mucus flow) occurring in the mucus and tissue layers. The rate at which 
mass concentration is absorbed into the mucus and tissue is determined by solving 
a system of transient diffusion equations: 
2
2
( , ) ( , )m m
m
C y t C y tD
t y
∂ ∂=∂ ∂ , [0, ]my H∈     (4.1a) 
2
2
( , ) ( , )t t
t
C y t C y tD
t y
∂ ∂=∂ ∂ ,  [ , ]m m ty H H H∈ +    (4.1b) 
where y є [0, Hm+Ht] is the spatial coordinate defining the depth into the mucus 
and tissue (Fig. 4.2). The variable t is the time dimension, where the period t > 0. 
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Cm(y,t) and Ct(y,t) are the concentrations (bulk densities) of a chemical species in 
the mucus and tissue with units of g/cm3. These concentrations are spatially and 
time dependent in each material. Dm and Dt are the species diffusivities in mucus 
and tissue, respectively. The diffusivity of each species in each material is 
constant. Initially, zero concentration is assumed in the mucus and tissue.  The 
boundary conditions are: 
0 0( , ) | ( , ) |m y ma a yC y t C y tλ= == ,     (4.2a) 
( , ) | ( , ) |
m mt y H tm m y H
C y t C y tλ= == ,     (4.2b) 
( , ) ( , )| |
m m
m t
m y H t y H
C y t C y tD D
y y= =
∂ ∂− = −∂ ∂ ,    (4.2c) 
( , ) | 0
m tt y H H
C y t = + = ,      (4.2d) 
where 0( , ) |a yC y t =  is not known and depends on the air layer concentration at the 
air-mucus interface. Equations (4.2a and 4.2b) imply that equilibrium occurs on 
each side of the air-mucus and mucus-tissue interfaces, where λma and λtm are the 
mucus-air and tissue-mucus partition coefficients, respectively. Equation (4.2c) 
implies that the vapor species mass flux (mass flow rate of a compound per unit 
area with units of g/s-cm2) leaving the mucus is equal to the flux entering the 
tissue. The system is shown in Fig. 4.2. 
 
Analytical Transient Solution 
 
An analytical solution to the coupled transient set of partial differential 
equations is presented in Appendix A.  Briefly, the transient ( ˆmC ) and steady state 
( mC% ) components of the solution can be separated.  A substitution approach can 
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then be used to evaluate the transient components of the equations.  The resulting 
combined Fourier series and linear solution is expressed  
2
2 ( )
1 0
ˆ( , ) ( , ) ( ) ( )
1 ( ) |( )sin( )sin( ) ( ) 1 ,
m
n
mm
m m m
Dt t
m y HHm t n
n n
n t m m m
C y t C y t f t C y
C yD H y dfW e d f t y
D H H d H
μ τ
τ
μ τμ ττ
∞ − − =
= =
= +
⎛ ⎞−= + −⎜ ⎟⎜ ⎟⎝ ⎠∑ ∫
%
%
 (4.3a) 
and  
2
2 ( )
1 0
ˆ( , ) ( , ) ( ) ( )
( )sin( )sin( )
( ) |
( ) ( )
m
n
m
m
t t t
Dt t
Hm m t
tm n n n
n t m
tm m y H
m t
t
C y t C y t f t C y
D H H y dfW e d
D H d
C y
f t H H y
H
μ τ
τ
τλ μ μ ττ
λ
∞ − −
= =
=
= +
+ −= +
⎛ ⎞+ −⎜ ⎟⎜ ⎟⎝ ⎠
∑ ∫
%
%
 (4.3b) 
where 0( ) ( , ) |m yf t C y t == , and ( ) | m t mm y H
m tm t t m
H DC y
H D H Dλ= = +% . 
In these equations, the eigenvalues μn were determined by solving a 
transcendental equation using Brent’s method (Brent 1973), as described in 
Appendix A.  The Fourier series coefficients Wn were determined by utilizing the 
orthogonal relation and zero concentration initial conditions. 
 
Flux Boundary Conditions at the Air-Mucus Interface 
 
As Fig. 4.3 shows, there are two boundary conditions at the air-mucus 
interface; one is Equation (4.2a), and the other boundary condition is: 
 0 0
( , ) ( , )| |a ma y m y
C y t C y tD D
y y= =
∂ ∂− = −∂ ∂ ,    (4.4) 
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where Ca(y,t) is the concentration (bulk density) of a chemical species in air with 
units of g/cm3. The concentration is spatially and time dependent in each material. 
Da is the constant species diffusivity in air.  
The analytical solution in the mucus (Eq. 4.3a)  and the two boundary 
conditions (Eqs. 4.2a and 4.4) at the air-mucus interface can combined into a 
desired transient flux boundary condition at the air-mucus interface. 
Differentiating ( , )mC y t  with respect to y , then substituting 0
( , ) |m y
C y t
y =
∂
∂   into 
Equation (4.4), the transient flux boundary condition at the air-mucus interface 
becomes 
2
2
0
( )
0
1 0
0
( , ) |
( , ) |1 sin( )
,
1 ( ) |
( , ) |
m
n
m
m
a
y
Dt t
a yHm t
n n n
nm t mm ma
a m y H
a y
m
C y t
y
dC yD HW e d
H D H dD
D C y
C y t
H
μ τ
τ
τμ μ ττλ
=
∞ − − =
= =
=
=
∂ =∂
⎛ ⎞⎜ ⎟−⎜ ⎟⎜ ⎟−⎜ ⎟⎜ ⎟⎝ ⎠
∑ ∫
%
 (4.5) 
Equation (4.5) is the transient flux boundary condition which accounts for the 
effects of diffusivity, solubility, medium thickness, and duration of exposure. For 
steady state conditions where  t →∞ , this boundary condition (4.5) simplifies to  
 0 0
( ) | ( ) | 0,a y a y
dC y KC y
dy = =
′ ′+ =% %       (4.6) 
where 
(1 ( ) | )
mm ma m y H
a m
D C y
K
D H
λ =−=
%
,      (4.7) 
In this expression, ( )aC y′% is the steady-state concentration in the air layer.  
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The Air-phase Transport 
 
The concentration in the air layer satisfies the diffusion equation given by 
2
2
( , ) ( , )a a
a
C y t C y tD
t y
∂ ∂=∂ ∂ , [ ,0]ay H∈ −  (4.8) 
Initially, zero concentration is assumed in the mucus and tissue. The boundary 
conditions are: 
( , ) |
aa y H air
C y t C=− = , (4.9) 
The transient flux boundary condition at the air-mucus interface can be found in 
Eq. (4.5). 
In order to develop a model system to test the importance of transient 
effects, the height of the air layer is set equal to a constant and small value, which 
was selected to be Hm. This distance is selected to be small in order to focus the 
analysis on transport in the mucus, tissue, and blood layers. In part of this study, 
numerical predictions are used to determine Ca in a simple AMTB model. The 
concentrations of acetaldehyde and benzene (Cair) at the top of the air layer are 
taken to be 100 ppm (1.83×10-7 g/cm3) and 1 ppm (3.19×10-9 g/cm3),  
respectively, which are below OSHA short term exposure limits. Values of 
transport parameters are reported in Table 3.2 for acetaldehyde and benzene. 
 
Solution Techniques in the AMTB Model 
 
In this study, the governing equations for the air-mucus-tissue-blood model 
were solved using two different solution approaches. First, a numerical solution of 
the system of Equations (4.1a), (4.1b), and (4.8), and boundary conditions (4.2a-
d), (4.4) and (4.9) was found in Transient Absorption of Chemical Species 
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(TAOCS) 1.0 program using a finite volume method for spatial discretization and 
an implicit backward Euler method for time stepping. Figure 4.4a shows the 
system setup for the numerical solutions in the multilayer system. For the second 
solution technique, a hybrid numerical-analytical method was employed. In the air 
layer, Equation (4.8) with boundary condition (4.9) and the analytical transient 
flux boundary condition (4.5) was solved using a finite difference method for 
spatial discretization and an implicit backward Euler method for time stepping. 
Analytical solutions in the mucus and tissue, which are dependent on the solution 
in the air layer, were then solved using Equations (4.3a and 4.3b). Figure 4.4b 
shows the system setup for the hybrid solution in the multilayer system. The cgs 
system of units was used for all simulations. Comparison of the two solution 
techniques is used to verify the hybrid numerical-analytical solution. This 
approach is then applied as a boundary condition in a CFD simulation of vapor 
absorption in the nasal-laryngeal geometry, as described below. 
 
Transport Equations in the Nasal-Laryngeal Airway Model 
 
The low-Reynolds-number (LRN) k ω− model of Wilcox (1998)  was 
selected for simulating the air flow in the nasal-laryngeal model because it has 
been shown to provide an accurate and numerically efficient solution for 
transitional and turbulent flows. Furthermore, this model was found to accurately 
predict laminar flow as the turbulent viscosity approaches zero. The transport 
equations governing the turbulent kinetic energy ( k ) and the specific dissipation 
rate ( ω ) were provided by Wilcox (1998) and were previously reported in 
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(Longest and Xi 2007b; Xi and Longest 2007a; Xi and Longest 2008b; Zhang and 
Kleinstreuer 2004; Zhang and Kleinstreuer 2006). 
      The turbulent vapor mass transfer equation in turbulent flow can be written on 
a mass fraction basis as  
( )j aa aT
a
j j C j
u CC CD
t x x x
ν
σ
⎡ ⎤∂ ⎛ ⎞∂ ∂∂+ = +⎢ ⎥⎜ ⎟∂ ∂ ∂ ∂⎢ ⎥⎝ ⎠⎣ ⎦
,    (4.10) 
where Ca is the mass fraction of a chemical species in air, Da is the species 
diffusivity in air, and νT is the turbulent viscosity. Vectors uj and xj are the fluid 
velocity vector and position, respectively, and σC is the turbulence Prandtl number, 
taken to be 0.9. 
 
Deposition Factors 
 
For the transport model, the total or regional deposition fraction at steady 
state can be expressed as 
 , ,w ii
in
m
DF
m
= &&         (4.11) 
where ,w im&  is the total mass absorption into the wall surface and inm&  is the inlet 
mass flow rate. The transient regional deposition fraction can be expressed as 
 
,
0
0
,
T
w i
i T
in
m dt
DF
m dt
=
∫
∫
&
&
       (4.12) 
where T  is the time period of the simulation. In this study, transient absorption is 
considered for periods of 2 s. 
The total mass absorption rate into the wall surface can be expressed as 
  62
 , , ,
1
( ) |
N
aT
w i m j a w j
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Cm A D
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νρ σ=
∂= − + ∂∑&      (4.13) 
where Aj is the local area, and the summation is performed over the total or 
i − region of interest. The mixture density is ρm. The vector n is the wall normal 
coordinate pointing out of the geometry. 
 The inlet mass flow rate can be determined as 
 in m inm QCρ=& ,        (4.14) 
where Q is the inlet inhalation flow rate. Cin is the inlet mass fraction, taken to be 
0.05. 
A deposition enhancement factor (DEF), similar to that suggested by Xi and 
Longest (2007b), was defined in order to quantify local deposition in region Aj 
with respect to the total deposition rate as follows. 
 
/
/
j j
j
i i
DF A
DEF
DF A
= ,        (4.15) 
where Ai is the total area.  
 
Flow Rates and Boundary Conditions 
 
Steady inhalation was assumed for all simulations. An inhalation flow rate 
of 20 L/min was considered, which is consistent with resting conditions (ICRP 
1994). During inhalation, airflow enters the nasal cavity, travels through the 
nostrils, nasal turbinates, pharynx, and exits the larynx. The transient flux 
boundary condition (Eq. 4.5) and steady flux boundary condition (Eq. 4.6) were 
considered for transient and steady absorption into the wall, respectively. 
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Two cases were  considered in the nasal-laryngeal airway model, as outlined 
in Table 4.1. Case 1 (S:S) and Case 2 (S:T) are intended to quantify the effects of 
transient absorption compared with steady state absorption. A steady state flow 
field and mass species profile were considered in both cases. Steady absorption 
versus transient absorption into the wall are then evaluated over a timescale 
consistent with one inhalation cycle.  
To solve the governing conservation equations, the CFD package Fluent 
6.2.16 (Ansys Inc.) was employed. User-supplied C programs were implemented 
for the calculation of the transient boundary condition, vapor absorption,  and 
deposition enhancement factors.  
 
4.3 Results 
Validation of the Transient Analytical Solution in the Air-Mucus-Tissue-Blood 
System 
 
A comparison between the transient numerical and hybrid solutions of 
concentration over time are shown in Fig. 4.5 for acetaldehyde and benzene. A 
point by point comparison of concentration values indicates that the transient 
numerical and hybrid solutions were on average within 0.1%. Agreement between 
the approaches considered provides confidence that the analytical flux boundary 
condition at the air-mucus interface and analytical solutions in the mucus and 
tissue are correct. The relative values of concentrations in the air, mucus and 
tissue sides of the interface also illustrate the effects of the air-mucus and mucus-
tissue partition coefficients.  For example, acetaldehyde is more soluble in mucus 
than in air at the air-mucus interface (λma > 1) and less soluble in tissue than in 
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mucus at the mucus-tissue interface (λtm < 1). Therefore, concentrations (g/cm3) 
of acetaldehyde are higher in the mucus compared with the air and lower in the 
tissue compared with the mucus. As a result, transient effects are also shown to be 
highly significant in the mucus and tissue layers over a timescale of 
approximately 2 seconds. 
 
Concentration Values 
 
Concentration values of acetaldehyde and benzene at the air-mucus and 
mucus-tissue interfaces are displayed in Fig. 4.6 over time based on the numerical 
solution.  These results indicate the timeframe for establishing steady state 
transport through the air and mucus. The concentration curves become flat over 
time as steady state conditions are approached. As observed, it is much faster to 
reach steady state in the air than in the mucus.  Considering the mucus and tissue 
layers, temporal effects for acetaldehyde and benzene appear relatively small after 
approximately 2 and 4 s, respectively. In the air layer, where the diffusion process 
is significantly faster, temporal effects for acetaldehyde and benzene are 
diminished after approximately 0.1 and 0.05 s, respectively. 
 
Flux and Uptake 
 
The fluxes of acetaldehyde and benzene into the mucus, tissue, and blood 
layers are reported in Fig. 4.7. Results in Fig. 4.7 indicate that the transient flux 
values for acetaldehyde and benzene are highly variable over approximately 4 and 
6 s, respectively. The fluxes into the mucus, tissue and the blood layers are equal 
and constant when steady state is reached quantitatively. The fluxes of 
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acetaldehyde and benzene reach constant steady state conditions (within 99%) in 
approximately 6 and 8 s, respectively. Since the concentrations at the air-mucus 
and mucus-tissue interfaces increase rapidly from zero initially, it is seen that the 
fluxes of each species into the mucus and tissue initially spike. Due to the zero 
concentration at the blood-tissue interface, the flux of each species into the blood 
is initially delayed and then approaches a steady state. Uptake within the mucus, 
tissue, and blood layers was estimated by time integrating the difference between 
the inlet and outlet flux values. The resulting uptake values for acetaldehyde and 
benzene are presented in Fig. 4.8. It is observed that transient absorption is 
significantly different from the steady state conditions. For acetaldehyde, uptake 
values in the mucus and tissue are higher than in the blood over a transient 
exposure. Based on these observations, the uptake in the blood is lower for a 
transient exposure compared with steady state conditions. It is observed that the 
transient blood uptake for acetaldehyde and benzene varied from steady state 
values by a factor of approximately 4 after 2 s.  
A comparison of steady state and transient blood uptake over time is 
presented in Fig. 4.9 as percent differences. The percent difference values are 
calculated as the absolute difference between steady and transient results divided 
by the transient value.  As shown in Fig. 4.9, percent differences for blood uptake 
range from approximately 100% to 1×105 % through 4 seconds. These percent 
differences between steady and transient uptake are also presented in Table 4.2. 
 
 
 
  66
Effects of Chemical Reactions 
 
To better evaluate the effects of chemical reactions on mucus, tissue, and 
blood uptake, acetaldehyde and benzene were considered over a range of first 
order reaction rate constants extending from 0.01 – 1×103 min-1. First order 
reaction rate constants are presented in Table 3.5 for a range of compounds 
considered to be non-reactive through highly reactive in mucus and tissue. 
Evaluation of chemical reactions requires that the governing diffusion 
equation in mucus, Equation (4.1a), be written as 
( )2 2( , ) ( , ) ,∂ ∂= −∂ ∂m mm m m
C y t C y tD K C y t
t y
, [0, ]my H∈    (4.16) 
where Km is the first-order reaction rate coefficient in mucus.  The governing 
equation for diffusion in tissue contains a similar reaction term for Kt.  The 
boundary conditions expressed as Eqs. (4.2a-d) remain unchanged for the reactive 
case. The resulting transient uptake values in mucus, tissue, and blood are shown 
in Fig. 4.10 for acetaldehyde and benzene across a range of K values.  In the 
numerical simulations, K values were assumed equal in mucus and tissue to 
maximize the effects of reactivity. 
It is observed that reactivity appears to only begin influencing uptake for K 
values greater than 100 min-1. This reaction rate coefficient is three orders of 
magnitude greater than the reported value of 0.1 min-1 for acetaldehyde and four 
orders of magnitude greater than the value assumed for benzene.  Therefore, it can 
be concluded that reactions do not influence the transient uptake of acetaldehyde 
and benzene at the concentrations considered in this study. 
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Deposition Fractions in the Nasal-Laryngeal Model 
 
Deposition fractions (DF) for acetaldehyde and benzene vapors in mucus, 
tissue, and blood in the nasal-laryngeal airway model for Case 1 (S:S) and Case 2 
(S:T) are shown in Fig. 4.11 for a 2 seconds inhalation. The DF values of 
acetaldehyde and benzene for both cases considered are also tabulated in Table 
4.3. It is observed that DF values for transient absorption (Case 2) are 
significantly different from steady state absorption (Case 1). Furthermore, DF 
values of acetaldehyde in mucus are approximately 8 times greater for transient 
absorption compared with steady state absorption. DF values of benzene in mucus 
are approximately 3 times greater for transient absorption compared with the 
steady absorption condition. For Case 1, the DF values are equal in mucus, tissue, 
and blood. For Case 2, the DF values of acetaldehyde in mucus are approximately 
6 times higher than in tissue and 40 times higher than in blood. The DF values of 
benzene in mucus are approximately 2 times higher than in tissue and 16 times 
higher than in blood. The higher absorption of acetaldehyde vapor may be 
attributed to its higher solubility in the mucus layer. 
 
Local Deposition 
 
DEF contours of acetaldehyde and benzene vapors are shown in Figures 
4.12 and 4.13, respectively, at an inhalation flow rate of 20 L/min. High DEF 
values were observed in the TR and VR regions,  and low DEF values were 
observed in the OR region. Differences of the DEF distribution for Cases 1 and 2 
are significant. The DEF values for Case 1 were distributed more uniformly, 
whereas DEF values for Case 2 were highly heterogeneous and localized. 
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4.4 Discussion 
This study has considered the transient absorption of highly and moderately 
soluble vapors into a simple multilayer AMTB model of the conducting airway 
walls.  Based on an analytic solution of absorption, a transient boundary condition 
for CFD simulations of vapor transport was developed for the first time and tested 
in comparison with the typically applied steady state approach.  Considering the 
AMTB model, results indicated that absorption was highly time dependent over 
the timescale of one inhalation cycle.  At 1 s, transient conditions resulted in 
approximately 2 – 3 times more uptake in tissue and 20 – 25 times less uptake in 
blood than at steady state for both acetaldehyde and benzene.  These results are 
consistent with the previous study of Tian and Longest (2010b), which neglected 
the air phase and only considered a mucus-tissue-blood wall model.  
Consideration of an AMTB wall representation in the current study allowed for 
the development of a novel transient flux boundary condition.  Application of this 
boundary condition to CFD simulations of a nasal-laryngeal geometry showed, as 
expected, that transient absorption significantly affected total deposition fractions 
in the mucus, tissue, and blood.  Moreover, transient absorption was also shown 
to significantly affect the local deposition pattern of acetaldehyde and benzene 
based on the DEF parameter.  As a result, local tissue doses predicted using the 
transient absorption model will be significantly higher than when a steady 
absorption assumption is made.  Based on these findings, previous studies that 
have assumed steady state absorption of vapors into the respiratory walls may 
have significantly under predicted mucus and tissue absorption, over predicted 
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blood absorption, and under predicted local vapor absorption in cases where 
transient uptake is important. 
In this study, transient vs. steady state absorption was compared for both the 
AMTB wall model and the nasal-laryngeal geometry.  The resulting difference 
ratios were calculated as the transient uptake divided by the steady state uptake 
value.  From a dosimetry perspective, uptake in the tissue and blood are most 
important.  Interestingly, difference ratios at 2 s for tissue and blood uptake were 
nearly identical between the AMTB and nasal-laryngeal models.  For both models 
at 2 s and both species considered, the difference ratios in tissue were 
approximately 1.5 – 2 and the difference ratios in blood were approximately 0.17 
– 0.24.  As shown in Tables 4.2 and 4.3, these values are significantly diminished 
from the differences predicted at 1 s.  Similarity in the difference ratio values 
between the two models indicates that the AMTB model may be used to predict 
potential errors in CFD calculations using a steady state absorption approximation.  
Moreover, the application of a steady state absorption model may be considered 
in future CFD studies in conjunction with corrections predicted by the much 
simpler AMTB wall model. 
Limitations of the current study include the assumption of steady state flow 
field conditions (air and vapor transport), the consideration of one inhalation 
cycle, neglecting reactions, selecting an arbitrary height of the air layer, and zero 
vapor concentration in the blood.  The assumption of steady state air flow is not 
consistent with transient inhalation and exhalation.  However, both transient 
inhalation in the air phase and transient absorption in the wall will affect uptake.  
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The assumption of a steady state air phase was made in this study to isolate the 
effect of transient wall absorption.  Considering the AMTB model, the timescale 
of one inhalation cycle was considered.  Vapor exposures often consist of 
exposure over multiple inhalations.  For highly and moderately soluble 
compounds, it is reasonable that full lung absorption occurs.  Furthermore, Tian 
and Longest (2010b) previously showed that concentrations did not accumulate in 
the mucus, tissue, and blood layers over multiple inhalations, provided that the 
species was fully absorbed by the lungs.  Chemical reactions are generally 
considered significant for most of the reaction rate values considered, which 
ranged from 0.01 to 100 min-1. However, by considering transient absorption, 
reactivity only occurred for K values of approximately 100 min-1, which is 
significantly greater than the first order reaction constant of acetaldehyde and 
benzene.  As described, a small arbitrary value was used to define the height of 
the air layer in the AMTB model.  By selecting a small value, diffusion through 
the air had a negligible impact on the transient absorption rates into the mucus, 
tissue, and blood components.  Finally, zero concentration of inhaled vapor was 
assumed in the blood, which is most accurate for short exposures or compounds 
that are highly metabolized in the circulation. 
In conclusion, transient absorption was found to be significant compared 
with steady state predictions for highly and moderately soluble compounds in the 
upper airways.  The influence of transient absorption was observed in both a 
multilayer AMTB wall model and a CFD model of the nasal-laryngeal region.  
Findings from the CFD model indicated that transient effects influenced both total 
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absorption as well as local tissue doses.  The complex transient flux boundary 
condition developed and tested in this study may be very useful in future more 
accurate simulations of vapor uptake in the respiratory airways.  Results also 
indicated that the much simpler AMTB model could be applied to predict the 
effect of transient absorption compared with steady state conditions in the CFD 
model of the nasal-laryngeal geometry.  Therefore, the AMTB model may be 
implemented to simplify future simulations of transient vapor uptake.  Future 
studies are needed to evaluate the effects of transient air flow, multiple breathing 
cycles, blood absorption and concentration levels, and chemical reactions. 
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Table 4.1. Two cases considered. 
 Air phase and mass 
species 
Absorption Designation 
Case 1  Steady  Steady flux  S:S 
Case 2 Steady Transient flux  S:T 
 
Table 4.2. Blood uptake difference (%) between steady state and transient 
conditions for acetaldehyde and benzene. 
 
Time Acetaldehyde Benzene 
t=0.5 s 7.1×104 3.5×104 
t=0.75 s 7.1×103 5.2×103 
t=1 s 2.2×103 1.9×103 
t=2 s 3.1×102 3.4×102 
t=3 s 1.4×102 1.6×102 
t=4 s 8.5×101 9.9×101 
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Table 4.3. Deposition fraction (%) in mucus, tissue, and blood for Cases 1 
and 2 considered during a 2 seconds inhalation. 
 Acetaldehyde Benzene 
 in mucus in tissue in blood in mucus in tissue in blood 
Case 1 6.22 6.22 6.22 0.58 0.58 0.58 
Case 2 53.68 9.71 1.46 1.64 1.07 0.10 
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Figure 4.1. (a) The AMTB system and (b) the nasal-laryngeal airway model. 
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Figure 4.2. System setup for analytic solutions in the mucus and tissue layers. 
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Figure 4.3. Boundary conditions at the air-mucus interface. 
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Figure 4.4. System setup for (a) the numerical solutions and (b) the hybrid 
solutions in the multilayer system. 
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Figure 4.5. Comparison of numerical transient and hybrid solutions for 
acetaldehyde and benzene concentrations in the mucus and tissue. 
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Figure 4.6. Acetaldehyde and benzene concentrations at the air-mucus and 
mucus-tissue interfaces. 
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Figure 4.7. Flux of acetaldehyde and benzene into the mucus, tissue and blood 
layers. 
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Figure 4.8. Uptake of acetaldehyde and benzene for transient and steady state 
conditions. 
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Figure 4.9. Percent differences between steady state vs. transient predictions 
of uptake for acetaldehyde and benzene. 
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Figure 4.10. Uptake of acetaldehyde and benzene for transient conditions 
including reactivity. 
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Figure 4.11. Deposition fraction of acetaldehyde and benzene vapors in mucus, 
tissue, and blood in the nasal-laryngeal airway model for Cases 1 
and 2 over a 2 seconds inhalation. 
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Figure 4.12. DEF contours of acetaldehyde for both cases considered. 
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Figure 4.13. DEF contours of benzene for both cases considered. 
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Chapter 5. Transient Absorption of Inhaled Vapors in the Mouth-Throat 
Region with an Air-Mucus-Tissue-Blood Wall Boundary Condition 
5.1 Introduction 
The objective of this study is to predict transient vapor mass absorption of 
acetaldehyde and benzene in a model of the extrathoracic oral airways with an air-
mucus-tissue-blood boundary representation. CFD simulations of air phase 
transport were coupled with an analytically based boundary condition that 
accounted for transient absorption into the mucus, tissue, and blood layers of a 
previously developed mouth-throat (MT) geometry. A well tested low Reynolds 
number (LRN) k ω−  turbulence model was employed to simulate the flow field. 
Results of this study indicate that transient absorption can significantly influence 
the transport and mass absorption of vapors onto the walls of the conducting 
airways. 
 
5.2 Methods 
Upper Airway Geometry 
 
As shown in Fig. 5.1, the upper respiratory tract model considered includes 
the oral cavity, pharynx, larynx, and upper trachea. This model was originally 
developed in Xi and Longest (2007b) based on a cast of the oral cavity combined 
with CT images of the pharyngeal and laryngeal regions.  The geometry was then 
simplified using elliptical cross sections, which maintained the flow area and 
hydraulic diameter of the original model (Xi and Longest 2007b). The geometry 
was modified for this study by including an elliptical mouth opening, which is 
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consistent with relaxed oral inhalation. This model is referred to as the mouth-
throat (MT) geometry. 
 
Flow Rates  
 
In this study, transient and steady state airflow fields are considered.  Both 
cases are based on one inhalation cycle with a breathing frequency ( f ) of 15 
breaths/minute and a tidal volume (VT) of 1000 cm3/breath. For steady airflow, 
the steady state inhalation flow rate QS (500 cm3/s or 30 L/min) is obtained using 
the equation 
QS = 2f VT ,         (5.1) 
For transient airflow, the transient inhalation flow rate Q(t) was approximated as a 
sinusoidal function with the form 
( ) sin( )mQ t Q tω= ,       (5.2) 
where 0.5ω π=  /radians s . The mean cyclic flow rate Qm (785.40 cm3/s) in Eq. 
(5.2) can be obtained by solving the equation 
/2
0
sin( )
T
m TQ t dt Vω =∫ ,       (5.3) 
where T = 4 s/breath.  In this manner, the tidal volume and breathing frequency 
are consistently applied to find both the steady and transient inhalation flow rates.  
It is noted that setting Qs to 500 cm3/s and satisfying Eq. (5.1) would require 
artificially modifying the reference inhalation frequency value (f = 15 
breaths/min) selected.  The resulting inlet Reynolds number (based on the inlet 
hydraulic diameter) for the steady flow rate and mean cyclic flow rate are 2320 
and 3645, respectively. 
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Transport Equations 
 
The low-Reynolds-number (LRN) k ω− model of Wilcox (1998) was 
selected for simulating the airflow in the MT model because it has been shown to 
provide an accurate and numerically efficient solution for transitional and 
turbulent flows. Furthermore, this model was found to accurately predict laminar 
flow as the turbulent viscosity approaches zero. The transport equations for the 
(LRN) k ω−  model, including those governing the turbulent kinetic energy ( k ) 
and the specific dissipation rate (ω ), were provided by Wilcox (1998) and were 
previously reported in Xi and Longest (2007b). 
The vapor mass transport equation for turbulent flow can be written on a 
mass fraction basis as  
 
( )j aa aT
a
j j C j
u CC CD
t x x x
ν
σ
⎡ ⎤∂ ⎛ ⎞∂ ∂∂+ = +⎢ ⎥⎜ ⎟∂ ∂ ∂ ∂⎢ ⎥⎝ ⎠⎣ ⎦
,    (5.4) 
where Ca is the mass fraction of a chemical species in air, Da is the species 
diffusivity in air, and νT is the turbulent viscosity. Vectors uj and xj are the fluid 
velocity and position, respectively, and σC is the turbulent Prandtl number, taken 
to be 0.9. 
 
Analytical Solution for Mass Transport in Mucus and Tissue Layers 
 
In this study, vapor absorption and transport are considered in both the 
airflow field and through the walls of the conducting airways. To approximate 
transport within the walls of the conducting airways, a model system was 
considered that consists of air, mucus, tissue, and blood layers.  The wall model 
along with governing equations in each layer are illustrated in Figure 5.2.  
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Assumptions made in the wall model are that convection is negligible compared 
with diffusion and that zero concentration of the absorbed chemical species exists 
in the blood.  Zero blood concentration over short term exposures is appropriate 
due to high convective transport rates in blood relative to diffusion through the 
wall.  However, 1-D models and experiments clearly show that blood 
concentrations increase over longer timescales (Kumagai and Matsunaga 1995).  
An analytical solution of this system was previously developed in Chapter 3 and 
extended to formulate a CFD boundary condition including the air phase in 
Chapter 4.  The analytical solution for the concentration of an absorbed species in 
the mucus and tissue layers is briefly reviewed below.  Flux-based boundary 
conditions for absorption are then provided for both transient and steady state 
conditions.  
The analytical solution for the transient absorption of a chemical species 
into a multilayer air-mucus-tissue-blood wall model was previously (Chapter 4) 
obtained using the Fourier series expansion as 
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In these expressions, mC  and tC  are the time-dependent mass fractions of a 
chemical species in mucus and tissue, respectively. Dm and Dt are the species 
diffusivities in mucus and tissue, respectively, which are assumed to be constant. 
λma and λtm are the mucus-air and tissue-mucus partition coefficients.  Hm and Ht 
are the thicknesses of the mucus and tissue in a specific region of the respiratory 
tract, respectively, as shown in Fig.  5.2.  Based on ICRP (1994) estimates for the 
extrathoracic region, values of Hm and Ht in this study were 1.5×10-3 cm and 
5×10-3 cm. The values of transport parameters for two model compounds, 
acetaldehyde and benzene, are reported in Table 3.1.  Based on the reported 
mucus-air partition coefficients, acetaldehyde can be considered highly soluble in 
mucus and benzene can be considered moderately soluble.  In Equations (5.5) and 
(5.6), the coefficient Wn can be determined by utilizing the orthogonal relation. 
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The eigenvalues, µn, are the sequential positive roots of the transcendental 
equation 
tan( ) tan( ) 0t m ttm n n
m t m
D D H
D D H
λ μ μ+ = ,    (5.14) 
and were determined using Brent’s method (Press et al. 1996). The coefficients 
nW  were determined by utilizing the orthogonal relation and zero concentration 
initial conditions. The first five values in the eigenvalue and constant series are 
provided in Table 5.1, which are accurate to four digits. 
 
Transient Flux Boundary Conditions 
 
The analytical solution in the mucus ( mC ), the value of the mucus-air 
partition coefficient, and an assumption of flux ( 2/g s cm− ) conservation can be 
combined into the transient flux boundary condition at the air-mucus interface. 
This boundary condition has the following form, which was developed in Chapter 
4 
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          (5.15) 
To determine uptake in the tissue and blood layers, flux boundary conditions into 
these phases are also needed.  The transient flux wall boundary condition at the 
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mucus-tissue interface can be found by differentiating mC  with respect to y , and 
has the form 
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The transient flux wall boundary condition at the tissue-blood interface can be 
found by differentiating tC  with respect to y , and has the form 
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          (5.17) 
 
Steady State Flux Boundary Conditions 
 
The transient boundary conditions developed above can be simplified to 
steady state conditions by removing the transient terms.  The steady flux 
boundary condition at the air-mucus interface results in 
0 0| | 0,a y a a y
dC K C
dy = =
′ ′+ =% %        (5.18) 
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In these expressions, aC′%  is the steady-state mass fraction of a chemical species in 
air.  
The steady flux boundary condition at the mucus-tissue interface reduces to 
0| | 0,m
m
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′ ′+ =% %        (5.20) 
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In these expressions, mC′%  is the steady-state mass fraction of a chemical species in 
mucus.  
The steady flux boundary condition at the tissue-blood interface results in 
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In these expressions, tC′%  is the steady-state mass fraction of a chemical species in 
tissue. Furthermore, it can be shown that the steady state fluxes into the mucus, 
tissue and blood layers are equal and constant, i.e., 
0| | | ,m m t
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ρ ρ ρ= = = +′ ′ ′− = − = −
% % %
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where the mixture density mρ  is assumed constant.  As a result, uptake in the 
mucus, tissue, and blood layers are equal and constant for steady state conditions. 
 
Deposition Factors 
 
For the transport model, the total deposition fraction at steady state can be 
expressed as 
 , ,w ii
in
m
DF
m
= &&         (5.25) 
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where ,w im&  is the total mass absorption rate into the wall surface and inm&  is the 
inlet mass flow rate of the chemical species. The transient total deposition fraction 
can be expressed as 
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       (5.26) 
The breathing period (T) is divided by two in order to account for only one 
inhalation cycle (T/2 = 2 s) in most cases considered.  For turbulent flow, the total 
mass absorption rate into the wall surface can be expressed as 
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w i m j a w j
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νρ σ=
∂= − + ∂∑&      (5.27) 
where Aj is the local area, and the summation is performed over the total or 
i − region of interest. The mixture density is ρm. The vector n is the wall normal 
coordinate pointing out of the geometry.  The inlet mass flow rate of the chemical 
species can be determined as 
 in m inm QCρ=& ,        (5.28) 
where Q is the inlet inhalation flow rate and Cin is the inlet mass fraction, taken to 
be 0.05. 
A deposition enhancement factor (DEF), similar to that suggested by 
Longest and Xi (2007a), was defined in order to quantify local deposition in local 
area Aj with respect to the total deposition rate, i.e.,  
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where Ai is the total area of the model.  Deposition enhancement factors represent 
the ratio of a compound depositing in a local area (taken to be a control volume 
surface with an area of approximately 0.5 mm x 0.5 mm) to the total deposition 
within the geometry. 
 
Numerical Method 
 
While effective, implementation of the transient absorption, or even the 
steady state absorption, boundary conditions can be complex.  For the transient 
case, the flux-based boundary conditions contain a series summation and require 
the evaluation of an integral term.  Eigenvalues μn and coefficients Wn are 
included in the summation term and must be determined from a transcendental 
equation and integral expression, respectively.  Application of this complex 
boundary condition in a CFD solution of the airflow phase can be difficult.  To 
facilitate implementation of the transient absorption boundary conditions, a new 
user-friendly program titled Transient Absorption of Chemical Species (TAOCS) 
1.0 was developed.  The TAOCS 1.0 program is based on the AMTB wall model 
and equations shown in Fig. 5.2.  The TAOCS graphical user interface (GUI) 
along with several input windows for specifying transport properties and 
determining the eigenvalues are shown in Fig. 5.3.  The user inputs the transport 
properties of the chemical species (from Table 3.1), wall conditions, and initial 
surface concentrations.  Based on the previous work in Chapters 3 and 4, and the 
boundary conditions presented in this study, the TAOCS program provides: 
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1. Ready to implement user-defined functions (UDFs) for use with a 
commercial CFD program (Fluent 6.3), which specify the transient 
flux boundary conditions, i.e., Eqs. (15) – (17). 
2. The μn and Wn coefficients through any order needed to evaluate the 
flux expressions (cf. Table 5.1). 
3. The analytical solution of transport into an air-mucus-tissue-blood 
system based on both steady and transient absorption. 
4. The numerical solution of transport into an air-mucus-tissue-blood 
system based on both steady and transient conditions for 
comparisons with the analytical solution and CFD results. 
In this study, the TAOCS program was used to calculate the μn and Wn 
coefficients for use in the transient boundary conditions (Table 5.1) and to 
generate the UDFs needed for implementation of the boundary conditions in the 
CFD code. 
To solve the governing conservation equations, the CFD package Fluent 6.3 
(Ansys Inc.) was employed. User-supplied C programs were implemented for the 
calculation of the transient boundary condition, vapor absorption, and deposition 
enhancement factors.  All transport equations were discretized to be at least 
second order accurate in space.  For the convective terms, a third order QUICK 
scheme was used to interpolate values from cell centers to nodes.  The diffusion 
terms were discretized using central differences.  A segregated implicit solver was 
employed to evaluate the resulting linear system of equations.  This solver uses 
the Gauss-Seidel method in conjunction with an algebraic multigrid approach.  
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The PISO algorithm was employed to evaluate pressure-velocity coupling in the 
transient solutions.  The outer iteration procedure was stopped when the global 
mass residual had been reduced from its original value by five orders of 
magnitude and when the residual-reduction-rates for both mass and momentum 
were sufficiently small.  To ensure that a converged solution had been reached, 
residual and reduction rate factors were decreased by an order of magnitude and 
the results were compared.  The stricter convergence criteria produced a 
negligible effect on both velocity and vapor absorption predictions. To improve 
accuracy, cgs units were employed, and all calculations were performed in double 
precision.  Grid converged results based on negligible change in the velocity and 
concentration fields (< 1%) as well as negligible differences in the total deposition 
fractions (< 3%) were established for a mesh consisting of 1×106 hexahedral 
control volumes.  The size of the first control volume next to the wall surfaces 
was found to strongly affect mesh convergence.  A value of 0.05 mm was needed 
to produce negligible (< 3%) changes in the absorption predictions. 
 
Cases Considered 
 
Six cases were considered in the MT airway model, as outlined in Table 5.2.  
Each case is represented by a combination of steady (S) vs. transient (T) airflow 
conditions and steady vs. transient vs. perfect (P) wall absorption.  Perfect wall 
absorption is defined as a concentration of zero on the wall boundary, which may 
be appropriate for very high absorption or reactivity rates.  These conditions are 
abbreviated for each case in terms of (flow field condition : wall absorption). For 
Case 1 (S:S) and Case 3 (S:T), steady state flow fields and mass concentration 
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fields were assumed. For Case 2 (T:S) and Case 4 (T:T), transient flow fields and 
mass concentration fields were simulated. Absorption was then modeled based on 
either the steady state or transient boundary condition over a timescale consistent 
with one inhalation cycle (2 s). For Case 5 (S:P) and Case 6 (T:P), perfect 
absorption was assumed, which can be mathematically expressed as 0( ) | 0a yC y =′ =%  
at the wall.  The focus of the results is then to identify differences between the 
most complex case (Case 4 (T:T)) and the other commonly used approximations. 
 
5.3 Results 
Mass Fraction 
 
Effects of airflow and wall absorption conditions on vapor mass fraction 
distributions of acetaldehyde and benzene in the MT model are shown in Figures 
4 and 5, respectively.  For the transient conditions shown, a 2 second inhalation 
period was applied.  Beginning with acetaldehyde, the concentration profiles for 
Case 4 (T:T) are highly complex (Fig. 5.4).  Considering airflow effects, steady 
state conditions appear to significantly change the concentration profiles (Case 3 
(S:T) vs. Case 4 (T:T)).  Considering absorption, steady state again appears to 
have a major impact on the concentration profiles (Case 2 (T:S)) vs. Case 4 (T:T)).  
Of the cases considered, transient airflow and perfect absorption (Case 6) appear 
to best match the transient conditions of Case 4.  However, similar mass fraction 
concentrations in the flow field do not necessarily imply that absorption into the 
walls will be similar between Cases 4 and 6. 
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Considering benzene, the lower solubility coefficient results in nearly 
constant concentrations for Case 4 (T:T) conditions (Fig. 5.5) at the selected 
contour levels.  Steady airflow is again observed to significantly impact the 
concentration profile (Case 3 (S:T) vs. Case 4 (T:T)).  With respect to absorption, 
steady state conditions Case 2 (T:S) appear to provide a reasonable approximation 
to the transient wall conditions of Case 4.  As expected, perfect absorption (Case 
6 (T:P)) provides very different contours from the transient absorption case. 
 
Deposition Fraction Values of Acetaldehyde and Benzene 
 
Deposition fractions (DF) for acetaldehyde and benzene vapors in mucus, 
tissue, and blood in the human upper airway model for Cases 1-4 are shown in Fig. 
5.6. The DF values of acetaldehyde and benzene for all cases considered are also 
tabulated in Table 5.3.  The DF is defined as the amount of inhaled vapor mass 
that enters each wall layer normalized by the amount of inhaled mass (cf. Eq. 
(26)).  As such, the DF provides a relative estimate of the amount of the species 
that reaches each level of the wall over a defined time period. It is observed that 
DF values for transient absorption (Cases 3 and 4) are significantly different from 
steady state absorption (Cases 1 and 2). Specifically, DF values of acetaldehyde in 
the mucus are approximately 10 to 15 times greater for transient absorption 
compared with steady state absorption. Deposition fraction values of benzene in 
the mucus are approximately 4 to 6 times greater for transient absorption 
compared with the steady absorption condition.  For Case 1 (S:S), the DF values 
are equal in mucus, tissue, and blood. For Case 2, the transient flow effects cause 
little difference in DF values for mucus, tissue, and blood. For Cases 3 and 4, the 
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DF values of acetaldehyde in mucus are approximately 6 times higher than in 
tissue and 40 times higher than in blood. The DF values of benzene in mucus are 
approximately 2 times higher than in tissue and 20 times higher than in blood. 
The higher deposition of acetaldehyde vapor may be attributed to its higher 
solubility in the mucus layer compared with benzene. Under the same absorption 
conditions, the differences of DF values in mucus between Case 1 and Case 2, 
Case 3 and Case 4, Case 5 and Case 6, are 11.3%, 28.1%, and 27.0% for 
acetaldehyde and 10.0%, 26.8%, and 27.1% for benzene, respectively. Therefore, 
it is concluded that the transient flow field also influences the deposition fraction, 
but to a much lesser extent than the transient absorption condition. 
Comparisons of DF values in mucus for the human upper airway model 
between Case 3 (S:T) and Case 5 (S:P), and between Case 4 (T:T) and Case 6 
(T:P) are shown in Fig. 5.7. Case 5 (S:P) and Case 6 (T:P) assume that the airway 
wall is a perfect sink for vapors, i.e., the boundary condition on the wall is 
0( ) | 0a yC y =′ =% .  However, this assumption is only reasonable for vapors of high 
solubility, or for estimating the maximum deposition of vapors in the airways.  
Compared with Case 3, the DF values of Case 5 are approximately 1.5 times 
greater for acetaldehyde and 40 times greater for benzene. Similarly, compared 
with Case 4, the DF values of Case 6 are approximately 1.5 times greater for 
acetaldehyde and 40 times greater for benzene.  Therefore, the perfect absorption 
boundary condition is accurate to within approximately 50% (calculated as a 
relative percent error) compared with transient absorption for the highly soluble 
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compound acetaldehyde and should not be applied for compounds with lower 
solubilities. 
 
Local Deposition 
 
Contours of local deposition enhancement factors (DEFs) for acetaldehyde 
and benzene vapors are shown in Figures 8 and 9, respectively.  As described, the 
DEF contours represent the locally absorbed mass divided by the area-averaged 
total absorption to give a normalized representation of local uptake.  Similarities 
in local deposition based on DEF patterns and maximum values were consistent 
with observations of total deposition fractions.  For acetaldehyde, Case 4 (T:T) 
local deposition values were most similar to Case 3 (S:T) indicating that the 
absorption condition is most significant.  Case 6 (T:P) DEF patterns were also 
similar with Case 4 (T:T), but with a much higher maximum (8.81 vs. 2.72) as 
expected for perfect absorption.  Considering benzene, Case 4 (T:T) local DEF 
values were found to be similar with Case 3 (S:T) and Case 2 (T:S).  The 
similarity with Case 3 was expected based on observations made with the total 
deposition fractions.  However, similarity between Cases 4 and 2 was not 
expected considering the order of magnitude difference in the total deposition 
fractions. 
 
Mass Absorption into the Wall Layers 
 
Mass absorption into the wall layers for acetaldehyde and benzene under 
Cases 1 (S:S) and 3 (S:T) conditions are presented in Fig. 5.10.  Steady airflow 
fields are considered to isolate the effects of transient vs. steady state absorption 
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over time. The mass absorption differences between Case 1 and Case 3 are highly 
significant. At 2 s, transient mass absorption into the mucus layer for 
acetaldehyde and benzene is approximately 15 times and 6 times higher than 
predicted with the steady state solution, respectively. Transient mass absorption 
into the tissue layer for acetaldehyde and benzene is approximately 3 times higher 
than predicted with the steady state solution. Similarly, the mass absorption into 
the blood for acetaldehyde and benzene is lower than with steady state conditions 
by a factor of approximately 4. 
 
Mass Absorption over Multiple Breaths 
 
The results presented in the previous figures are for one inhalation cycle.  
However, buildup of species concentrations in the wall layer over multiple 
breathing cycles may diminish transient absorption effects.  To evaluate the 
buildup of concentrations in the wall layers, three breath cycles (2 s inhalation and 
2 s exhalation) were simulated for Case 4 (T:T) and compared with the Case 1 
(S:S) results.  The species concentrations entering the model at the larynx during 
exhalation were estimated based on expected lung uptake values.  Considering the 
high and moderate solubilities of acetaldehyde and benzene, the estimated 
concentrations entering the larynx during expiration were assumed to be 0 and 
30% of the inhaled mass concentrations, respectively, which assumes 100 and 
70% lung absorption.  These values are only intended to explore the potential for 
buildup in the wall layers during absorption and desorption and may not provide 
quantitative estimates of acetaldehyde and benzene uptake in vivo.  It is noted that 
an accurate prediction of the concentration entering the geometry during 
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exhalation will require a linked CFD and 1-D model, as performed in other 
studies (Frederick et al. 1998; Kimbell et al. 2001a; Overton et al. 2001). 
Multiple breath simulation results are shown in Fig. 5.11 in terms of 
absorption rate (g/s).  To allow a direct comparison between the steady state Case 
1 and transient Case 4 estimates, a time average was taken of the transient mass 
absorption rate (time-averaged transient rate).  During the first inhalation cycle for 
acetaldehyde and benzene, a rise is observed in the transient absorption rate.  
However, after the first inhalation cycle the transient absorption rate appears to 
repeat for subsequent breaths without significant change.  Specifically, 
differences in the maximum transient absorption value between breaths 2 and 3 
are less than 0.2% for both compounds.  This implies that some buildup of the 
species occurs in the wall after the first breath due to incomplete desorption.  
Thereafter, a cyclic pattern emerges that is repeated for subsequent breaths.  This 
first breath buildup has a relatively minimal effect on the absorption rate of 
acetaldehyde.  In contrast, a more visible effect is observed for benzene arising 
from the non-zero concentration entering the model during exhalation.  While 
concentration buildup in the wall layer is expected to reduce transient effects, the 
transient fluctuations still clearly influence mass absorption.  Specifically, the 
transient mass absorption rate averaged over breaths 2 and 3 (once a repeating 
pattern occurs) is 7 times greater than the steady state prediction for acetaldehyde 
and 3.5 times greater than the steady state prediction for benzene.  Absorption 
results evaluated in the tissue and blood layers were similar to those found in the 
mucus. 
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5.4 Discussion 
This study has considered transient absorption of inhaled vapors into a 
multilayer air-mucus-tissue-blood system in a human upper airway model. The 
transient flux boundary condition at the air-mucus interface was employed for 
CFD simulations of gas phase transport and mass transfer. Six cases were 
intended to quantify the effects of transient absorption compared with steady state 
conditions. A new dosimetry program TAOCS 1.0 was used in conjunction with a 
CFD model to apply and evaluate both steady state and transient wall absorption 
conditions. 
Conclusions of the model results can be summarized as described below.  
These conclusions are based on the single inhalation cycle simulations performed 
in this study, which neglect reactions in the airway wall, and assume zero species 
concentration in the blood. 
• For both highly and moderately soluble compounds: 
o Steady state absorption cannot capture transient absorption 
conditions.  After 2 seconds, differences were at least one order 
of magnitude. 
o Steady state airflow produces significant changes in the 
concentration field compared with transient airflow.  However, 
steady state airflow conditions only influence total deposition 
fractions by approximately 10 – 30%. 
o Steady airflow also produced reasonable approximates of local 
DEF values compared with transient airflow conditions. 
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• For highly soluble compounds (λma ≥ 320) 
o Perfect absorption provides a reasonable estimate (within 
~50%) of total deposition compared with the transient boundary 
condition. 
o Considering local deposition, perfect absorption significantly 
over predicts maximum DEF values. 
• For moderately soluble compounds (λma ~ 4) 
o Total deposition fractions cannot be approximated with either 
steady state or perfect absorption boundary conditions.  
Therefore, consideration of transient wall absorption is required. 
o Based on total absorption findings, local absorption should not 
be approximated with steady or perfect absorption conditions. 
To summarize these observations, steady state airflow provides a reasonable 
approximately to transient airflow conditions (within 10 – 30%) in terms of total 
and local deposition.  However, the simulation of transient wall absorption is 
critical unless the compound is highly soluble (λma ≥ 320) and a perfect absorption 
boundary condition can be applied.  Still, the perfect absorption boundary 
condition does not adequately model local DEF values. 
A primary limitation of this study is the omission of chemical reactivity in 
the mucus, tissue, and blood.  Other studies have shown that reactivity can 
significantly influence uptake under steady state absorption conditions (Cohen 
Hubal et al. 1996b; Cohen Hubal et al. 1997; Keyhani et al. 1997; Kimbell et al. 
2001a; Zhang and Kleinstreuer 2006).  However, the previous studies of Tian and 
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Longest (2010a; 2010b) have shown that when transient absorption is considered, 
the effects of chemical reactions are significantly diminished.  This is because of 
finite reaction rate times over 1 – 2 s with transient absorption vs. infinite reaction 
rate times associated with a steady absorption model.  The results of Tian and 
Longest (2010a; 2010b) indicated that reactions were not significant compared 
with transient absorption for both acetaldehyde and benzene at typical inhalation 
concentrations and short term exposures with zero blood concentrations. However, 
for highly reactive compounds like ozone, reactions cannot be neglected. Future 
work is needed to extend the current transient absorption boundary condition 
developed by our group to account for chemical reactions in a time-dependent 
manner.  Because reactions were neglected in this study, the quantitative values 
reported for acetaldehyde and benzene should be examined further and interpreted 
as representative of general highly and moderately soluble compounds. 
A second limitation of the current study is the focus on a single breath or a 
small number of breaths.  Buildup of concentrations in the tissue and blood are 
known to have an effect on absorption (Kumagai and Matsunaga 1995) and are 
expected to reduce the overall importance of time dependence.  To evaluate 
concentration buildup in the wall under the assumption of zero blood 
concentration, a multiple breath simulation was conducted (Fig. 5.11).  While 
exact values of concentrations entering the larynx are not known, results of these 
multiple breath simulations were informative.  In summary, it was found that 
buildup in the wall influences transient flux values between the first and second 
breaths.  Thereafter, a cyclic repeating transient absorption pattern was observed.  
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Despite an expected reduction in transient absorption effects, the time-averaged 
transient absorption rate remained 3.5 to 7 times greater than the corresponding 
steady state estimate.  Therefore, it can be concluded that buildup in the wall 
layers does not significantly diminish transient absorption effects, even if 30% (or 
potentially more) of the inspired concentration is exhaled. 
Similar to buildup in the wall layers, absorption and buildup of chemicals in 
the blood may diminish transient differences from steady state values.  Previous 
1-D models have shown that blood concentrations of species can increase over 
long exposure timescales on the order of hours (Kumagai and Matsunaga 1995).  
It is expected that until saturated blood levels are reached, transient absorption 
and desorption from the wall layer into the air will produce absorption rate values 
different from steady state estimates.  However, this analysis is beyond the scope 
of the current study. 
It is stressed that the results of this study are for zero concentration of the 
absorbed species in the blood, which may be referred to as the initial wash-in 
phase of vapor exposure.  During this period, it is expected that absorption rates 
will be elevated, potentially heightening the effects of cyclic inhalation and 
transient wall absorption.  In comparison, it is noted that previous experimental 
and numerical results have indicted that steady and transient exposures produce 
similar absorption rates.  For example, Morris and Blanchard (1992) showed that 
the fractional upper respiratory tract absorption in a rodent model was similar 
between steady state and cyclic experimental conditions at equivalent flow rates 
for an exposure period of 40 minutes.  Both steady state and cyclic total 
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absorption results were reasonably well predicted by the model of Aharonson et al. 
(1974).  Using a CFD-PBPK model that updated blood concentration and exhaled 
fraction with time, Frederick et al. (1998) showed that transient and steady state 
predictions of acrylic acid concentration in tissue varied by a factor of 2 over an 
exposure period of three minutes.  As indicated earlier, this study included 
transient flow field and inlet concentration effects, but the CFD model most likely 
applied steady state flux equations to describe transport through the walls of the 
nasal cavity model.  Furthermore, previous experimental studies have highlighted 
the importance of chemical reactions in the airways (Morris and Blanchard 1992; 
Morris and Cavanagh 1987).  One potential reason that the results of the current 
study differ from previous experimental and numerical results is the time scale 
considered.  It is suggested that during the initial wash-in phase, when zero blood 
concentrations can be assumed, transient effects are highly significant as 
suggested in the current study.  As blood concentrations increase, absorption is 
reduced, and the effects of cyclic breathing and transient absorption are 
diminished.  Therefore, long-term exposures to environmental type pollutants 
may be appropriately modeled using a steady state approach.  In contrast, shorter 
exposures described by the wash-in phase of airway kinetics (and zero or near 
zero blood concentrations) may need to consider the transient effects described in 
this study.  Examples of short term exposures where transient effects will likely 
be most important include smoking, the delivery of vaporized pharmaceuticals, 
and the inhalation of high concentrations of noxious chemicals that may be 
released during an environmental accident, fire, or chemical weapons attack. 
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The model presented in this study is a first step toward better estimating 
transient absorption using CFD predictions, which can provide highly localized 
uptake values.  The simulations clearly show that the implementation of a 
transient flux boundary condition appears critical to predict total and local 
deposition characteristics for even highly soluble compounds.  However, future 
work is needed to make toxicologically relevant predictions in many cases.  First, 
the transient absorption boundary condition currently neglects reactions in the 
airway wall.  While Tian and Longest (2010a; 2010b) clearly showed that 
transient effects diminished the influence of reactivity, future work is needed to 
confirm this finding over a range of exposure concentrations and times.  The 
transient absorption model is most appropriate for predicting uptake over short 
term exposures before significant buildup in blood concentrations occurs.  
Examples of these types of exposures include smoking and inhalation of noxious 
compounds.  Simulations of multiple breaths showed that a cyclic pattern of 
mucus absorption and desorption is quickly reached.  However, buildup of species 
in the blood and the effect on subsequent absorption needs to be considered in 
future studies.  To address longer term exposures, a combination of the proposed 
CFD model with a lumped parameter or 1-D whole-body model is suggested 
which can accurately predict both local transient absorption and blood 
concentrations over time.  Still, the results as presented provide a valuable next 
step toward time-resolved CFD predictions of vapor absorption in the respiratory 
airways. 
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In conclusion, the effects of transient airflow and absorption vs. steady state 
conditions were considered for highly and moderately soluble compounds in an 
upper airway model.  The use of the TAOCS program in conjunction with CFD 
simulations resulted in a new dosimetry approach to effectively simulate steady 
state and transient absorption on a regional and highly localized basis.  Findings 
highlighted the need for considering transient wall absorption.  However, 
differences associated with steady state flow fields may be acceptable.  Future 
studies are needed to consider chemical reactions, the buildup of concentrations in 
the blood, absorption throughout the respiratory tract and over longer time periods, 
and to validate the model with experimental results. 
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Table 5.1. The first five eigenvalues µn and coefficients Wn. 
Acetaldehyde Benzene 
µ1= 0.5092 W 1=-1.4549 µ1=0.4050 W 1=-1.3355 
µ2=0.9992 W 2=0.5802 µ2=0.8708 W 2=0.2435 
µ3=1.4243 W 3=-0.4656 µ3=1.3677 W 3=-0.1033 
µ4=1.7934 W 4=0.3618 µ4=1.8712 W 4=0.0787 
µ5=2.2359 W 5=-0.2578 µ5=2.3646 W 5=-0.1027 
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Table 5.2. Definition of steady and transient cases considered. 
 Airflow (Air and mass species) Absorption Designation 
Case 1  Steady  Steady flux  S:S 
Case 2 Transient  Steady flux T:S 
Case 3 Steady Transient flux  S:T 
Case 4 Transient  Transient flux T:T 
Case 5 Steady  
0| 0a yC =′ =%  S:P 
Case 6 Transient  
0| 0a yC =′ =%  T:P 
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Table 5.3. Total deposition fractions (DF) as percentages in mucus, tissue, 
and blood. 
 Acetaldehyde Benzene 
 in mucus in tissue in blood in mucus in tissue in blood 
Case 1 2.13 2.13 2.13 0.20 0.20 0.20 
Case 2 1.89 1.87 1.87 0.18 0.17 0.17 
Case 3 29.87 4.75 0.71 1.12 0.51 0.05 
Case 4 21.49 3.66 0.55 0.82 0.45 0.04 
Case 5 44.13 0 0 46.14 0 0 
Case 6 32.21 0 0 33.66 0 0 
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Figure 5.1. Surface model of the mouth-throat region including the oral cavity, 
pharynx, larynx, and a portion of the upper trachea. 
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Figure 5.2. Submodel of the airway wall including air, mucus, tissue, and 
blood (AMTB) layers.  Equations governing transport in this 
multilayer system are also shown. 
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Figure 5.3. Graphical user interface (GUI) of the Transient Absorption of 
Chemical Species (TAOCS) 1.0 model.  Windows shown include 
the main GUI and input panels for transport properties and finding 
the eigenvalues. 
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Figure 5.4. Contours of acetaldehyde mass fractions in the air phase (Ca) for 
all cases considered.  For cases with either transient airflow or wall 
absorption, conditions at 2 seconds are shown.  The inlet mass 
fraction of each chemical species considered was 5% for all cases. 
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Figure 5.5. Contours of benzene mass fractions in the air phase (Ca) for all 
cases considered.  For cases with either transient airflow or wall 
absorption, conditions at 2 seconds are shown. 
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Figure 5.6. Total deposition fractions of acetaldehyde and benzene vapors in 
mucus, tissue, and blood in the MT model for Cases 1 – 4 after 2 
seconds. 
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Figure 5.7. Total mucus deposition fraction of acetaldehyde and benzene for 
the evaluation of the perfect absorption condition. 
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Figure 5.8. Deposition enhancement factors (DEFs) and total deposition 
fractions (DFs) for acetaldehyde and all cases considered after 2 s. 
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Figure 5.9. Deposition enhancement factors (DEFs) and total deposition 
fractions (DFs) for benzene and all cases considered after 2 s. 
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Figure 5.10. Mass absorption of acetaldehyde and benzene in individual wall 
layers under steady airflow conditions over time. 
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Figure 5.11. Mass absorption rate (g/s) of acetaldehyde and benzene into the 
mucus based on Case 1 (S:S) and Case 4 (T:T) conditions 
considered over multiple breaths. 
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Chapter 6. Evaluation of Enhanced Condensational Growth (ECG) for 
Respiratory Drug Delivery in a Realistic Mouth-Throat and 
Tracheobronchial Single Path Model 
6.1 Introduction 
 The feasibility of improving respiratory drug delivery using enhanced 
condensational growth (ECG) has previously been demonstrated using both in 
vitro and CFD models of the upper respiratory airways. Previous studies have 
indicated that ECG is an effective approach for significantly reducing MT aerosol 
deposition and increasing aerosol size from the submicrometer range to 
approximately 2-4 µm, which is expected to produce nearly 100% lung retention. 
However, condensational growth and deposition in the tracheobronchial (TB) 
region beyond approximately generation G4 was not considered.  It is currently 
not clear how far into the lungs condensational growth will continue.  It is also 
conceivable that some evaporation may occur in the deep lung once subsaturated 
conditions are reached for non-hygroscopic aerosols. To verify full lung retention 
of the aerosol under ECG conditions, the aerosol size change and deposition 
needs to be characterized throughout the TB airways. To address these issues, a 
model of ECG delivery within the medium and small TB airways is needed. 
 The objective of this study is to evaluate the ECG delivery of respiratory 
submicrometer pharmaceutical aerosols in a single path model extending from the 
mouth-throat (MT) to the end of the TB region.  This single path model is 
constructed by continuing only one branch of each bifurcation through generation 
G16. Separate streams of nebulized submicrometer aerosol and saturated 
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humidified air are combined as they are introduced into a realistic MT-TB single 
path geometry. Initially monodisperse aerosol sizes of 560 and 900 nm are 
delivered in conjunction with control subsaturated air and ECG conditions with 
saturated air at temperatures of 39 and 42 ◦C, consistent with previous 
experimental studies of ECG (Longest et al. 2010). A previously validated CFD 
model of aerosol transport and deposition during ECG delivery in the respiratory 
airways is applied. 
 
6.2 Methods 
MT-TB Geometry 
 
 A physical model of the MT-TB geometry was considered as shown in Fig. 
6.1. The geometry consists of the MT region, the upper TB airways extending 
from the trachea to the third respiratory bifurcation (B3), and an individual path 
model of the medium and small TB airways extending to the terminal bronchioles 
(B15). The trachea and the initial part of the main bronchi constitute bifurcation 
B1. The MT geometry includes the oral cavity, pharynx, and larynx. The MT 
model was originally developed in Xi and Longest (2007b) based on a cast of the 
oral cavity (Cheng et al. 1997) combined with CT images of the pharyngeal and 
laryngeal regions. The geometry was then simplified using elliptical cross 
sections which maintained the flow area and hydraulic diameter of the original 
model. 
The upper TB airways are considered extending from the trachea to the third 
bifurcation (B3). This asymmetrical model was generated using the anatomical 
cast dimensions reported by Yeh and Schum (1980) and scaled to a functional 
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residual capacity (FRC) of 3.5 L, which is consistent with an adult male (ICRP 
1994). The individual bifurcation units were based on the physiological realistic 
bifurcation (PRB) parameters reported by Heistracher and Hofmann (1995). 
Surface properties of the bifurcations such as carinal ridge and curvature radius of 
branches were based on the measurement reported by Horsfield et al. (1971) and 
Hammersley and Olson (1992). These bifurcation parameters such as branch 
diameter, length, bifurcation angle, and gravity angle were taken from Yeh and 
Schum (1980). In the TB model, B2 of the right lung braches into the right upper 
lobe directly, whereas the lower third bifurcation branches into the right middle 
and right lower lobes. In the left lung, B2 branches into the left upper and left 
lower lobes. 
The upper TB model is asymmetrical and includes out-of-plane rotations of 
individual bifurcations. The asymmetrical model is considered to be sufficiently 
accurate to characterize aerosol growth and deposition in the upper airways, 
which will be verified with comparisons to the upper TB deposition data of Zhou 
and Cheng (2005). 
Beyond the third bifurcation, an individual path model was considered by 
continuing from the trachea to the end of the TB region (B15) of the right lower 
lung lobe. Bifurcations within the model were based on PRB units with the airway 
dimensions reported by Yeh and Schum (1980). Use of the individual path model 
based on PRB units allows for the application of a hexahedral mesh, which 
improves solution accuracy, and an adequate number of computational cells to 
fully resolve the flow domain (Longest and Vinchurkar 2007a; Vinchurkar and 
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Longest 2008). Based on available data, the bifurcations in the individual path 
model section (B4-B15) were symmetric and included a symmetric outflow 
assumption at each bifurcation level. At each bifurcation, continuation of the left 
or right branch was selected at random. Consecutive branches were rotated at 90◦ 
to approximate physiological conditions (Phalen et al. 1978). This individual path 
model is not intended to exactly mimic a specific connection of bronchi as with a 
patient specific model. Instead, it is intended to provide and effective 3-D 
representation of transport and deposition in the medium and small TB airways. 
Branch 15 was assumed to end with the terminal bronchioles, based on the 
existing anatomical data (Yeh and Schum 1980). 
 
Boundary and Delivery Conditions 
 
 Separated streams of aerosol and humidified air are delivered to the mouth 
inlet for both control and ECG growth conditions. As illustrated in Fig. 6.1, the 
humidified air is delivered through an outer circle whereas the aerosol stream is 
delivered through an inner ring at the mouth inlet. To allow separate streams of 
aerosol and humidified air to be introduced into the MT, Hindle and Longest 
(2010) developed and presented a dual flow mouthpiece. As reported by Hindle 
and Longest (2010), the inlet areas of the aerosol and humidity streams are 
balanced to maintain a constant velocity. The total inlet flow rate considered in 
this study is approximately 30 L/min under steady state conditions. 
 The airway walls were assumed to be at body temperature. As a result, the 
RH of the airway wall was set at 99.5%. Previous studies have reported variable 
wall temperatures from the mouth to core body temperature downstream. 
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However, correlations describing this change are based on the inhalation of 
ambient environmental conditions. During ECG delivery, which is via a nebulizer 
and requires multiple inhalations (Hindle and Longest 2010), it is expected that 
the inhalation of warm air will significantly decrease any airway wall temperature 
gradients. The walls of the airway model are assumed fixed and rigid. 
 Outflow conditions from the upper TB model into each lung lobe were 
based on the estimates of Horsfield et al. (1971). Beyond the lobar bronchi, 
symmetric outflow conditions were assumed at each bifurcation level (B4-B15). 
This assumption is not expected to largely influence the growth and regional 
deposition characteristics of interest in this study. 
 Aerosol and humidified air inlet conditions are shown in Table 6.1 for the 
delivery of 560 and 900 nm droplets. Both control and ECG delivery cases were 
considered. For the control scenarios, the aerosol was delivered with ambient air 
(25 ◦C) and assumed to be a non-evaporating particle (Case 1) or a droplet 
experiencing either evaporation or condensation (Case 2). The humidified air inlet 
condition for Case 1 is identical to Case 2. Considering the one-way coupled 
results, continuous field variables such as temperature and RH conditions for Case 
1 are the same as for Case 2. ECG conditions were evaluated as the remaining two 
cases. Under these conditions, the aerosol and humidified air were delivered at 
either 39 ◦C (Case 3) or 42 ◦C (Case 4). Increasing the aerosol and humidity 
stream temperatures allows for more water vapor mass to be delivered to the 
airways, which is expected to increase the final aerosol size and alter the 
deposition profile. Albuterol sulfate (AS) was considered as a model drug in the 
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aerosol. The mass fractions of drug in the initial 560 and 900 nm droplets were 
assumed to be 31% and 49%, respectively, based on a previous experimental 
study in which these aerosols were formed using a small particle aerosol generator 
(Longest et al. 2010). At these mass fractions, the hygroscopic effects of AS are 
expected to enhance size increase initially for RH values below 100%. However, 
hygroscopic effects are expected to significantly diminish once the aerosol 
increases in size above approximately 1 μm (Longest et al. 2010). 
 
Deposition Factors 
 
 Deposition within regions of the respiratory tract can be reported as either 
a fraction or efficiency. The deposition fraction (DF) for the ith region is 
calculated as 
 number of particles depositing in regionDF
number of particles entering the mouthi
i=    (6.1) 
 In contrast, the corresponding deposition efficiency (DE) for region i is 
calculated as 
 number of particles depositing in regionDE
number of particles entering region i
i
i
=    (6.2) 
 To determine a total deposition fraction, DFi values in individual regions 
can be directly summed. Deposition efficiency values are an effective method to 
report the characteristics of an individual section of the respiratory tract without 
the influence of upstream aerosol losses. In this study, DE values are calculated 
for each bifurcation. Sectional DE values are then computed by combining the 
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individual bifurcation values (ICRP 1994). For example, the DE in region B4 to 
B7 is calculated as 
 4 7 4 5 6 7DE 1 (1 DE )(1 DE )(1 DE )(1 DE )B B B B B− = − − − − −    (6.3) 
The total DF for the entire MT-TB network is then calculated as 
 
1
DF 1 (1 DE )
I
MT TB i
i
−
=
= − −∏       (6.4) 
which includes all regions (i=1 to I) from the MT to B15. It is noted that the total 
DE of the model is equal to the total DF. 
 
CFD Simulations 
 
 The low-Reynolds-number (LRN) k ω− model of Wilcox (Longest and 
Hindle 2009a; Longest et al. 2009) was selected for simulating mixing of the 
delivery streams and flow in the MT-TB model because it has been shown to 
provide an accurate and numerically efficient solution for laminar, transitional 
and turbulent flows. Furthermore, this model was found to accurately predict 
aerosol transport and deposition in upper airway models (Longest and Xi 2008). 
The coupled governing equations of heat and mass transport were considered to 
evaluate the variable temperature and RH fields in the MT-TB model. These 
transport equations were previously reported in Longest and Xi (2007) and 
Longest et al. (2007). The Lagrangian transport equations interconnected with 
user defined functions were employed to calculate droplet trajectories, 
condensation, evaporation, deposition, near-wall anisotropic turbulence correction 
(Longest and Xi 2007b), near-wall particle interpolation (Longest and Xi 2007b), 
and Brownian motion (Longest and Vinchurkar 2007a; Vinchurkar and Longest 
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2008) in the complex three-dimensional temperature and humidity fields. The 
discrete phase transport model includes the Kelvin effect, drug hygroscopicity, 
and the effect of droplet temperature on surface vapor pressure. In simulating 
aerosol evaporation and growth, the effect of the droplets on the continuous phase 
was typically neglected, resulting in a one-way coupled approach. One-way 
coupled simulations are expected to be accurate in this study due to the presence 
of wetted walls. However, to assess the validity of this assumption, the effect of 
the discrete aerosol phase on the continuous heat and water vapor fields was also 
included in some simulations, which is referred to as two-way coupling. An 
experimentally measured concentration of 2.8×105 particles/cm3 for the 900 nm 
aerosol (after mixing with the humidity stream) was employed to assess the two-
way coupling effects. 
 To solve the governing equations, the CFD package Fluent 6.3, (ANSYS 
Inc.) coupled with user defined functions was employed. All transport equations 
were discretized to be at least second order accurate in space.  For the convective 
terms, a third order QUICK scheme was used to interpolate values from cell 
centers to nodes.  The diffusion terms were discretized using central differences.  
A segregated implicit solver was employed to evaluate the resulting linear system 
of equations.  This solver uses the Gauss-Seidel method in conjunction with an 
algebraic multigrid approach. The SIMPLEC algorithm was employed to evaluate 
pressure-velocity coupling. The outer iteration procedure was stopped when the 
global mass residual had been reduced from its original value by five orders of 
magnitude and when the residual-reduction-rates for both mass and momentum 
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were sufficiently small.  To ensure that a converged solution had been reached, 
residual and reduction rate factors were decreased by an order of magnitude and 
the results were compared.  The stricter convergence criteria produced a 
negligible effect on both velocity and particle deposition fields. To improve 
accuracy, all calculations were performed in double precision. As shown in Fig. 
6.2, the computational mesh was composed of approximately 2×106 hexahedral 
elements and a very fine near-wall grid. Hexahedral meshing has been shown to 
provide a better quality solution in aerosol deposition studies compared with 
tetrahedral and hybrid grids (Vinchurkar and Longest 2008).  Grid converged 
results based on negligible change in the velocity and concentration fields (< 1%) 
as well as negligible differences in the total deposition fractions (< 3%) were 
established for a mesh consisting of 2.4 million control volumes. In order to 
produce convergent aerosol deposition results, 1.2×105 monodisperse droplets 
were injected at the aerosol inlet stream for each aerosol size and inlet case 
considered.  MMAD values after growth were calculated based on the midpoint 
diameters of a standard Andersen cascade impactor (Vinchurkar et al. 2009). 
Doubling the number of droplets considered had a negligible impact on both total 
and sectional deposition results. 
 
Model Validation 
 
 The CFD model employed in this study has previously been extensively 
tested in comparison with experimental deposition results. For both constant-sized 
particles and evaporating droplets, the CFD model was shown to accurately 
predict local and sectional deposition profiles in comparison with in vitro 
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experiments (Longest and Hindle 2009a; Longest et al. 2009b; Longest and 
Vinchurkar 2007b). Longest and Hindle (2010) recently presented a CFD model 
of ECG aerosol delivery in detail. In this study, excellent agreement was found 
between experimental measurements of final particle size after condensational 
growth and CFD predictions. Hindle and Longest (2010) compared in vitro results 
and numerical predictions of aerosol drug deposition in a MT–TB geometry 
extending to the fifth respiratory generation. Good agreement was found between 
the experimental and numerical predictions of deposition for both control and 
ECG conditions on a sectional basis and for the entire MT–TB geometry. 
 
Comparison of Upper TB Deposition to Previous Studies 
 
 As discussed, some differences are observed between the upper TB model 
considered in this study and previously reported models. An advantage of the 
current model is the use of a standard well described bifurcation unit (the PRB) 
that can be reproduced by other researchers. Furthermore, the characteristic TB 
model considered can accommodate a hexahedral mesh. However, differences in 
deposition from potentially more realistic models may be a concern. To address 
this issue, deposition in the current upper TB model was compared to the 
experimental results of Zhou and Cheng (2005) on a regional basis. Particles in 
the range of 0.93- 30 µm were considered at an inhalation flow rate of 30 L/min. 
Particle deposition efficiency in the upper tracheobronchial airway as a function 
of Stokes number are compared with the correlation by Zhou and Cheng (2005). 
The Stokes number is defined as St=ρpdp2U/18μDp, where ρp is the particle 
density, dp is the particle diameter, U is the mean velocity, μ is the air viscosity, 
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and D is the parent diameter of each bifurcation. As shown in Fig. 6.3, deposition 
efficiencies in the trachea, first bifurcation, second bifurcation, and third 
bifurcation provide an excellent match to the experimental data. As a result, it is 
concluded that the current model is sufficiently detailed to capture regional 
deposition characteristics in the upper TB airways. Furthermore, this comparison 
provides an additional validation study indicating that our CFD model is accurate. 
 
6.3 Results 
Temperature Fields 
 
 Contours of temperature are shown for the MT, upper TB airways, and 
selected medium and small TB airways in Fig. 6.4 for Cases 1-4. Temperature 
contours are presented as mid-plane slices within each of the airway regions 
shown. For Cases 1 and 2, the initially cool 25 ◦C airstream is rapidly warmed by 
effective mixing in the MT and reaches approximately 30-34 ◦C in the trachea. 
Temperatures are generally above 34 ◦C in B4-B7 and near 37 ◦C in B12-B15. 
However, some areas below 36.5 ◦C are observed in the distal airway branches. 
For the inlet conditions of Cases 3 and 4, rapid cooling is observed in the MT 
with temperatures in the range of 37-39 ◦C in the trachea for Case 3, and in the 
range of 39-41 ◦C for Case 4. Temperatures of approximately 37 ◦C are observed 
in B4-B7 for Case 3, and approximately 38 ◦C for Case 4. Temperature is nearly 
uniform at 37◦C in the B12-B15 region for Case 3 and 37.5 ◦C for Case 4. 
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Relative Humidity 
 
 Contours of RH for Cases 1-4, presented as midplane slices, are illustrated 
in Fig. 6.5. As expected, the cool subsaturated inlet conditions of Cases 1 and 2 
result in low RH values through a majority of the upper TB airways. Due to mass 
transfer from the wet walls, RH values of 95% and greater are observed in 
bifurcations B4-B7. In the distal bifurcations B12-B15, RH values are 
predominately equal to the wall value of 99.5%. However, contour levels below 
walls conditions are also observed even in the most distal airways considered. For 
inlet conditions of Cases 3 and 4, rapid cooling of the saturated airstream results 
in a rapid progression to supersaturation, with values as high as 101% observed in 
the pharynx for Case 3, and as high as 103% for Case 4. RH values remain in the 
range of 100-101% for Case 3 and 101-103% for Case 4 through a majority of the 
upper TB geometry and bifurcations B4-B7. In B12-B15, RH values are near wall 
conditions of approximately 99.5% for Case 3 and in the range of 99.5-101% for 
Case 4. 
 
Droplet Trajectories 
 
 Trajectories of initially monodisperse 900 nm droplets in the full MT–TB 
geometry are illustrated in Fig. 6.6 for Cases 2–4. Considering Case 2, rapid 
droplet evaporation occurs in the oral cavity until only a solid drug particle 
remains. As RH increases due to the warm and wet walls, some hygroscopic 
growth of the aerosol is observed with B15 trajectories in the range of 0.9–1.0 μm. 
For ECG delivery (Cases 3 and 4), rapid aerosol growth is observed throughout 
the MT and first bifurcation. In the medium and small TB branches, growth slows 
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due to reduced RH values and a decreased hygroscopic effect associated with 
higher droplet mass fractions of water. However, slower droplet velocities in the 
more distal airways allow more time for growth to occur. The net result is 
observed to be continued growth without visible evaporation throughout the 
airways. For Cases 3 and 4, individual trajectories passing through bifurcation 
B15 are found to have increased in size from 900 nm to ranges of  2 to >2.5 μm 
and 2.5 to >3 μm, respectively. 
 
Exit Size Distribution 
 
 Droplet size distributions sampled at specific cross-sectional locations in 
the model are presented in Fig. 6.7 in terms of mass fraction per micrometer of 
sampling bin size. MMAD values are also presented for each aerosol size 
distribution. Considering Case 2, MMAD values change little from the initial 
sizes of 560 and 900 nm. However, mixed evaporation and hygroscopic growth 
result in a spreading of the size distribution from the initial monodisperse 
condition. In contrast with Case 2, ECG conditions result in a definite shift in the 
distribution profile to larger sizes. Considering Case 3 and initial sizes of 560 and 
900 nm, both the MMAD and size distribution indicate significant and successive 
growth at the tracheal inlet and B5 outlet. However, some decrease in MMAD 
size is observed between the B5 outlet and B15 outlet for the 560 (~0.4 μm 
reduction) and 900 nm (~0.2 μm reduction) aerosols. This decrease in MMAD 
may arise from (i) deposition of the larger particles and (ii) minor evaporation as 
RH approaches 99.5%. Considering that only a small size decrease is observed for 
the 900 nm aerosol under Case 3 conditions, the decrease of the 560 nm aerosol is 
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likely due to minor evaporation arising from a lower drug concentration in the 
droplet and a reduced hygroscopic effect. Under Case 4 delivery conditions, size 
decreases between the B5 and B15 outlets of approximately 0.2 μm are observed 
for both aerosol sizes. Size distribution profiles indicate that 20–40% of the 
aerosol mass is associated with droplets of 4 μm and above. Furthermore, RH 
values shown in Fig. 6.5 were generally above 100% for Case 4 delivery 
conditions. As a result, this minor decrease in aerosol size may be primarily due 
to the deposition of larger droplets in the bifurcating airways. 
 MMADs of the polydisperse aerosol entering each bifurcation (B1–B15) 
are presented in Fig. 6.8 for the various delivery conditions. For Case 2, results 
indicate sudden evaporation followed by very slow growth, as expected. 
Considering the ECG conditions, rapid growth is observed from the mouth to the 
tracheal (B1) inlet. It is noted that the reported MMADs are calculated over all 
droplets entering each bifurcation, i.e., as they cross the inlet plane. However, 
details of growth for the aerosol ensemble are not resolved within each model 
segment due to the number of droplets considered. In the figure, significant 
growth is observed to occur through approximately B3. Thereafter, minor growth 
is observed through approximately B8, and some size decrease occurs between B8 
and B15. As described above, this size decrease is generally in the range of 0.2–
0.4 μm and likely arises from both deposition and minor evaporation; however, 
deposition appears to be the primary cause.  
 To evaluate the validity of the one-way coupled assumption, two-way 
coupled simulations were also considered. In two-way coupling, heat and mass 
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transfer from the droplets are accounted for as source terms in the continuous 
phase equations and influence subsequent droplet size change. The 900 nm 
aerosol was considered under Case 3 and 4 conditions, where the effects of two-
way coupling are expected to be the strongest (Longest et al. 2010).  An aerosol 
concentration of 2.8 × 105 particles/cm3 was considered, based on the 
experimental study of Longest et al. (2010),  in which the 900 nm aerosol was 
formed. In general, two-way coupling is expected to slow both size decrease and 
increase as changes in air phase RH damp evaporation and condensation. 
However, the simulation results indicate that two-way coupling has a minimum 
effect on aerosol size change, likely because of the wet-wall boundary conditions. 
Specifically, relative percent differences were calculated as |MMADone-way - 
MMADtwo-way|/MMADtwo-way × 100. The comparisons of one-way and two-way 
coupling on MMADs of the polydisperse aerosol entering each bifurcation (B1–
B15) are presented in Fig. 6.9 for Cases 3 and 4. Percent differences in MMADs 
for aerosols entering each bifurcation were less than approximately 10%. 
 
Aerosol Deposition 
 
 Particle deposition locations of individual droplets are illustrated for the 
900 nm aerosol with Cases 1-4 delivery conditions in Fig. 6.10. The droplets are 
colored based on their size at the time of deposition. Deposition efficiencies were 
calculated for each bifurcation and then combined (e.g., Eq. (6.3)) to represent the 
total deposition efficiencies for the sections reported along the individual path. 
Considering Cases 1 and 2, very little deposition is observed with a maximum of 
only 7.1% in the airways B8–B15. For ECG delivery conditions of Cases 3 and 4, 
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the MT deposition efficiency remains very small (~1%) as observed by Hindle 
and Longest (2010). In contrast with this low MT value, deposition efficiencies in 
B4–B7 and B8–B15 are increased by an order of magnitude compared with the 
evaporating control case (Case 2). Furthermore, deposited particles beyond B4 are 
2 μm and above, which provides evidence that the observed minor reduction in 
MMAD is due to the loss of the larger aerosols in the polydisperse size 
distribution. 
 The results of two-way coupling on particle deposition locations and 
regional deposition efficiencies (DE) of drug mass for an initially 900 nm aerosol 
in Cases 3 and 4 are presented in Fig. 6.11. Two-way coupling is observed to 
slightly increase the DE with relative percent differences less than approximately 
10%. 
 To support the accuracy of transport and deposition within the bifurcations 
of each lung lobe, two additional individual paths were randomly generated. 
Particle deposition locations and regional deposition efficiencies of drug mass for 
an initially 900 nm aerosol of the individual paths 2 and 3 for Case 4 are shown in 
Fig. 6.12. It is observed that MT and upper TB deposition values are slightly 
different than previous results.  Considering similarities in these results, it appears 
that use of the stochastic individual path approach provides a reasonable estimate 
of deposition within an individual lung lobe. 
 A complete description of deposition efficiencies for each inhalation case 
considered is presented in Fig. 6.13 and Table 6.2. Deposition efficiencies are 
again calculated as the combination of the values determined for each bifurcation. 
  142
For all cases, MT and upper TB deposition remained extremely low 
(approximately <2%). Deposition in the more distal airways is then observed to 
increase by an order of magnitude for the ECG conditions (Cases 3 and 4) vs. the 
controls (Cases 1 and 2). For both initial sizes, Case 4 conditions approximately 
double deposition in B4–B7 and increase deposition in B8–B15 by a relative 
difference of approximately 25% compared with Case 3. Considering the ECG 
growth cases, minor differences in regional deposition efficiencies are observed 
for the initial 560 nm aerosol vs. the 900 nm aerosol. As a result, it appears that 
overall deposition is more influenced by inlet conditions than initial aerosol size. 
Deposition efficiencies of Case 4 with an initially 900 nm aerosol are reported for 
multiple paths in Table 6.3. The averages of these deposition efficiencies are also 
reported and the small standard deviation values provide evidence that the 
individual path approach is accurate. 
 Predicted total DEs of the TB airways are compared with the in vivo-
based correlations of Stahlhofen et al. (1989) and Chan and Lippmann (1980)  in 
Table 6.4. To calculate the total DE of the TB region from the CFD predictions, 
the deposition efficiencies of each bifurcation were combined using an expression 
similar to Eq. (6.3) from B1 to B15. The major assumption here is that the DEs of 
each bifurcation in the right lower lobe single path are representative of 
conditions in the other four lung lobes. For comparison, the TB correlations based 
on in vivo deposition data from Stahlhofen et al. (1989) (Eq. 15) and Chan and 
Lippmann (1980) (Eq. 3) were employed. The single characteristic aerosol size 
required in these correlations was assumed to be the calculated MMAD exiting 
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B5, as shown in Table 6.4. The tracheal inlet flow rate of 30 L/min used in the 
CFD simulation was approximated in the correlations as an inhalation flow rate of 
500 cm3/s with an inhalation volume of 1500 cm3 to represent deep inspiration, 
which is characteristic of pharmaceutical aerosol delivery. As shown in Table 6.4, 
the predicted DEs from this study are in general agreement with the in vivo data, 
but the CFD predictions are somewhat higher. Considering the in vivo variability 
reported by Stahlhofen et al. (1989), it is observed that the CFD predictions are 
well within the range of the experimental data. The CFD predictions are likely 
higher than the mean experimental data because of the use of a single lobe and 
single path model to represent the remainder of the TB airways, a larger CFD 
lung volume than in the experiments (3.5 vs. ~3.0 L), and the use of a single 
droplet diameter to account for the deposition of a polydisperse aerosol that is 
increasing in size. 
 To approximate whole lung retention of the aerosol, the MT–TB 
deposition fractions predicted with Eq. (6.4) are reported in Table 6.5. These 
values are combined with the alveolar deposition efficiency correlation of 
Stahlhofen et al. (1989) to provide estimates of total lung deposition (DFtotal). 
Again, an inhalation rate of 500 cm3/s was employed along with a volume of 1500 
cm3. As observed from Table 6.5, total lung deposition fractions for the ECG 
conditions are 90% and above, except for Case 3 and the 560 nm aerosol, where 
the DFtotal is 83%. These whole lung deposition values could be increased further 
with the inclusion of a breath pause. In contrast, for both controls (Cases 1 and 2), 
the total lung deposition fraction was between approximately 23–38%. 
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6.4 Discussion 
 In this study, the concept of ECG applied to respiratory drug delivery was 
tested in a representative airway model extending from the oral cavity to the end 
of the TB airways. Droplet transport, size change, and deposition were simulated 
using a previously well-tested and experimentally validated CFD model. 
Simulations were conducted in a previously developed MT-TB model whereas 
deposition throughout the TB region was approximated using an individual path 
approach. Results indicate that both control and ECG delivery conditions produce 
very little deposition and aerosol loss in the MT and upper TB airways. With 
ECG delivery, significant size increases of the initially submicrometer aerosols 
were observed to occur, resulting in MMADs of 2–3 μm in the medium and small 
TB airways. This increase in aerosol size was shown to produce an order of 
magnitude increase in drug deposition in the TB airways, with TB deposition 
efficiencies of approximately 32–46% for ECG conditions. Estimates of 
downstream pulmonary deposition indicted near full lung retention of the aerosols 
during ECG delivery. 
 As previously demonstrated by Hindle and Longest (2010) delivering 
pharmaceutical aerosols using the ECG approach resulted in very low MT 
deposition (~1%). In contrast, MT depositional losses are currently reported as 
~60% for a typical MDI with a HFA propellant (Cheng et al. 2001),  ~70% for a 
typical DPI (Zhang et al. 2007) , and 30–40% for state-of-the-art breath-actuated 
nebulizers (Newman 2009; Nikander et al. 2010). For the same MT and similar 
upper TB geometry as considered in this study, Hindle and Longest (2010) 
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reported experimental values of drug deposition using a Proventil HFA MDI. The 
mean (and standard deviation) AS deposition in the MT–TB model was found to 
be 49.7 (7.2)% of the dose. The majority of the dose from the MDI was deposited 
in the MT region (46.0%), with only 3.6% deposited in the B1–B5 airways. Minor 
differences between this study and that of Hindle and Longest (2010) include the 
use of an initially monodisperse aerosol and an upper TB model that is complete 
through B3 in the current study. Equivalent aerosol and humidity inlet 
temperatures are also employed for ECG conditions in the current study, which 
were only considered for one case in Hindle and Longest (2010). As a result, MT 
and upper TB deposition values are slightly different than previously reported. 
However, the primary motivation behind the current study was to investigate 
conditions throughout an individual path model of the entire TB region. 
 Prior to this study, airway conditions and aerosol behavior in the medium 
and small TB bifurcations was unknown for ECG delivery. Previous results of 
aerosol size change during the inhalation of cool saturated air in the upper airways 
indicated that aerosol size increase may be temporary and some evaporation may 
occur (Ferron et al. 1984; Zhang et al. 2006b). However, results of this study 
indicate that with the inhalation of warm saturated air, several degrees above body 
temperature, supersaturated conditions extend well into the respiratory tract. This 
increased region of supersaturation likely occurs due to the larger mass of water 
vapor that enters the airways with the inhalation of warm vs. cool saturated air. As 
a result of extensive supersaturation in the flow field, aerosol growth was 
observed to occur throughout a majority of the TB airways without visible 
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evaporation of individual trajectories under ECG conditions. Minor decreases in 
the aerosol MMAD were observed beginning with B8 (Fig. 6.8). However, this 
decrease in MMAD can be largely explained as resulting from the higher 
deposition fraction of the larger droplets in the medium and small TB bifurcations 
(Fig. 6.9). With ECG, deposition within the TB airways beginning with B4 was 
increased by an order of magnitude compared to the evaporating control case 
resulting in single path deposition efficiencies of 32–46%. Aerosols exiting B15 
had MMADs ranging from 2.00 to 2.95 μm. As a result of these observations, it is 
concluded that the advantages of ECG delivery are maintained throughout the TB 
region and that negligible evaporation of individual droplets occurs. Furthermore, 
estimates indicate that alveolar deposition will result in near full lung retention of 
the aerosol (Table 6.4). Based on the aerosol behavior observed in the medium 
and small TB airways, only negligible evaporation is expected in the alveolar 
region. 
 For the prescribed inhalation flow conditions (Q = 500 cm3/s and VT = 
1500 cm3), application of the Stahlhofen et al. (1989) equation for alveolar 
deposition in combination with the TB deposition values predicted in this study 
indicated near full lung retention of the aerosol with ECG delivery. The alveolar 
estimates are based on the aerosol size exiting B5, which is approximately 3 μm 
for ECG conditions. It is noted that full lung retention of an aerosol is 
significantly influenced by both particle size and inhalation parameters. In vivo 
studies of the full lung deposition of monodisperse stable 3 μm particles indicate 
that retention may be less than 100% for different breathing parameters. For 
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example, the review article of Kim (2009) shows that the in vivo total lung 
deposition fraction of a 3 μm aerosol with Q = 500 cm3/s and VT = 1000 cm3 is 
approximately 60% based on a bolus delivery technique. One factor that may 
contribute to the predicted high lung deposition values compared with previous in 
vivo studies is that the approximate aerosol size of 3 μm is based on droplets 
which have not deposited and exit B15. It is difficult to determine a representative 
droplet size for predicting full lung deposition with ECG due to the combination 
of both active growth and deposition in the airways. Figure 6.9 clearly shows that 
the majority of deposited particles are greater than 3 μm and further analysis of 
the data indicates a number of deposited 4 μm particles. Table 6.3 also shows that 
the CFD predicted values for TB deposition are representative of, but greater than, 
the corresponding correlation-based values using an average static inlet diameter. 
Therefore, 3 μm may be a small approximate static size for comparing the 
predictions of the current study with previously reported whole lung deposition 
data. Further investigation is needed to better predict deposition in the alveolar 
region and to approximate the total lung doses delivered with ECG. However, the 
CFD predictions of TB deposition presented in this study are expected to be 
accurate based on the extensive validations that have previously been performed 
in terms of both aerosol size increase and deposition (Hindle and Longest 2010; 
Longest and Hindle 2010).  
 In addition to significantly reducing MT deposition and enabling full lung 
retention, results also illustrate the ability of ECG to target deposition within 
regions of the TB airways. Specifically, increasing the ECG delivery temperature 
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from 37 to 39 ◦C approximately doubled the amount of drug mass deposited in 
region B4–B7 (e.g., 4.7–9.2%). This increase was observed for both aerosol sizes. 
Increasing both the delivery temperature and initial size increased deposition in 
B8– B15 by a factor of 1.25 (e.g., 28.6–37.0%). In general, the initial size of the 
aerosol (560 vs. 900 nm) had a minor influence on the final size and deposition 
fraction. As observed by Longest et al. (2010), surrounding temperature and RH 
conditions and not initial size generally control the final aerosol size achieved 
with ECG delivery. However, the initial size may become a more significant 
factor if hygroscopic effects are larger, for high number concentration aerosols, 
and if shorter times are available for growth as may occur with targeted upper 
airway delivery. The observed variations in TB deposition associated with ECG 
initial conditions may be reduced in vivo due to variations in patient anatomy and 
inhalation profiles. Furthermore, ECG does not provide a means to produce 
highly localized targeted deposition, as may potentially be achieved with 
magnetic aerosols (Xie et al. 2010).  
 In this study, an individual path model was used for the first time to 
characterize flow field conditions and aerosol transport from the fourth 
bifurcation to the end of the TB region. As indicated above, this approach is not 
intended to fully resolve all pathways throughout the conducting airways. Instead, 
it serves as a representative model for assessing transport and deposition. In future 
analyses, it is proposed to use individual paths to stochastically characterize 
transport and deposition within the bifurcations of each lung lobe. Randomly 
generated individual path models can be simulated to create an ensemble of 
  149
deposition efficiencies. Averages of these ensemble results can then be used to 
quantify transport conditions and deposition fractions (branch-averaged and 
highly localized) on a stochastic basis. However, a full characterization of the 
entire TB tree was not necessary to achieve the objective of this study. In this 
study, deposition efficiencies calculated from each branch of the individual path 
model were used to estimate total deposition in the TB region. The fact that these 
estimates were in general agreement with existing correlations for TB deposition 
in vivo provided evidence that the individual path model approach is reasonable 
and also supports the accuracy of the CFD predictions. 
 The predicted MT deposition of approximately 1–2% may initially appear 
low considering that the typical aerosol size entering the trachea is 2 μm with 
ECG conditions. Furthermore, the elliptical MT model is known to be a 
representation of a more realistic geometry (Xi and Longest 2007b). The previous 
study of Longest et al. (2008b) showed that 2 μm particles at a steady flow rate of 
30 L/min resulted in a MT deposition of approximately 5%. Xi and Longest 
(2007b) reported that the deposition of a 2 μm aerosol in the MT model at 30 
L/min was approximately 10%. Several factors contributed to the observed 
reduction in MT deposition in this study. First, droplet growth occurs 
continuously, so the actual deposition is expected to be smaller than would occur 
for the final aerosol size at the MT outlet. Second, the dual flow mouthpiece 
centralized the aerosol and surrounded it with a layer of clean air. The previous 
study of Longest and Oldham (2006) showed that reducing the aerosol inlet cross-
sectional area could significantly reduce aerosol deposition. The deposition results 
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of Xi and Longest (2007b) are likely high for particles in the 1–2 μm size range, 
because of the use of the k–ω turbulence model without an anisotropic correction, 
as employed in the current study. However, the results of Xi and Longest (2007b) 
did show very little difference in the MT total deposition values between a more 
realistic geometry and the current elliptical model at 30 L/min, which provides a 
justification for the use of the elliptical model. The low MT deposition values of 
the current study are in good agreement with the experimental upper airway 
results of Hindle and Longest (2010), which further supports the validity of the 
current simulations. However, some differences between the in vitro data and 
current results likely arise due to the factors described above, such as the 
implementation of an initially monodisperse aerosol distribution with the CFD 
model of this study.  
 Limitations of the current study are associated with the geometry 
employed, simulation conditions, and numerical model. As previously discussed, 
the MT and upper TB models implemented some simplifications to facilitate a 
mathematically described geometry and allow for the use of more accurate 
hexahedral meshes (Vinchurkar et al. 2009). Furthermore, wall motion of the 
airways, particularly in the range of B15, may influence aerosol deposition. The 
assumed rotation angle of 90◦ for successive bifurcations may also be an 
overestimation of physiological conditions. The current model assumed steady 
state flow, which may impact the transport and deposition of some near-wall 
particles in the distal branches. The lobar ventilation rates were based on the 
volume estimates of Horsfield et al (1971). More accurate representations may be 
  151
available from numerical models (Asgharian and Price 2006; Asgharian et al. 
2006), or for supine individual patients (Yin et al. 2010). Higher accuracy 
representations of the turbulent laryngeal jet can be computed with more time 
intensive models, such as direct numerical simulation and large eddy simulation 
(Lin et al. 2007; Matida et al. 2006). However, our previous results indicate good 
agreement between the LRN k–ω approximation with near-wall corrections and 
experimental predictions of growth and deposition. In conclusion, ECG delivery 
resulted in supersaturated RH fields throughout large portions of the TB airways. 
Initial submicrometer aerosols were observed to increase in size to a target range 
of 2–4 μm and evaporation of individual droplets was not evident. As a result, 
ECG provides an effective method to virtually eliminate MT depositional losses, 
and the associated intersubject variability, while providing for high TB deposition 
and near full lung retention of the aerosol. Targeting drug deposition within 
specific lung regions was also demonstrated. Future studies are needed to consider 
the effects of unsteady flow, drug concentrations in the droplets, additional 
individual path models for full TB characterization, and deposition in the alveolar 
region with moving boundaries. 
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Table 6.1. All cases considered. 
 Aerosol inlet Humidified air inlet 
Case 1: control Q: 9 L/min  Q: 20 L/min  
non-evaporating (150 cm3/s) (333.3 cm3/s) 
560 and 900 nm T:  25 OC T:  25 OC 
 RH: 97.5% RH: 50% 
Case 2: control Q: 9 L/min  Q: 20 L/min  
evaporating (150 cm3/s) (333.3 cm3/s) 
560 and 900 nm T:  25 OC T:  25 OC 
 RH: 97.5% RH: 50% 
Case 3: ECG 1 Q: 9 L/min (150 cm3/s) Q: 20 L/min (333.3 cm3/s) 
560 and 900 nm T:  39 OC T:  39 OC 
 RH: 97.5% RH: 100% 
Case 4: ECG 2 Q: 9 L/min (150 cm3/s) Q: 20 L/min (333.3 cm3/s) 
560 and 900 nm T:  42 OC T:  42 OC 
 RH: 97.5% RH: 100% 
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Table 6.2. Deposition efficiency (%) for each case. 
 MT Trachea-B3 B4-B7  B8-B15 
Case 1: 560 nm 1.65 0.44 1.46 2.49 
             900 nm 2.26 0.57 1.73 6.98 
Case 2: 560 nm 1.35 0.46 1.45 2.47 
             900 nm 2.18 0.73 1.85 7.09 
Case 3: 560 nm 0.92 0.69 4.70 28.57 
             900 nm 1.31 0.80 7.08 33.00 
Case 4: 560 nm 0.90 0.81 9.19 35.36 
             900 nm 0.92 0.83 13.35 36.97 
 
Table 6.3. Stochastic analysis of deposition efficiency (%) for Case 4. 
Case 4: 900 nm MT Trachea-B3 B4-B7  B8-B15  
Path 1 0.92 0.83 13.35 36.97 
Path 2 0.93 0.79 12.06 34.29 
Path 3 0.91 0.80 14.46 34.72 
Average 0.92 0.81 13.29 35.54 
SD 0.0001 0.0002 0.0098 0.0119 
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Table 6.4. Comparison with existing TB correlations (DE). 
 MMAD at 
the B5 
outlet (µm) 
Predicted DE TB DE TB 
(Stahlhofen 
et al. 1989; 
Eq. 15) 
DE TB (Chan 
and Lippmann 
1980; Eq. 3) 
Case 1: 560 nm 0.56 0.04 0.01 0.01 
             900 nm 0.9 0.09 0.03 0.03 
Case 2: 560 nm 0.47 0.04 0.01 0.01 
             900 nm 0.74 0.09 0.02 0.02 
Case 3: 560 nm 2.39 0.32 0.17 0.19 
             900 nm 2.58 0.38 0.20 0.22 
Case 4: 560 nm 3.13 0.42 0.27 0.30 
             900 nm 3.28 0.46 0.30 0.32 
 
  155
 
Table 6.5. Predicted pulmonary and total deposition fractions. 
 MMAD at the 
B15 outlet (µm) 
Predicted 
DFMT-TB 
DFalveolar 
(Stahlhofen et 
al.,1989; Eq. 19) 
DFtotal 
Case 1: 560 nm 0.56 0.06 0.17 0.23 
             900 nm 0.9 0.11 0.27 0.38 
Case 2: 560 nm 0.57 0.06 0.17 0.23 
             900 nm 0.84 0.11 0.26 0.37 
Case 3: 560 nm 2.00 0.33 0.50 0.83 
             900 nm 2.23 0.39 0.52 0.91 
Case 4: 560 nm 2.89 0.42 0.54 0.96 
             900 nm 2.95 0.46 0.54 1 
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Figure 6.1. Geometry used to evaluate the  enhanced condensational growth 
(ECG) delivery of submicrometer aerosol in the mouth-throat 
(MT) and tracheaobronchial (TB) regions extending down a single 
path to bifurcation 15 (B15) of the right lower lung lobe. 
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Figure 6.2. Computational mesh of the MT-TB airway model. 
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Figure 6.3. Comparison of aerosol deposition efficiency in the upper TB 
airways between CFD predictions with the MT-TB geometry 
considered in this study and the experimental results Zhou and 
Cheng (2005) for a cast-based replica model. 
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Figure 6.4. Predicted temperature conditions for (a) Cases 1 and 2, (b) Case 3, 
and (c) Case 4  conditions. 
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Figure 6.5. Predicted relative humidity (RH) conditions for (a) Cases 1 and 2, 
(b) Case 3, and (c) Case 4 conditions. 
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Figure 6.6. Predicted droplet trajectories for initially 900 nm monodisperse 
aerosols and (a) Case 2, (b) Case 3, and (c) Case 4 conditions. 
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Figure 6.7. CFD predictions of exiting polydisperse size distributions for 
initially 560 nm and 900 nm monodisperse aerosols under Case 2-4 
conditions. 
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Figure 6.8. Comparisons of the mass median aerodynamic diameters (MMAD) 
with the aerosol entering one branch of each bifurcation through 
bifurcation 15 (B15) for Cases 2-4. 
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Figure 6.9. Comparisons of the mass median aerodynamic diameters (MMAD) 
with the aerosol entering one branch of each bifurcation through 
bifurcation 15 (B15) for Cases 3 and 4 with one-way and two-way 
coupling. 
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Figure 6.10. Particle deposition locations and regional deposition efficiencies 
(DE) of drug mass for an initially 900 nm aerosol and (a) Case 1, 
(b) Case 2, (c) Case 3, and (d) Case 4 conditions. 
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Figure 6.11. Particle deposition locations and regional deposition efficiencies 
(DE) of drug mass for an initially 900 nm aerosol with (a) Case 3 
and two-way coupling and (b) Case 4 and two- way coupling. 
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Figure 6.12. Particle deposition locations and regional deposition efficiencies 
(DE) of drug mass for an initially 900 nm aerosol and (a) Case 4 
down path 2 vs. (b) Case 4 down path 3. 
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Figure 6.13. Comparison of deposition efficiencies (DE) for initially (a) 560 
and (b) 900 nm droplets. 
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Chapter 7. Effects of Transient Inhalation on Enhanced Condensational 
Growth (ECG) in a Realistic Mouth-Throat and Tracheobronchial 
Single Path Model 
7.1 Introduction 
 Previous results indicate the enhanced condensational growth (ECG) can 
improve the delivery of pharmaceutical aerosols to the lungs based on steady 
inhalation conditions in a realistic mouth-throat (MT) and tracheobronchial (TB) 
single path model.  However, transient inhalation will influence the transport, 
growth, and deposition of droplet aerosols by modifying the (i) inertia of the 
particles, (ii) the time available for growth, and (iii) the relative humidity (RH) 
field.  A more complete picture of aerosol growth and deposition in the MT-TB 
single path model is needed.   
 The objective of this study is to evaluate the effect of a transient inhalation 
waveform on the ECG delivery of respiratory aerosols, using the realistic MT-TB 
single path model previously described in Chapter 6. CFD methods will be 
employed to evaluate aerosol deposition and outlet particle sizes under transient 
inhalation conditions. The CFD results will then be compared with steady 
inhalation conditions to determine if steady state approximations are adequate, or 
if more detailed transient simulations are needed. 
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7.2 Methods 
Transient Inhalation Waveform 
 
 The steady state inhalation flow rate considered in Chapter 6 is 
approximately 30 L/min. In this chapter, one inhalation cycle (2 s inhalation and 2 
s exhalation) with a breathing frequency (f) of 15 breaths/minute and a tidal 
volume (VT) of 1 L/breath is considered. Using the format from the Chapter 3, the 
transient inhalation waveform Q(t) (L/min) was approximated as the sinusoidal 
function shown in Fig. 7.1 and represented as 
 Q(t)=47sin(0.5πt) (7.1) 
This waveform is equivalent to a steady state inhalation flow rate of 30 L/min 
based on the Eqs. (5.1) and (5.3). 
 
Boundary and Delivery Conditions 
 
As in Chapter 6, a wall temperature of approximately 37 oC with a surface 
RH of 99.5% was considered. The airflow and droplet inlet boundary conditions 
employed in the CFD simulations are presented in Table 7.1. As shown in the 
table, Case 3 from the Chapter 6 was considered under transient inhalation 
conditions. In this case, an inlet temperature condition of 39 oC was selected for 
both the aerosol and humidity streams. Monodisperse nebulized aerosol droplets 
with initial diameters of 900 nm were simulated with a surrounding air phase RH 
condition of 97.5% at a total flow rate of 9 L/min. The humidified air inlet stream 
was generated with RH conditions of 100% at 20 L/min. The outlet flow 
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distribution in the MT-TB model was consistent with the values reported by 
Horsfield et al. (1971) at the exit of the third bifurcations. 
 
Transport Equations in MT-TB Single Path Model 
 
The low-Reynolds-number (LRN) k ω− model of Wilcox (1998) was 
selected for simulating mixing of the delivery streams in the MT-TB single path 
model because it has been shown to provide an accurate and numerically efficient 
solution for laminar, transitional and turbulent flows. Furthermore, this model was 
found to accurately predict aerosol transport and deposition in upper airway 
models (Longest and Hindle 2009a; Longest et al. 2009). The coupled governing 
equations of heat and mass transport were considered to evaluate the variable 
temperature and RH fields in the MT-TB model. These transport equations were 
previously reported in Longest and Xi (2008) and Longest et al. (2007). The 
Lagrangian transport equations interconnected with user defined functions were 
employed to calculate droplet trajectories, condensation, evaporation, deposition, 
near-wall anisotropic turbulence correction (Longest et al. 2007), near-wall 
particle interpolation (Longest and Xi 2007b), and Brownian motion (Longest and 
Xi 2007b) in the complex three-dimensional temperature and humidity fields. The 
discrete phase transport model includes the Kelvin effect, drug hygroscopicity, 
and the effect of droplet temperature on surface vapor pressure. 
 
Numerical Methods 
 
To solve the transport governing equations, the CFD package Fluent 6.3, 
(ANSYS Inc.) coupled with user defined functions was employed. All transport 
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equations were discretized to be at least second order accurate in space.  For the 
convective terms, a third order QUICK scheme was used to interpolate values 
from cell centers to nodes.  The diffusion terms were discretized using central 
differences.  A segregated implicit solver was employed to evaluate the resulting 
linear system of equations.  This solver uses the Gauss-Seidel method in 
conjunction with an algebraic multigrid approach. The PISO algorithm was 
employed to evaluate pressure-velocity coupling in the transient solutions. The 
outer iteration procedure was stopped when the global mass residual had been 
reduced from its original value by five orders of magnitude and when the 
residual-reduction-rates for both mass and momentum were sufficiently small.  To 
ensure that a converged solution had been reached, residual and reduction rate 
factors were decreased by an order of magnitude and the results were compared.  
The stricter convergence criteria produced a negligible effect on both velocity and 
particle deposition fields. To improve accuracy, all calculations were performed 
in double precision. The computational mesh developed from the Chapter 6 
composed of approximately 2.4×106 unstructured hexahedral elements and a very 
fine near-wall grid and was constructed in Gambit 2.3.16 (ANSYS, Inc.). 
Hexahedral meshing has been shown to provide a better quality solution in 
aerosol deposition studies compared with tetrahedral and hybrid grids (Longest 
and Vinchurkar 2007a; Vinchurkar and Longest 2008).  Grid converged results 
based on negligible change in the velocity and concentration fields (< 1%) as well 
as negligible differences in the total deposition fractions (< 3%) were established 
for a mesh consisting of 2.4×106 control volumes. In order to produce convergent 
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aerosol deposition results, 1.2×105  initially 900 nm monodisperse droplets  were 
released at the aerosol inlet stream from 0-1 s during inhalation. 
 
7.3 Results 
Temperature Fields 
 
 Contours of temperature are shown for the MT, upper TB airways, and 
selected medium and small TB airways in Fig. 7.2 for steady and transient 
inhalation conditions. Temperature contours are presented as mid-plane slices 
within each of the airway regions shown. For steady state conditions, rapid 
cooling is observed in the MT with temperatures in the range of 37-39 ◦C in the 
trachea. Temperatures of approximately 37 ◦C are observed in the B4-B7 and 
B12-B15 regions. Temperature values at t=0.5 s were found to be similar with 
steady state conditions. This similarity is likely because the inhalation flow rate at 
t=0.5 s is near 30 L/min. Temperature values at t=2 s in the MT are less than the 
values at t=0.5 s and steady state due to an decreased inhalation rate. 
 
Relative Humidity 
 
 Predicted contours of RH for steady and transient conditions (t=0.5 and 2 
s) are displayed for midplane and cross-sectional slices in Fig. 7.3. For steady 
state conditions, rapid cooling of the saturated airstream results in a rapid 
progression to supersaturation, with values as high as 101% observed in the 
pharynx. RH values remain in the range of 100-101% through a majority of the 
upper TB geometry and bifurcations B4-B7. In B12-B15, RH values are near wall 
conditions of approximately 99.5%. Again, RH values at t=0.5 s were similar to 
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those values found under steady state conditions. The increased RH values in the 
MT from t=0.5 s to t= 2 s are likely because of the decreased temperature values 
already discussed and can be expected to enhance aerosol growth. 
 
Aerosol Transport and Growth 
 
 Comparisons of droplet size distributions at specific cross-sectional 
locations for initially 900 nm monodisperse aerosols in the model between steady 
and transient inhalation conditions are presented in Fig. 7.4 in terms of mass 
fraction per micrometer of sampling bin size. Mass median aerodynamic 
diameters (MMAD) values are also presented for each aerosol size distribution. 
For steady state conditions, the MMADs of an initially 900 nm aerosol increased 
to 1.88 µm at the trachea inlet and continued condensational growth was observed 
with the aerosol exiting B5 with a predicted size of 2.58 µm. The MMAD of the 
aerosol exiting B15 had decreased to 2.23 µm. This decrease in MMAD likely 
arises from deposition of the larger particles as discussed in Chapter 6.  For the 
transient case, size increase was based on all particles crossing the planes of 
interest from particle release at t = 0 s through t=2 s.  For the transient simulation, 
condensational growth was observed as droplets enter the trachea with a predicted 
MMAD of 1.76 µm and continued with a predicted size of 2.42 µm at the exit of 
B5. The MMAD of the aerosol exiting B15 had decreased to 2.23 µm. Size 
distribution profiles indicate that 75-85% of the aerosol mass is associated with 
droplets of approximately 3 μm exiting B5 and B15 under steady inhalation 
conditions, but this has decreased to 55-60% in the same locations after 2s in the 
transient case. This may be because the higher peak flows occurring in the 
  175
transient case result in increased deposition of the larger particle sizes. 
Interestingly, percent differences in MMADs for aerosols at specific locations are 
less than approximately 2% between steady state and transient cases. 
 MMADs of the polydisperse aerosol entering each bifurcation (B1–B15) 
are presented in Fig. 7.5 for steady and transient inhalation conditions. For both 
conditions, significant growth is observed to occur through approximately B3. 
Thereafter, minor growth is observed through approximately B8, and some size 
decrease occurs between B8 and B15. This decrease may arise due to deposition 
of the larger particles. Percent differences in MMADs for aerosols entering each 
bifurcation were less than approximately 10% between steady and transient 
inhalation conditions (t=2 s). 
 
Aerosol Deposition 
 
 Particle deposition locations of individual droplets are illustrated for the 
900 nm aerosol for steady and transient inhalation conditions in Fig. 7.6. The 
droplets are colored based on their size at the time of deposition. Deposition 
efficiencies were calculated for each bifurcation and then combined to represent 
the total deposition efficiencies for the sections reported along the individual path. 
For both inhalation conditions, the MT deposition efficiencies remain very small 
(~1%) as observed by Hindle and Longest (2010). In contrast, deposition 
efficiencies in Trachea-B3 are increased approximately 2 times compared with the 
steady state conditions. Percent differences in DE between steady and transient 
inhalation conditions in B4–B7 and B8–B15 are approximately 9% and 13%, 
respectively. Predicted total DE of the TB airways under transient conditions is 
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approximately 12% higher (relative difference) than the total DE under steady 
state conditions. 
 To approximate whole lung retention of the aerosol, the predicted MT-TB 
deposition fractions are combined with the alveolar deposition efficiency in vivo-
based correlations of Stahlhofen et al. (1989) and Chan and Lippmann (1980). An 
inhalation rate of 500 cm3/s was employed along with a volume of 1500 cm3. As 
observed from Table 7.2, total lung deposition fractions under steady and 
transient inhalation conditions are 91% and 95%, respectively. 
 
7.4 Discussion 
 In this study, a CFD model was used to evaluate the effect of a transient 
inhalation waveform on the ECG delivery of respiratory aerosols, using the 
realistic MT-TB single path model. The CFD model results were then compared 
with steady inhalation conditions. Results of this study indicate that both steady 
and transient conditions produce very little deposition and aerosol loss in the MT. 
The drug deposition in the TB airways increased approximately 10% for transient 
inhalation conditions. The low MT deposition values of the current study are in 
good agreement with the experimental upper airway results of Hindle and Longest 
(2010), which further supports the validity of the current simulations.  
 Limitations of the current study are associated with simulation conditions. 
Constant wall temperatures consistent with mean body conditions were previously 
assumed.  The wall temperature of the upper respiratory airways is known to be 
below average body temperature conditions.  This change in wall surface 
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temperature will alter the RH surrounding the inhaled nanoparticles and modify 
condensational growth rates.  
A number of factors will affect targeted deposition to specific lung region 
when the ECG approach is employed.  These include initial aerosol size, 
temperature and humidity of the incoming air, hygroscopicity, inhalation flow rate 
and the release time of the aerosol during the breathing cycle.  Modifying the 
release time of the aerosol, or bolus delivery, is a potentially useful method to 
target deposition in the lungs.  Coupling bolus release with ECG may provide the 
control required for effectively targeting inhaled aerosols. 
 In conclusion, an ECG delivery approach under transient inhalation 
conditions was shown to increase aerosol deposition in the TB airways by only a 
small amount (relative difference of 12%), as compared with steady state 
conditions. Future studies are needed to consider transient ECG aerosol delivery 
under variable wall temperature conditions. The influence of inhalation flow rate, 
saturated air temperature, and release time of the aerosol also need to be 
considered. 
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Table 7.1. Inlet conditions considered. 
 Aerosol inlet Humidified air inlet 
900 nm Q: 9 L/min (150 cm3/s) Q: 20 L/min (333.3 cm3/s) 
 T:  39 OC T:  39 OC 
 RH: 97.5% RH: 100% 
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Table 7.2. Pulmonary and total deposition fractions. 
 MMAD at the 
B15 outlet 
(µm) 
Predicted DFMT-TB DFalveolar 
(Stahlhofen et al., 
1989; Eq. 19) 
DFtotal 
Steady state 2.23 0.39 0.52 0.91 
t=2 s 2.24 0.43 0.52 0.95 
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Figure 7.1. Transient inhalation waveform. 
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Figure 7.2. Predicted temperature conditions for (a) steady state, (b) t=0.5 s , 
and (c) t=2 s. 
  182
 
 
 
Figure 7.3. Predicted relative humidity (RH) conditions for (a) steady state, 
(b) t=0.5 s,  and (c)  t=2 s. 
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Figure 7.4. CFD predictions of exiting polydisperse size distributions for 
initially 900 nm monodisperse aerosol during (a) steady state and 
(b) transient inhalation (t=2 s). 
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Figure 7.5. Comparisons of the mass median aerodynamic diameters (MMAD) 
with the aerosol entering one branch of each bifurcation through 
bifurcation 15   (B15) for steady and transient inhalation conditions 
(t=2 s). 
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Figure 7.6. Particle deposition locations and regional deposition efficiencies 
(DE) of drug  mass for an initially 900 nm aerosol for (a) steady 
state and (b) transient  inhalation (t=2s). 
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Chapter 8. Effects of Inhalation Profiles on the Deposition of MDI and 
DPI Generated Aerosols in a Representative Model of the Mouth-Throat 
and Tracheobronchial Airways 
8.1 Introduction 
 A number of recent studies have reported deposition in model geometries 
of the upper tracheobronchial (TB) airways for environmental and pharmaceutical 
aerosols (Kleinstreuer and Zhang 2009; Liu et al. 2007; Xi and Longest 2008b; Xi 
et al. 2008; Zhang et al. 2005; Zhang et al. 2009). Other studies have focused on 
the deposition of pharmaceutical aerosols from metered dose inhalers (MDIs) and 
dry powder inhalers (DPIs) in the MT models (Kleinstreuer et al. 2007; Longest 
and Hindle 2009a; Longest and Hindle 2009b; Longest et al. 2009; Longest et al. 
2007; Longest et al. 2008a; Longest et al. 2008b). For current MDIs, 
approximately 25-60% of drug is lost in the mouth-throat (MT), and for current 
DPIs, MT deposition is approximately 70% (Cheng et al. 2001; Longest et al. 
2008a; Zhang et al. 2007). CFD studies of inhaler performance have highlighted 
the underlying causes of large MT deposition as high spray momentum for MDIs 
(Longest et al. 2008a; Longest et al. 2008b) and large jet effects for DPIs 
(DeHaan and Finlay 2004). Current studies have also highlighted the significant 
size change of MDI droplets (Longest et al. 2008a). Considering the substantial 
loss of drug, system complexity, and the associated variability in lung dose, a 
better understanding of MDI and DPI delivery in the MT and upper 
tracheobronchial (TB) airways is needed.  The objective of this study is to 
develop a CFD model of orally inhaled drug products that can account for inhaler 
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attributes (spray or jet momentum), physicochemical properties (polydisperse 
aerodynamic size distribution), and physiological parameters (breathing pattern, 
airway geometry) in determining local and regional deposition in a realistic MT 
and TB model of the upper airways. 
 
8.2 Methods 
Upper MT-TB Geometries 
 
 In this study, MT and TB deposition will be evaluated for two 
representative inhalers. The MT geometry is the elliptical model developed by Xi 
and Longest (2007b) and the upper TB airways are considered extending from the 
trachea to the third bifurcation (B3). This asymmetrical model was generated 
using the anatomical cast dimensions reported by Yeh and Schum (1980) and 
scaled to a functional residual capacity (FRC) of 3.5 L, which is consistent with 
an adult male (ICRP 1994). Further details of the upper TB model are provided in 
the Chapter 6. For the current study, cartilaginous rings were added to the trachea 
of the TB geometry and a crescent-shaped or D-shaped tracheal cross section was 
adapted.  Both of these features are expected to influence deposition and are 
intended to improve the realism of the model.  Crescent-shaped tracheal cross-
sections arise due to pressure from the esophagus.  This distortion may change 
depending on the position of the subject (supine, prone, standing) and may also be 
different during inhalation vs. exhalation.  As a general approximation, one-
quarter of the tracheal cross-section was assumed to be compressed into a flat 
profile, which is consistent with in-house medical scans.  The cadaver 
measurements of Russo et al. (2008) were used to include the effects of the 
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cartilaginous rings on the tracheal geometry.  Thirteen rings, spaced 2.98 mm 
apart, were included protruding into the trachea by a distance of 0.254 mm.  A 
sinusoidal wave was used to approximate the effect of the ring impressions on the 
soft tissue.  The thickness of the rings was 3.21 mm, except near the top of the 
trachea, where the thickness was 3.07 mm for two of the rings.  This was done to 
allow the rings to fit without altering the geometry of the existing MT. 
The elliptical MT model of Xi and Longest (2007b) was modified to fit both 
the MDI and DPI devices selected for this study.  For the MDI, the entire actuator 
was modeled to better assess the mixing of inhaled air with the spray exiting the 
nozzle. Based on measurements, the nozzle through which the spray enters the 
actuator was included with a 0.5 mm diameter (Fig. 8.1a). For the DPI, inner 
surfaces of the inhalers from the point of aerosol formation to the inlet of the MT 
were included. These internal surfaces include the 3 mm jet through which the 
aerosol enters the mouthpiece, two 0.5 mm jets, and the inner surface of the 
mouthpiece (Fig. 8.1b).  The MT geometry of Xi and Longest (2007b) is based on 
a mouth opening of 22 mm.  The MDI mouthpiece has a top to bottom outer 
diameter of 16 mm, which was judged sufficiently close to the mouth opening of 
the current model.  As a result, modification of the current MT oral cavity was not 
made and the inhaler was directly connected to the model.  For the DPI, the 
mouthpiece has a leading edge height of 12 mm.  To account for this more closed 
mouth position, the top and bottom profiles of the oral cavity were moved inward 
5 mm.  The inhaler was then connected to this reduced volume oral cavity.  The 
pharynx and larynx regions of the MT model were not altered.  The resulting MT 
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volumes for the MDI and DPI MT geometries were 57.7 and 55.0 cm3, 
respectively. 
 
Hollow Models of Upper MT-TB Geometries 
 
For the in-vitro deposition experiments, hollow models of the upper MT-TB 
geometries with rings included were fabricated using solid modeling software 
(Gambit 2.6 and SolidWorks) and a rapid prototyping process. To improve 
comparisons between the in-vitro results and CFD predictions, and to better 
validate the CFD model, a sectioned upper MT-TB geometry was created. The 
four sections of the geometry are MT, trachea, and upper left and right lung 
bronchi.  
 
Inhalers 
 
 In this study, aerosol deposition will be evaluated for two representative 
inhalers, both delivering the same corticosteroid, in a MT and upper TB model. 
For the MDI, the model inhaler considered is the Flovent HFA produced by GSK 
delivering fluticasone proprionate as a suspension in a HFA 134a formulation. 
The DPI model is the Flovent Diskus (GSK) delivering fluticasone proprionate as 
a powder aerosol. The computational models developed in this study can be 
applied to any MDI, DPI or Nebulizer. However, specific inhalers are required to 
effectively evaluate MT deposition and validate the model. An investigation of 
the initial aerosol size distribution was conducted in Dr. Hindle's lab. The size 
distribution of the drug aerosol emitted from the Flovent HFA MDI was 
determined using the next generation impactor (NGI) operated at a constant flow 
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rate of 37 L/min. The Flovent Diskus DPI was sampled directly into a NGI with a 
square wave inhalation profile and a flow rate of 75 L/min.  
 
Inhalation Waveforms 
 
 The inhalation waveforms used by patients with different inhalers and 
even the same inhaler are highly variable (Byron et al. 2010; Delvadia et al. 2010; 
Marielle et al. 2003; Meijer et al. 1996; Persson et al. 1997). In this study, two 
representative waveforms were approximated for healthy subjects based on the 
existing data. Waveforms representative of "inhale slowly and deeply" (SD) and 
"inhale quickly and deeply" (QD) were developed from existing data (Byron et al. 
2010; Delvadia et al. 2010; Marielle et al. 2003; Meijer et al. 1996; Persson et al. 
1997). These SD and QD profiles are intended to represent correct usage of the 
Flovent MDI and Flovent Diskus DPI, respectively.  Considering these two 
waveforms in both of the inhalers provides a measure of patient waveform 
variability and its effect on transport and deposition.  
 Common characteristics among studies reporting waveform characteristics 
with inhalers are a nearly linear acceleration to peak flow followed by a 
sinusoidal pattern during deceleration (Byron et al. 2010; Delvadia et al. 2010; 
Marielle et al. 2003; Meijer et al. 1996; Persson et al. 1997). Furthermore, the 
peak inhalation flow rate (PIFR) typically occurs during the first 1/6 to 1/4 of the 
inhalation period.  Equations describing this waveform pattern and developed for 
this study are 
 ( ) 0 PIFR
PIFR
PIFRQ t t t T
T
= ≤ ≤      (8.1) 
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where all parameters are defined in Table 8.1.  To describe the SD and QD 
waveforms, inhalation volume and mean inhalation flow rate need to be set.  The 
remaining parameters are then derived from the waveform shape.  In this study, 
deep inhalation is represented by a 3L inhaled volume.  This value is consistent 
with the study of Broeders et al. (2003), who report an approximate 3L inhalation 
volume with the use of both an MDI and DPI (Diskus) for stable asthmatic and 
mild to moderate COPD patients.  The mean inhalation flow rate was also a 
defined parameter to allow for comparisons between steady state and transient 
deposition results.  A mean inhalation flow rate of 37 L/min was selected for the 
SD profile, as a typical value for MDI steady state testing.  A mean inhalation 
flow rate of 75 L/min (which is approximately twice the SD value) was selected 
to represent QD inspiration.  Based on observations from reported waveforms as 
described above, the time fractions to peak inhalation flow rate (TFPIFR) for the 
SD and QD waveforms was 1/4 and 1/6, respectively.  Equations to find the 
remaining inhalation parameters are shown below. 
 [ ] ( ) [ ]
/ min 2 ( )cos
2 60 60 4 1
PIFR
T
PIFR PIFR
PIFRT
PIFR L T t TPIFR dt V L
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Results from solving these equations for the SD and QD parameters are reported 
in Table 8.2. The resulting PIFRs for the SD and QD profiles are 61.4 L/min and 
122.2 L/min, respectively.  The SD and QD waveforms are shown in Fig. 8.2. 
Considering the MDI, the typical recommended PIFR for correct usage is between 
25 and 90 L/min (Broeders et al. 2003).  Furthermore, Ross and Schultz (1996) 
showed that inhalation flow rate had little effect on MDI drug delivery.  The PIFR 
of the MDI (i.e., 61.4 L/min) is approximately in the middle of the recommended 
range and therefore a representative approximation of correct usage. For the 
Diskus DPI, Broeders et al. (2003) observed a characteristic PIFR of 
approximately 120 L/min after training among 42 patients with stable asthma and 
mild to moderate COPD.  Van der Palen (2003) observed an average PIFR of 118 
L/min for Diskus among 50 patients that received medication for asthma and 
COPD.  Byron et al. (2010) reported a PIFR of approximately 120 L/min for a 
single healthy subject with a Novolizer DPI, which has a similar resistance 
compared with the Diskus.  As a result, the PIFR of the Diskus appears consistent 
with literature data for both healthy and asthmatic/COPD patients. 
 
CFD Simulations 
 
 Based on Reynolds number conditions, laminar through fully turbulent 
flow is expected in the upper airway model.  To resolve these multiple flow 
regimes, the low Reynolds number (LRN) k-ω model will be implemented based 
on its ability to accurately predict pressure drop, velocity profiles, and shear stress 
for transitional and turbulent flows on a transient basis (Ghalichi et al. 1998; 
  193
Wilcox 1998) as well as particle deposition profiles (Longest and Vinchurkar 
2007b).  The Reynolds-averaged equations governing the conservation of mass 
and momentum were previously reported by Longest et al. (2006).  Simulations of 
thermal energy and water vapor transport, along with the laminar and turbulent 
governing equations, were previously described (Longest and Hindle 2010; 
Longest and Xi 2008). For the MDI simulations, the firing process induces 
significant spray momentum that affects the aerosol and surrounding flow field. 
The resulting transport conditions are locally supersonic near the nozzle and 
compressible. As a result, the individual species of air and water vapor were 
assumed to behave as ideal gases. For the DPI simulations, an incompressible 
flow field was assumed. 
 The Lagrangian transport equations governing particle motion in the upper 
airways were solved using Fluent 12.  Our previous validation case studies have 
indicated that this CFD algorithm produces an effective solution for aerosol 
transport and deposition results provided that a number of user-defined 
enhancements and corrections are supplied.  These user-defined supplements 
include (i) a correction for near-wall anisotropic turbulence (Longest et al. 2007), 
(ii) a correction for the Brownian motion routine (Longest and Xi 2007b), and (iii) 
a modification for near-wall interpolation of particle locations (Longest and Xi 
2007b).   In order to produce convergent deposition results for all particle sizes 
considered with the MDI inhaler, a total of 72000 particles were released over 0.2 
seconds.  For the DPI inhaler, a total of 36000 particles were released over 0.5 
seconds. The experimentally determined initial droplet distributions were used in 
  194
the CFD simulations. Doubling the number of droplets considered had a 
negligible impact on both total and sectional deposition results. 
 
Model Validation 
 
CFD simulations of aerosol deposition for the MDI and DPI inhalers are 
compared to the in vitro experimental results in Fig. 8.3.  The simulations were 
conducted to be as similar to the in vitro experiments as possible.  For the MDI 
simulation, an airflow of 37 L/min was established through the actuator before the 
inhaler was fired with an aerosol generation time of 0.2 s.  For the DPI simulation, 
a square inhalation waveform was implemented with a mean of 75 L/min.  The 
aerosol was released over the course of the first 0.5 s, consistent with the 
experiments. 
Results indicate that the CFD model predictions match the in vitro 
experiments to a high degree.  Differences in the MT deposition between the 
model and experiments remain below 7%, which is very good considering the 
complexity of the system.  Due to the presence of significant turbulence, 
deposition of multiple particle sizes is observed throughout the geometry. 
The MDI inhaler demonstrates less MT deposition than the DPI.  However, 
when the MDI actuator fraction is added with the MT loss, the amount of wasted 
dose is similar between the inhalers.  The DPI delivers approximately 4 times 
more dose to the TB section under square waveform inhalation conditions.  This 
increase in deposition is clearly beneficial for bronchodilators, but is undesirable 
for medicines targeted to the alveolar airways. 
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8.3 Results 
Velocity Fields in the Upper MT-TB Model 
 
 Velocity fields in the MDI and DPI from the CFD simulations for SD and 
QD waveforms at selected times are displayed in Figs. 8.4-6.  Midplane and 
cross-sectional slices of velocity magnitude and velocity vectors are shown.  
Times considered for each waveform are mean accelerating flow (Ta-mean), peak 
inspiratory flow (TPIFR), and mean decelerating flow (Td-mean), as shown in Fig. 
8.2. Flow conditions from the MDI simulations for SD and QD at Ta-mean are 
shown in Figs. 8.4a and c, respectively. The activation of the inhaler and resulting 
spray exiting the nozzle creates a significant source of momentum in the flow 
field. As a result, high velocity and turbulent flow is induced. Under QD 
conditions for the MDI, the momentum continues to increase and propagates 
quickly through the flow field, creating further flow disruption at t=TPIFR (Fig. 
8.5c), while the momentum change has dispersed at Td-mean (Fig. 8.6c) due to the 
completion of the activation. Similarly for the SD conditions, momentum near the 
MT inlet has dispersed at t=TPIFR and Td-mean (Fig. 8.5a and 8.6a). For the DPI, 
significant flow disruption and a high velocity jet flow were observed in the 
region near the MT inlet (Fig. 8.4b and d). At t= TPIFR, the jet velocity increases 
due to acceleration (Fig. 8.5b and d). At t= Td-mean, the jet velocity decreases due 
to deceleration (Fig. 8.6b and d). 
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Transient MDI Drug Deposition in the Upper MT-TB Model 
 
Figure 8.7 illustrates transient MDI simulation results for the SD and QD 
waveforms.  The SD waveform is considered to be the correct usage for the MDI 
and has a mean flow rate of 37 L/min.  In contrast, the QD waveform is 
considered incorrect use of the MDI with a mean flow rate of 75 L/min.  Inhaler 
deposition is markedly reduced and TB deposition is increased for both transient 
waveforms compared with steady state conditions (Fig. 8.7 vs. Fig. 8.3).  The 
correct usage of the MDI (SD waveform) results in approximately 10% lower MT 
deposition and 2% more TB deposition than with the QD inhalation. These 
differences are likely small compared with expected intersubject variability.  
Therefore, it is concluded that the MDI device is not largely sensitive to the 
transient inhalation waveform employed. 
 
Transient DPI Drug Deposition in the Upper MT-TB Model 
 
Transient SD and QD waveforms results for the DPI are illustrated in Fig. 
8.8.  For the DPI, QD inhalation is preferred and SD inhalation can be considered 
incorrect.  As expected, the QD results are the most similar to the square 
inhalation waveform because both had a mean flow rate of 75 L/min.  However, 
reducing the mean flow rate to 37 L/min with the SD waveform only reduced MT 
deposition by 2% and upper TB deposition by 1%.  Compared with the MDI SD 
and QD cases, the DPI inhaler delivered less aerosol to the upper TB region.  This 
is surprising because with the square inhalation waveform validation case (Fig. 
8.3), the DPI delivered more drug dose to the TB airways.  As a result, it appears 
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very important to consider the transient inhalation waveform when assessing 
aerosol deposition in the MT and upper TB airways, especially for MDI devices. 
 
8.4 Discussion 
 In this study, a CFD model was developed to evaluate aerosol deposition 
for the MDI and DPI inhalers in a realistic MT and upper TB model. Variations in 
breathing profiles were considered using SD and QD conditions, based in part on 
common characteristics among the reported waveforms. The CFD results were 
then compared with in vitro results. Results of this study indicate that the CFD 
model predictions match the in vitro experiments to a high degree. The DPI 
delivers approximately 4 times more dose to the TB section under square 
waveform inhalation conditions compared with MDI delivery under steady state 
inhalation conditions. The CFD results also indicate that it is critical to consider 
transient inhalation effects when assessing aerosol deposition, especially for MDI 
devices. 
This current study only considered transport and deposition in the upper 
airways. However, transport and deposition in the medium and small TB airways 
should be also evaluated to better understand differences in MDI and DPI delivery 
to the lung under correct and incorrect inhalation profiles. 
In conclusion, this study has demonstrated that transient inhalation can 
significantly influence the transport and deposition of aerosol in the upper airways, 
especially for MDI devices.  Future studies are needed to consider aerosol 
deposition in the lower airways under both steady and transient conditions. 
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Table 8.1. Parameters describing transient inhalation waveforms. 
Parameter Units Description 
PIFR L/min Peak inspiratory flow rate 
Q(t) L/min Transient inspiratory flow rate 
Q  L/min Mean inhalation flow rate 
T s Period of inhalation 
Ta-mean  s Time to mean inhalation flow rate during acceleration 
TPIFR s Time to peak inhalation flow rate 
Td-mean s Time to mean inhalation flow rate during deceleration 
TFPIFR -- Time fraction of peak inspiratory flow rate to total 
inhalation period (T) 
V L Total volume inhaled 
 
Table 8.2. Waveform parameters for the QD and SD profiles. 
Parameters QD Profile SD Profile 
PIFR [L/min] 122.2 61.4 
Q  [L/min] 75 37 
T [s] 2.40 4.86 
Ta-mean [s] 0.25 0.73 
TPIFR [s] 0.4 1.22 
Td-mean [s] 1.56 3.38 
TFPIFR 1/6 1/4 
V [L] 3 3 
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Figure 8.1. Upper MT-TB geometries for testing drug aerosol deposition 
connected to the (a) Flovent MDI and (b) Flovent Diskus DPI.  
The MDI model includes a narrow air passage between the 
actuator body and canister and a 0.5 mm nozzle for the 
introduction of the propellant and particles/droplets. The DPI 
model includes a 5 mm jet for the introduction of the drug powder 
and airflow, two 0.5 mm jets, which are consistent with the Flovent 
Diskus Inhaler, as well as the inner surface of the mouthpiece. 
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Figure 8.2. Inhalation waveforms for SD and QD waveforms. 
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Figure 8.3. Comparison of experimental (exp) and simulated deposition results 
with steady state and square waveform inhalation flow conditions 
for the (a) MDI at 37 L/min and (b) DPI at 75 L/min.  The CFD 
predictions are shown to match the in vitro results to a high degree. 
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Figure 8.4. Velocity vectors and contours for SD and QD waveforms  
at t= Ta-mean. 
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Figure 8.5. Velocity vectors and contours for SD and QD waveforms  
at t=TPIFR. 
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Figure 8.6. Velocity vectors and contours for SD and QD waveforms  
at t= Td-mean. 
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Figure 8.7. CFD predicted results of MDI deposition in the MT-TB model for 
(a) SD and (b) QD inhalation waveforms.  Deposition results are 
similar between the two inhalations. However, significant 
differences are observed between the transient inhalation, shown 
here, and steady state conditions shown in Figure 8.3. 
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Figure 8.8. CFD predicted results of DPI deposition in the MT-TB model for 
(a) SD and (b) QD inhalation waveforms.  Deposition results are 
similar between the two inhalations. Furthermore, deposition 
appears similar between the transient inhalation, shown here, and 
square wave conditions shown in Figure 8.3. 
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Chapter 9. Development of a Stochastic Individual Path Model for 
Assessing Pharmaceutical Aerosol Deposition:  Effects of Transient 
Inhalation Waveform and Sampling the Tracheobronchial Airways 
9.1 Introduction 
 In Chapter 8 the deposition of pharmaceutical aerosols from metered dose 
inhalers (MDIs) and dry powder inhalers (DPIs) was reported in a realistic mouth-
throat (MT) and upper tracheobronchial (TB) model extending to the third 
respiratory bifurcation (B3). However, conditions beyond B3, where deposition is 
expected to be the highest, were not considered. Lin et al. (2009) reported a 
coupled 3-D and 1-D lung transport model that mimicked the entire TB region on 
a patient specific basis. However,1-D models do not provide information about 
aerosol distributions at the level of individual bifurcations. Koblinger and 
Hofmann (1990) introduced the idea of a Monte Carlo lung simulation approach 
in which paths down the airway tree were generated at random and used 1-D 
algebraic predictions of lung deposition. Depositions within these "individual 
paths" were used to build a representation of deposition within the lung. This 
approach is applied in this study for 3-D CFD modeling and termed stochastic 
individual path (SIP) modeling. 
 The objective of this study is to evaluate the effects of steady state vs. a 
transient waveform on transport and deposition of pharmaceutical aerosols from a 
DPI within the right lower lung lobe using the SIP modeling approach.  
Deposition variability among different SIP paths in the right lower lung lobe will 
also be assessed. The transient QD waveform, consistent with patient instructions 
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to "inhale quickly and deeply" (previously developed in Chapter 8) is 
implimented. The transient QD results will then be compared with steady state 
(SS) conditions to determine if steady state approximations are adequate, or if 
more detailed transient simulations are needed.  Deposition within multiple SIP 
paths is also assessed. 
 
9.2 Methods 
DPI MT-TB SIP Geometry 
 
 In this study, deposition in the lower TB airways will be evaluated for the 
DPI. For this inhaler, inner surfaces of the device from the point of aerosol 
formation to the inlet of the MT were included. These internal surfaces include 
the 3 mm jet through which the aerosol enters the mouthpiece, two 0.5 mm jets, 
and the inner surface of the mouthpiece (Fig. 9.1). The upper MT-TB geometry 
previously developed in the Chapter 8 was used. Beyond the third bifurcation, 
three individual paths of the right lower lung lobe are considered in which one 
branch of each bifurcation is continued and one is not (Fig. 9.1).  This approach 
allows for upstream effects of the flow field and drug aerosol profile to be fully 
integrated in a highly efficient manner.  Furthermore, use of the individual path 
model based on PRB units allows for the application of a hexahedral mesh, which 
improves solution accuracy, and an adequate number of computational cells to 
fully resolve the flow domain (Longest and Vinchurkar 2007a; Vinchurkar and 
Longest 2008).  Bifurcations within the model are constructed as PRB units with 
the dimensions of Yeh and Schum (1980), scaled to an adult FRC of 3.5 L.  Based 
on available data, the bifurcations in the individual path model are symmetric and 
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include a symmetric outflow assumption.  At each bifurcation, continuation of the 
left or right branch is selected at random.  However, if the selection leads out of 
the general region of the particular lung lobe, the other branch is selected.  
Consecutive branches are rotated at 90o to approximate physiological conditions.  
This individual path model is not intended to exactly mimic a specific connection 
of bronchi in a patient specific model.  Instead, it is intended to provide an 
effective 3-D representation of transport and deposition in the medium and small 
TB airways.  Branch 15 is assumed to end with the terminal bronchioles, based on 
existing anatomical data (Weibel 1963; Yeh and Schum 1980). 
 
Stochastic Individual Path (SIP) Modeling 
 
 Koblinger and Hofmann (1990) proposed a Monte Carlo approach to 
simulating deposition throughout the airways using a 1-D algebraic model.  In this 
method, an individual path is selected at random down the TB tree. Deposition is 
then calculated in this simulated path using algebraic correlations. Additional 
paths and deposition fractions are then calculated and an average deposition 
fraction is estimated on a regional and local basis.  Once a sufficient number of 
paths have been simulated, the deposition fraction converges.  In this study, paths 
are selected to remain in the general region of the right lower lung-lobe, based on 
the lobar position taken from CT scans. Three paths are shown in Fig. 9.1 and 
considered to provide convergent local and regional deposition fractions. 
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CFD Simulations 
 
 The low-Reynolds-number (LRN) k ω− model of Wilcox (1998) was 
selected for simulating flow regimes in the MT-TB SIP model because it has been 
shown to provide an accurate and numerically efficient solution for laminar, 
transitional and turbulent flows. Furthermore, this model was found to accurately 
predict aerosol transport and deposition in the airway models (Longest and Hindle 
2009a; Longest et al. 2009). The Lagrangian transport equations interconnected 
with user defined functions were employed to calculate deposition, near-wall 
anisotropic turbulence correction (Longest et al. 2007), near-wall particle 
interpolation (Longest and Xi 2007b), and Brownian motion (Longest and Xi 
2007b). In order to produce convergent deposition results for all particle sizes 
considered and the DPI inhaler, total of 36000 particles were released over 0.5 
seconds. Experimentally determined initial droplet distributions were used in the 
CFD simulations. Doubling the number of droplets considered had a negligible 
impact on both total and sectional deposition results. 
 
Model Validation 
 
CFD simulations of aerosol deposition for the DPI inhaler in the upper 
airways are compared to the in vitro experimental results in Fig. 9.2.  These 
results were presented in Chapter 8, but are repeated here for completeness and 
discussed in more detail.  The simulations were conducted to be as similar to the 
in vitro experiments as possible. For the DPI simulation, a square inhalation 
waveform was implemented with a mean flow rate of 75 L/min.  The aerosol was 
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released over the course of the first 0.5 s, consistent with experimental 
observations. Results indicate that the CFD model predictions match the in vitro 
experiments to a high degree.  Differences in deposition fraction (DF) values in 
the MT between the model and experiments remain below 7%, which is very 
good considering the complexity of the system.  Due to the presence of significant 
turbulence, deposition of multiple particle sizes is observed throughout the 
geometry.  It was necessary to simulate the square waveform used in the 
experiments to match the in vitro deposition data.  Use of steady state conditions 
over-predicted the experimental deposition values by an unacceptable amount. 
 
Outlet Distributions and Flow Profiles for use as Inputs in SIP models 
 
 The geometry consists of the MT region, upper TB airways (Trachea-B3) 
and the middle/lower TB airways (B4-B15). Stochastic individual path (SIP) 
modeling will be employed to simulate DPI deposition in the middle and lower 
TB airways (B4-B15). A sufficient number of paths will be considered in each 
lobe to provide convergent local and regional deposition fractions. Therefore, an 
interpolation routine is needed to reduce computing time. Specifically, flow and 
particle outlet conditions from the B3 outlet were used as inlet conditions for the 
SIP model.  The necessary interpolation modules have been developed and are 
proven effective in Fig. 9.3. Specifically, the algorithm for the flow field 
interpolation is the following: 
1. Read data from each face in the outlet boundary zone. 
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2. Store and write flow variables at each face to a data file at the end of each 
time step. 
3. According to the coordinates, allocate these values to the faces in the inlet 
boundary zone. 
Note that  
1. Face (grid) size in the inlet boundary zone must be same as the previous 
outlet boundary zone. 
2. Time step size and number of time steps in the current simulation must be 
same as the previous simulation. 
The algorithm for the particle interpolation is the following: 
1. Store and write particle data from the outlet boundary zone. 
2. Read and assign these data onto the inlet boundary zone. 
 
9.3 Results 
DPI Drug Deposition in the MT and Upper TB Airways 
 
Deposition results for the steady state and transient QD waveforms and the 
DPI are illustrated in Fig. 9.4.  It is observed that deposition fraction (DF) values 
in the upper airways for the QD conditions are significantly different from steady 
state conditions. Deposition fraction values are approximately 25% (relative 
difference) less in the MT region and approximately 100% (relative difference) 
higher in the upper TB airways for the QD conditions compared with steady state 
conditions. As a result, it appears very important to consider the transient 
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inhalation waveform when assessing deposition values in the upper airways, as 
observed in Chapter 8. 
 
DPI Drug Deposition in the Individual Paths of the Right Lower Lung Lobe 
 
 Deposition locations of polydisperse aerosols in the lower TB airways are 
illustrated for three SIPs with SS and QD conditions in Fig. 9.5. The aerosols are 
colored based on their size at time of deposition. Deposition efficiencies were 
calculated for each bifurcation and then combined (e.g., Eq. (6.3)) to represent the 
total deposition efficiencies (DE) for the sections reported along the three 
individual paths. It is observed that DE values in both the B4-B7 and B8-B15 
sections are slightly higher under QD conditions than the values under SS 
conditions.  However, the maximum total difference was less than 2% for all 
cases considered. Furthermore, large size particles (> 9 μm) deposited in B4-B7 
under QD conditions were more densely populated than under SS conditions. This 
is likely due to higher flow rates associated with the QD waveform compared 
with the SS case. 
 Fig. 9.6 compares the mean deposition efficiencies of polydisperse 
aerosols in the trachea-B3, B4-B7, B8-B15, and total TB airways between SS and 
QD conditions.  The mean values were computed across the three SIP models 
considered and the error bars in the figure represent standard deviations. The 
predictions under SS conditions match the QD results well. The percentage 
differences in deposition efficiency between SS and QD conditions in the 
Trachea-B3, B4-B7, and B8-B15 are 10%, 8%, and 3%, respectively. To calculate 
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the total DE of the TB region from the CFD predictions, the deposition 
efficiencies of each bifurcation were combined from B1-B15 (e.g., Eq. (6.3)).  
The relative difference in the total DE between SS and QD conditions is 
approximately 8%.  
 The mean deposition efficiencies of polydisperse aerosols are illustrated in 
Fig. 9.7 for each bifurcation of 3 SIPs between SS and QD conditions. The SS 
results produced an excellent agreement with the QD results, especially between 
B9 and B15. It is observed that deposition efficiency increases through B6, and 
decreases between B6 and B15. A complete description of deposition efficiencies 
for SS and QD conditions are reported for each bifurcation in Tables 9.1 and 9.2.  
 
9.4 Discussion 
 In this study, the effects of transient vs. steady state flow fields on the 
transport and deposition of pharmaceutical aerosols from a DPI were evaluated 
within the right lower lung lobe using the SIP modeling approach. The transient 
results were compared with steady state (SS) conditions and variability in the 
results across three SIP models was assessed. Results indicate that steady state 
approximations are adequate (within a total difference of 2%) to predict 
deposition efficiencies in the TB airways. Therefore, a steady state inhalation 
approximation can be used to evaluate deposition in the SIP model. Furthermore, 
deposition estimates changed very little between the three SIP models considered 
with maximum total differences of approximately 2% for the regions considered.  
Therefore, it also seems reasonable that deposition within a lobe lung can be 
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estimated using a single SIP geometry.  However, this finding only holds true 
when considering averaged regions such as B4-B7, B8-B15 and the total TB 
airways in a single lobe, as assessed in this study. 
 The current study only considered transport and deposition in the right 
lower lung lobe. However, transport and deposition values in the right upper, right 
middle, left upper, and left lower lung lobes are needed to better predict total TB, 
alveolar regional, and whole lung deposition. 
In conclusion, this study has demonstrated that steady state inhalation can 
be used to predict deposition efficiencies in the TB airways using SIP model and 
that a single SIP model can be used to assess deposition within a single lobe.  
Future studies are needed to generate SIP models in each lung lobe. 
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Table 9.1. Deposition efficiency under QD conditions for 3 SIP models. 
QD SIP 1 (%) SIP 2 (%) SIP 3 (%) Mean (%) SD (%) 
B4 2.78 2.64 1.93 2.45 0.37 
B5 3.42 3.06 3.06 3.18 0.17 
B6 4.01 3.48 3.06 3.52 0.39 
B7 3.63 3.23 2.73 3.20 0.37 
B8 2.18 3.1 2.6 2.63 0.38 
B9 2.05 2.72 1.59 2.12 0.46 
B10 1.48 1.34 1.47 1.43 0.06 
B11 1.39 1.25 1.21 1.28 0.08 
B12 1.34 1.07 0.95 1.12 0.16 
B13 0.94 0.72 0.74 0.80 0.01 
B14 0.81 0.72 0.61 0.71 0.08 
B15 0.63 0.54 0.44 0.54 0.08 
 
Table 9.2. Deposition efficiency under steady state (SS) conditions for 3 SIP 
 models. 
SS SIP 1 (%) SIP 2 (%) SIP 3 (%) Mean (%) SD (%) 
B4 2.30 1.79 1.73 1.94 0.26 
B5 3.16 2.91 2.82 2.96 0.14 
B6 3.65 3.40 2.94 3.33 0.29 
B7 3.16 3.15 2.58 2.96 0.27 
B8 2.05 2.66 2.34 2.35 0.25 
B9 1.92 2.66 1.25 1.94 0.58 
B10 1.42 1.29 1.12 1.28 0.12 
B11 1.29 1.16 1.00 1.15 0.12 
B12 1.16 1.03 0.87 1.02 0.12 
B13 0.91 0.70 0.63 0.75 0.12 
B14 0.78 0.65 0.50 0.64 0.11 
B15 0.52 0.52 0.38 0.47 0.07 
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Figure 9.1. MT-TB SIP geometries for testing drug aerosol deposition from a 
Flovent Diskus DPI. 
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Figure 9.2. Comparison of in vitro and simulated deposition results with 
square waveform inhalation flow conditions for the DPI at 75 
L/min.  The CFD predictions are shown to match the in vitro 
results to a high degree. 
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Figure 9.3. Stochastic individual path (SIP) model extending from the end of 
the MT-TB geometry into the right lower lung.  The arrow 
indicates the site of velocity field and particle profile interpolation 
between the upper airway model and SIP geometry. 
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Figure 9.4. CFD predicted results of DPI deposition in the upper MT-TB 
model for (a) SS and (b) QD inhalation waveforms. 
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Figure 9.5. Particle deposition locations and regional deposition efficiencies 
(DE) of drug mass for (a) SS for SIP 1, (b) QD for SIP 1, (c) SS 
for SIP 2, (d) QD for SIP 2,  (e) SS for SIP 3, and (f) QD for SIP 3. 
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Figure 9.6. Comparison of steady state and transient deposition efficiencies of 
drug mass within specific regions.  The error bars denote +/- one 
standard deviation. 
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Figure 9.7  Comparison of steady state and QD deposition efficiencies of drug 
mass in each bifurcation of 3 SIPs. Symbols represent mean values 
and the error bars denote +/- one standard deviation. 
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Chapter 10. Conclusions and Future Work 
The three objectives stated in Chapter 1 have been achieved in this 
dissertation. In conclusion: (1.1) a CFD model was developed to predict the 
transient absorption of inhaled vapors into a multilayer mucus-tissue-blood 
(MTB) system; (1.2) a transient CFD boundary condition in a multilayer air-
mucus-tissue-blood (AMTB) system was developed in a nasal-laryngeal airway 
model; (1.3) effects of both transient inhalation and transient absorption on 
regional and local uptake in a representative upper airway model were evaluated; 
(2.1) enhanced condensational growth (ECG) for respiratory drug delivery was 
evaluated for models of the mouth throat (MT) and tracheobronchial (TB) region; 
(2.2) effects of transient inhalation waveforms on the ECG process in the upper 
TB airways were considered; (3.1) transport and deposition of pharmaceutical 
polydisperse aerosols from inhalers in upper airways were evaluated; (3.2) 
transport and deposition of pharmaceutical polydisperse aerosols from inhalers 
throughout the TB airways were evaluated using a stochastic individual path (SIP) 
modeling approach.  Results of these studies and suggested topics for future 
analyses are summarized below. 
 
10.1 Transient Absorption of Inhaled Vapors. 
Objective 1.1: Considering transient absorption of inhaled vapors into a 
multilayer mucus-tissue-blood (MTB) system, three models of the wall were 
evaluated based on dimensions for the ET2, BB, and bb regions. Results indicated 
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that transient absorption can significantly influence the transport and uptake of 
vapors in the walls of the conducting airways. Objective 1.2: In order to 
investigate transport and absorption of inhaled vapors over time into a multilayer 
air-mucus-tissue-blood (AMTB) system in a nasal-laryngeal airway model, a 
transient CFD boundary condition was developed. Results indicated that 
absorption was highly time dependent over the timescale of one inhalation cycle. 
Objective 1.3: Evaluating the effects of both transient inhalation and transient 
absorption on regional and local uptake in a model upper airway geometry, the 
transient CFD boundary condition was employed for CFD simulations of gas 
phase transport and mass transfer. A new dosimetry program TAOCS 1.0 was 
used in conjunction with a CFD model to apply and evaluate both steady state and 
transient wall absorption conditions. Results indicated that the implementation of 
a transient flux boundary condition appears critical to predict total and local 
deposition characteristics for even highly soluble compounds. 
 
10.2 The Concept of Enhanced Condensational Growth. 
Objective 2.1: Using both control and ECG delivery cases, the effectiveness 
for respiratory drug delivery in a realistic mouth-throat (MT) and 
tracheobronchial (TB) single path model was evaluated. Results indicated that 
ECG is an effective method to virtually eliminate MT depositional losses, and the 
associated intersubject variability, while providing for high TB deposition and 
near full lung retention of the aerosol. Objective 2.2: Considering the effects of 
transient inhalation waveforms on the ECG process in the upper TB airways, CFD 
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methods were employed to evaluate aerosol deposition. Results indicated that the 
ECG delivery approach under transient inhalation conditions increased aerosol 
deposition in the TB airways by only a small amount, as compared with steady 
state conditions. 
 
10.3 Local and Regional Deposition of Pharmaceutical Aerosols. 
Objective 3.1: The effect of transient waveforms and interactions at the 
patient-device interface on the transport and deposition of pharmaceutical 
polydisperse aerosols from inhalers in upper airways was considered. Results 
indicated that the CFD model predictions matched the in vitro experiments to a 
high degree. The DPI delivers approximately 4 times more dose to the TB section 
under square waveform inhalation conditions compared with MDI delivery under 
steady state inhalation conditions. The CFD results also indicate that it is critical 
to consider transient inhalation effects when assessing aerosol deposition, 
especially for MDI devices. Objective 3.2: The stochastic individual path (SIP) 
modeling approach was implemented to evaluate the transport and deposition of 
pharmaceutical polydisperse aerosols from inhalers in the lower airways. Results 
indicated that steady state inhalation can be used to predict deposition efficiencies 
in the TB airways. 
  227
 
List of References 
Aharonson, E. F., Menkes, H., Gurtner, G., Swift, D. L., and Proctor, D. F. 
(1974) Effects of respiratory airflow rate on removal of soluble vapors by 
the nose. Journal of Applied Physiology. 37, 654-657. 
 
Anderson, J. C., Babb, A. L., and Hlastala, M. P. (2003) Modeling soluble 
gas exchange in the airways and alveoli. Annals of Biomedical 
Engineering. 31, 1402-1422. 
 
Asgharian, B., Hofmann, W., and Bergmann, R. (2001) Particle deposition 
in a multiple-path model of the human lung. Aerosol Science and 
Technology. 34, 332-339. 
 
Asgharian, B., and Price, O. T. (2006) Airflow distribution in the human 
lung and its influence on particle deposition. Inhalation Toxicology. 18, 
795-801. 
 
Asgharian, B., Prince, O. T., and Hofmann, W. (2006) Prediction of 
particle deposition in the human lung using realistic models of lung 
ventilation. Aerosol Sci. 37, 1209-1221. 
 
ATSDR, Agency for Toxic Substances and Disease Registry. (2007a) 
Toxicological Profile for Acetaldehyde (Update). Atlanta, GA: U.S. 
Department of Public Health and Human Services, Public Health Service. 
 
ATSDR, Agency for Toxic Substances and Disease Registry. (2007b) 
Toxicological Profile for Benzene (Update). Atlanta, GA: U.S. 
Department of Public Health and Human Services, Public Health Service. 
 
Balashazy, I., Hofmann, W., and Heistracher, T. (2003) Local particle 
deposition patterns may play a key role in the development of lung cancer. 
Journal of Applied Physiology. 94, 1719-1725. 
 
Bird, R. B., Steward, W. E., and Lightfoot, E. N. (1960) Transport 
Phenomena, John Wiley & Sons, New York. 
 
Brent, R. (1973) Algorithms for Minimization and Without Derivatives, 
Prentice-Hall. 
 
Broday, D. M., and Georgopoulous, G. (2001) Growth and deposition of 
hygroscopic particulate matter in the human lung. Aerosol Science and 
Technology. 34, 144-159. 
 
  228
Broeders, M. E. A. C., Molema, J., Hop, W. C. J., and Folgering, H. T. M. 
(2003) Inhalation profiels in asthmatics and COPD patients: 
Reproducibility and effect of instruction. Journal of Aerosol Medicine. 
16(2), 131-141. 
 
Byron, P. R., Delvadia, R. R., Longest, P. W., and Hindle, M. (2010) 
Stepping into the trachea with realstic physical models: uncertainties in 
regional drug deposition from powder inhalers. Respiratory Drug Delivery. 
1, 215-224. 
 
Chan, T. L., and Lippmann, M. (1980) Experimental measurements and 
emperical modeling of the regional deposition of inhaled particles in 
humans. American Industrial Hygiene Association Journal. 41, 399-409. 
 
Chang, J. C. F., Gross, E. A., Swenberg, J. A., and Barrow, C. S. (1983) 
Nasal cavity deposition, histopathology, and cell proliferation after single 
or repeated formaldehyde exposures in B6C3F1 mice and F-344 rats. 
Toxicol. Appl. Pharmacol. 68, 161-176. 
 
Cheng, K. H., Cheng, Y. S., Yeh, H. C., and Swift, D. L. (1997) 
Measurements of airway dimensions and calculation of mass transfer 
characteristics of the human oral passage. Journal of Biomechanical 
Engineering. 119, 476-482. 
 
Cheng, Y. S. (2003) Aerosol deposition in the extrathoracic region. 
Aerosol Science and Technology. 37, 659-671. 
 
Cheng, Y. S., Fu, C. S., Yazzie, D., and Zhou, Y. (2001) Respiratory 
deposition patterns of salbutamol pMDI with CFC and HFA-134a 
formulations in a human airway replica. Journal of Aerosol Medicine. 
14(2), 255-266. 
 
Cinkotai, F. F. (1971) The behavior of sodium chloride particles in moist 
air. Journal of Aerosol Science. 2, 325-329. 
 
Cohen, B. S., Sussman, R. G., and Lippmann, M. (1990) Ultrafine particle 
deposition in a human tracheobronchial cast. Aerosol Science and 
Technology. 12, 1082-1093. 
 
Cohen Hubal, E. A., Fedkiw, P. S., and Kimbell, J. S. (1996a) Mass-
transport models to predict toxicity of inhaled gases in the upper 
respiratory tract. Journal of Applied Physiology. 80(4), 1415-1427. 
 
Cohen Hubal, E. A., Kimbell, J. S., and Fedkiw, P. S. (1996b) 
Incorporation of nasal-lining mass-transfer resistance into a CFD model 
  229
for prediction of ozone dosimetry in the upper respiratory tract. Inhalation 
Toxicology. 8, 831-857. 
 
Cohen Hubal, E. A., Schlosser, P. M., Conolly, R. B., and Kimbell, J. S. 
(1997) Comparison of inhaled formaldehyde dosimetry predictions with 
DNA-protein cross-link measurements in the rat nasal passages. 
Toxicology and Applied Pharmacology. 143, 47-55. 
 
Comer, J. K., Kleinstreuer, C., Hyun, S., and Kim, C. S. (2000) Aerosol 
transport and deposition in sequentially bifurcating airways. Journal of 
Biomechanical Engineering. 122(2), 152-158. 
 
Darquenne, C. (2002) Heterogeneity of aerosol deposition in a two-
dimensional model of human alveolated ducts. Journal of Aerosol Science. 
33(9), 1261-1278. 
 
Darquenne, C., and Paiva, M. (1996) Two- and three dimensional 
simulations of aerosol transport and deposition in alveolar zone of human 
lung. Journal of Applied Physiology. 80(4), 1401-1414. 
 
DeHaan, W. H., and Finlay, W. H. (2004) Predicting extrathoracic 
deposition from dry powder inhalers. Journal of Aerosol Science. 35, 309-
331. 
 
Delvadia, R. R., Byron, P. R., Longest, P. W., and Hindle, M. (2010) In 
Vitro prediction of regional drug deposition from dry powder inhalers. 
Respiratory Drug Delivery. 1, 908-912. 
 
EPA. (1999) National-Scale Air Toxics Assessment. 
http://www.epa.gov/ttn/atw/nata1999/. 
 
Ferron, G. A. (1977) The size of soluable aerosol particles as a function of 
the humidity of the air:  Application to the human respiratory tract. 
Journal of Aerosol Science. 3, 251-267. 
 
Ferron, G. A., Haider, B., and Kreyling, W. G. (1984) Conditions for 
measuring supersaturation in the human lung using aerosols. Journal of 
Aerosol Science. 15, 211-215. 
 
Ferron, G. A., Kreyling, W. G., and Haider, B. (1988) Inhalation of salt 
aerosol particles - II.  Growth and deposition in the human respiratory 
tract. Journal of Aerosol Science. 19(5), 611-631. 
 
Ferron, G. A., Oberdorster, G., and Hennenberg, R. (1989) Estimation of 
the deposition of aerosolised drugs in the human respiratory tract due to 
hygroscopic growth. Journal of Aerosol Medicine. 2, 271. 
  230
 
Finlay, W. H., and Stapleton, K. W. (1995) The effect on regional lung 
deposition of coupled heat and mass-transfer between hygroscopic 
droplets and their surrounding phase. Journal of Aerosol Science. 26(4), 
655-670. 
 
Foster, W. M., Langenback, E., and Bergofsky, E. H. (1980) Measurement 
of tracheal And bronchial mucus velocities in man - Relation to lung 
clearance. Journal of Applied Physiology. 48(6), 965-971. 
 
Franks, S. J. (2005) A mathematical model for the absorpiton and 
metabolism of formaldehyde vapors in humans. Toxicology And Applied 
Pharmacology. 206, 309-320. 
 
Frederick, C. B., Bush, M. L., Lomax, L. G., Black, K. A., Finch, L., 
Kimbell, J. S., Morgan, K. T., Subramaniam, R. P., Morris, J. B., and 
Ultman, J. S. (1998) Application of a hybrid computational fluid dynamics 
and physiologically based inhalation model for interspecies dosimetry 
extrapolation of acidic vapors in the upper airways. Toxicology And 
Applied Pharmacology. 152(1), 211-231. 
 
George, S. C., Babb, A. L., Deffebach, M. E., and Hlastala, M. P. (1996) 
Diffusion of nonelectrolytes in the canine trachea:  Effect of thigh junction. 
Journal of Applied Physiology. 80, 1687-1695. 
 
Ghalichi, F., Deng, X., Champlain, A. D., Douville, Y., King, M., and 
Guidoin, R. (1998) Low Reynolds number turbulence modeling of blood 
flow in arterial stenoses. Biorheology. 35(4&5), 281-294. 
 
Goswami, C., and Banerji, K. K. (1970) The mechanism of the oxidation 
of acetaldehyde by chromic acid. Bulletin of the Chemical Society of 
Japan. 43, 2643-2645. 
 
Hammersley, J. R., and Olson, D. E. (1992) Physical models of the 
smaller pulmonary airways. Journal of Applied Physiology. 72, 2402-2414. 
 
Heistracher, T., and Hofmann, W. (1995) Physiologically realistic models 
of bronchial airway bifurcations. Journal of Aerosol Science. 26(3), 497-
509. 
 
Hindle, M., and Longest, P. W. (2010) Evaluation of enhanced 
condensational growth (ECG) for controlled respiratory drug delivery in a 
mouth-throat and upper tracheobronchial model. Pharm. Res. 27, 1800-
1811. 
 
  231
Hlastala, M. P., and Robertson, H. T. (1998) Complexity in Structure and 
Function of the Lung, Informa Health Care. 
 
Hofmann, W., Golser, R., and Balashazy, I. (2003) Inspiratory deposition 
efficiency of ultrafine particles in a human airway bifurcation model. 
Aerosol Science and Technology. 37(12), 988-994. 
 
Horsfield, K., Dart, G., Olson, D. E., and Cumming, G. (1971) Models of 
the human bronchial tree. Journal of Applied Physiology. 31, 207-217. 
 
Ibsen, L. M., and Bratton, S. L. (1999) Current therapies for severe asthma 
exacerbations in children. New Horizons-The Science and Practice of 
Acute Medicine. 7(3), 312-325. 
 
ICRP. (1994) Human Respiratory Tract Model for Radiological 
Protection, Elsevier Science Ltd., New York. 
 
Isaacs, K. K., Rosati, J. A., and Martonen, T. B. (2005) Mechanisms of 
particle deposition. Aerosols Handbook, L. S. Ruzer and N. H. Harley, 
eds., CRC Press, New York, 75-99. 
 
Jarabek, A. M. (1995) The application of dosimetry models to identify key 
processes and parameters for default dose-response assessment approaches. 
Toxicology Letters. 79, 171-184. 
 
Karch, S. B., and Peat, M. (2007) Drug Abuse Handbook, CRC Press. 
 
Karl, A., Henry, F. S., and Tsuda, A. (2004) Low Reynolds number 
viscous flow in an alveolated duct. Journal Of Biomechanical 
Engineering-Transactions Of The Asme. 126(4), 420-429. 
 
Keyhani, K., Scherer, P. W., and Mozell, M. M. (1997) A numerical 
mdoel of nasal odorant transport for the analysis of human olfocation. 
Journal of Theoretical Biology. 186, 279-301. 
 
Kim, C. S. (2009) Deposition of aerosol particles in human lungs: in vivo 
measurement and modeling. Biomakers. 14(S1), 54-58. 
 
Kimbell, J. S., Gross, E. A., Joyner, D. R., Godo, M. N., and Morgan, K. T. 
(1993) Application of computational fluid dynamics regional dosimetry of 
inhaled chemicals in the upper respiratory tract of the rat. Toxicol. Appl. 
Pharmacol. 121, 253-263. 
 
Kimbell, J. S., Overton, J. H., Subramaniam, R. P., Schlosser, P. M., 
Morgan, K. T., Conolly, R. B., and Miller, F. J. (2001a) Dosimetry 
  232
modeling of inhaled formaldehyde: Binning nasal flux predictions for 
quantitative risk assessment. Toxicological Sciences. 64(1), 111-121. 
 
Kimbell, J. S., and Subramaniam, R. P. (2001) Use of computational fluid 
dynamics models for dosimetry of inhaled gases in the nasal passages. 
Inhalation Toxicology. 13(5), 325-334. 
 
Kimbell, J. S., Subramaniam, R. P., Gross, E. A., Schlosser, P. M., and 
Morgan, K. T. (2001b) Dosimetry modeling of inhaled formaldehyde: 
Comparisons of local flux predictions in the rat, monkey, and human nasal 
passages. Toxicological Sciences. 64(1), 100-110. 
 
Kleinstreuer, C., Shi, H., and Zhang, Z. (2007) Computational analyses of 
a pressurized metered dose inhaler and an new drug-aerosol targeting 
methodology. Journal of Aerosol Medicine. 20(3), 294-309. 
 
Kleinstreuer, C., and Zhang, Z. (2009) An adjustable triple-bifurcation 
unit model for air-particle flow simulations in human tracheobronchial 
airways. Journal of Biomechanical Engineering. 131(021007). 
 
Koblinger, L., and Hofmann, W. (1990) Monte Carlo modeling of aerosol 
deposition in human lungs. Part I: Simulation of particle transport in a 
stochastic lung structure. Journal of Aerosol Science. 21(5), 661-674. 
 
Kumagai, S., and Matsunaga, I. (1995) Physiologically based 
pharmacokinetic model for acetone. Occup. Environ. Med. 52, 344-352. 
 
LaBelle, C. W., Long, J. E., and Christofano, E. E. (1955) Synergistic 
effects of aerosols. Arch. Ind. Health. 11, 297-304. 
 
Li, W., and Hopke, P. K. (1993) Initial size distributions and 
hygroscopicity of indoor combustion aerosol particles. Aerosol Science 
and Technology. 19, 305-316. 
 
Lin, C. L., Tawhai, M. H., Mclennan, G., and Hoffman, E. A. (2007) 
Characteristics of the turbulent laryngeal jet and its effect of airflow in the 
human intro-thoracic airways. Respir. Physiol. Neurobiol. 157, 295-309. 
 
Lin, C. L., Tawhai, M. H., Mclennan, G., and Hoffman, E. A. (2009) 
Multiscale simulation of gas flow in subject-specific models of the human 
lung. IEEE Eng. Med. Biol. 28, 25-33. 
 
Liu, Y., Matida, E. A., Gu, J., and Johnson, M. R. (2007) Numerical 
simulation of aerosol deposition in a 3-D human nasal cavity using RANS, 
RANS/EIM, and LES. Aerosol Science. 38, 683-700. 
 
  233
Liu, Y., So, R. M. C., and Zhang, C. H. (2002) Modeling the bifurcation 
flow in a human lung airway. Journal of Biomechanics. 35, 465-473. 
 
Longest, P. W., and Hindle, M. (2009a) Evaluation of the Respimat Soft 
Mist inhaler using a concurrent CFD and in vitro approach. J. Aerosol 
Med. Pulm. Drug Deliv. 22(2), 99-112. 
 
Longest, P. W., and Hindle, M. (2009b) Quantitative analysis and design 
of a spray aerosol inhaler. Part 1:  Effects of dilution air inlets and flow 
paths. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 22(3), 
271-283. 
 
Longest, P. W., and Hindle, M. (2010) CFD simulations of enhanced 
condensational growth (ECG) applied to respiratory drug delivery with 
comparisons to in vitro data. J. Aerosol Sci. 41, 805-820. 
 
Longest, P. W., Hindle, M., and Das Choudhuri, S. (2009) Effects of 
generation time on spray aerosol transport and deposition in models of the 
mouth-throat geometry. Journal of Aerosol Medicine and Pulmoary Drug 
Delivery. 22(3), 67-84. 
 
Longest, P. W., Hindle, M., Das Choudhuri, S., and Byron, P. R. (2007) 
Numerical simulations of capillary aerosol generation:  CFD model 
development and comparisons with experimental data. Aerosol Science 
and Technology. 41, 952-973. 
 
Longest, P. W., Hindle, M., Das Choudhuri, S., and Byron, P. R. (2008a) 
Developing a better understanding of spray system design using a 
combination of CFD modeling and experiment. Proceedings of 
Respiratory Drug Delivery 2008, R. N. Dalby, P. R. Byron, J. Peart, J. D. 
Suman, S. J. Farr, and P. M. Young, eds., Davis Healthcare International 
Publishing, Illinois, 151-163. 
 
Longest, P. W., Hindle, M., Das Choudhuri, S., and Xi, J. (2008b) 
Comparison of ambient and spray aerosol deposition in a standard 
induction port and more realistic mouth-throat geometry. Journal of 
Aerosol Science. 39, 572-591. 
 
Longest, P. W., Mcleskey, J. T., and Hindle, M. (2010) Characterization 
of nanoaerosol size change during enhanced condensational growth. 
Aerosol Sci. Technol. 44, 473-483. 
 
Longest, P. W., and Oldham, M. J. (2006) Mutual enhancements of CFD 
modeling and experimental data: A case study of one micrometer particle 
deposition in a branching airway model. Inhalation Toxicology. 18(10), 
761-772. 
  234
 
Longest, P. W., and Vinchurkar, S. (2007a) Effects of mesh style and grid 
convergence on particle deposition in bifurcating airway models with 
comparisons to experimental data. Medical Engineering and Physics. 
29(3), 350-366. 
 
Longest, P. W., and Vinchurkar, S. (2007b) Validating CFD predictions of 
respiratory aerosol deposition: effects of upstream transition and 
turbulence. Journal of Biomechanics. 40, 305-316. 
 
Longest, P. W., Vinchurkar, S., and Martonen, T. B. (2006) Transport and 
deposition of respiratory aerosols in models of childhood asthma. Journal 
of Aerosol Science. 37, 1234-1257. 
 
Longest, P. W., and Xi, J. (2007a) Computational investigation of particle 
inertia effects on submicron aerosol deposition in the respiratory tract. 
Journal of Aerosol Science. 38(1), 111-130. 
 
Longest, P. W., and Xi, J. (2007b) Effectiveness of direct Lagrangian 
tracking models for simulating nanoparticle deposition in the upper 
airways. Aerosol Science and Technology. 41, 380-397. 
 
Longest, P. W., and Xi, J. (2008) Condensational growth may contribute 
to the enhanced deposition of cigarette smoke particles in the upper 
respiratory tract. Aerosol Science and Technology. 42, 579-602. 
 
Marielle, E. A. C., Broeders, Molema, J., Hop, W. C. J., and Flgering, H. 
T. M. (2003) Inhalation profiles in asthmatics and COPD patients: 
reproducibility and effect of instruction. Journal of Aerosol Medcine. 16, 
131-141. 
 
Martonen, T., Fleming, J., Schroeter, J., Conway, J., and Hwang, D. 
(2003) In silico modeling of asthma. Advanced Drug Delivery Reviews. 55, 
829-849. 
 
Martonen, T. B. (1993) Mathematical model for the selective deposition of 
inhaled pharmaceuticals. Journal of Pharmaceutical Sciences. 82(12), 
1191-1199. 
 
Martonen, T. B., Bell, K. A., Phalen, R. F., Wilson, A. F., and Ho, A. 
(1982) Growth rate measurements and deposition modeling of 
hygroscopic aerosols in human tracheobronchial models. Inhaled Particles 
V, W. H. Walton, ed., Pergamon Press, Oxford, 93-107. 
 
  235
Martonen, T. B., Burton, R., and Fleming, J. S. (2005a) 3D in silico 
modeling of aerosol behavior within airways of the human head and 
throat. Frontiers in Aerosol Dosimetry Research, Irvine, CA. 
 
Martonen, T. B., Guan, X., and Schreck, R. M. (2001) Fluid dynamics in 
airway bifurcations: I. Primary flows. Inhalation Toxicology. 13(4), 261-
279. 
 
Martonen, T. B., Rosati, J. A., and Isaacs, K. K. (2005b) Modeling 
deposition of inhaled particles. Aerosols Handbook, L. S. Ruzer and N. H. 
Harley, eds., CRC Press, New York, 113-155. 
 
Matida, E. A., Finlay, W. H., Breuer, M., and Lange, C. F. (2006) 
Improving prediction of aerosol deposition in an idealized mouth using 
large-eddy simulation. Journal of Aerosol Medicine. 19(3), 290-300. 
 
McClellan, R. O., and Henderson, R. F. (1995) Concepts in Inhalation 
Toxicology, CRC Press. 
 
Meijer, R. J., Mark Th, W. v. d., Aalders, B. J., Postma, D. S., and Koeter, 
G. H. (1996) Home assessment of peak inspiratory flow through the 
Turbohaler in asthmatic patients. Thorax. 51, 433-434. 
 
Miller, F. J., Overton, J. H., Jaskot, R. H., and Menzel, D. B. (1985) A 
model of the regional uptake of gaseous pollutants in the lung. Toxicology 
and Applied Pharmacology. 79, 11–27. 
 
Morris, J. B., and Blanchard, K. T. (1992) Upper respiratory tract 
deposition of inspired acetaldehyde. Toxicol. Appl. Pharmacol. 114, 140-
146. 
 
Morris, J. B., and Cavanagh, D. G. (1986) Deposition of ethanol and 
acetone vapors in the upper respiratory tract of the rat. Fundam. Appl. 
Toxicol. 6, 78-88. 
 
Morris, J. B., and Cavanagh, D. G. (1987) Metabolism and deposition of 
propanol and acetone vapors in the upper respiratory tract of the hamster. 
Fundam. Appl. Toxicol. 9, 34-40. 
 
NCRP. (1997) Deposition, Retention and Dosimetry of Inhaled 
Radioactive Substances, National Council on Radiation Protection and 
Measurements, Bethesda. 
 
Newman, S. (2009) Respiratory Drug Delivery: Essential Theory and 
Practice. Richmond: RDD online. 
 
  236
Nikander, K., Prince, I., Coughlin, S., Warren, S., and Taylor, G. (2010) 
Mode of breathing-tidal or slow and deep through the I-ned adaptive 
delivery (ADD) system affects lung deposition of 99mTc-DTPA. J. 
Aerosol Med. 23(S1), S37-S43. 
 
NIST.(2008) NIST Chemistry WebBook. 
http://webbook.nist.gov/chemistry/. 
 
Oldham, M. J., Phalen, R. F., and Heistracher, T. (2000) Computational 
fluid dynamic predictions and experimental results for particle deposition 
in an airway model. Aerosol Science and Technology. 32(1), 61-71. 
 
Overton, J. H., Kimbell, J. S., and Miller, F. J. (2001) Dosimetry modeling 
of inhaled formaldehyde: The human respiratory tract. Toxicological 
Sciences. 64, 122-134. 
 
Peng, C., Chow, A. H. L., and Chan, C. K. (2000) Study of the 
hygroscopic properties of selected pharmaceutical aerosols using single 
particle levitation. Pharmaceutical Research. 17, 1104-1109. 
 
Persson, G., Olsson, B., and Soliman, S. (1997) The impact of inspiratory 
effort on inspiratory flow through Turbuhaler in asthmatic patients. Eur 
Respir J. 10, 681-684. 
 
Phalen, R. F., Yeh, H. C., Schum, G. M., and Rabbe, O. G. (1978) 
Application of an idealized model to morphometry of the mammalian 
tracheobronchial tree. Anat, Rec. 190, 167-176. 
 
Press, W. H., Teukolsky, S. A., Vetterling, W. T., and Flannery, B. P. 
(1996) Numerical Recipes in Fortran 77: The Art of Scientific Computing, 
Cambridge University Press, Cambridge. 
 
Robinson, R., and Yu, C. P. (1998) Theoretical analysis of hygroscopic 
growth rate of mainstream and sidestream cigarette smoke particles in the 
human respiratory tract. Aerosol Science and Technology. 28, 21-32. 
 
Ross, D. L., and Schultz, R. K. (1996) Effect of inhalation flow rate on the 
dosing characteristics of dry powder inhaler (DPI) and metered dose 
inhaler (MDI) products. Journal of Aerosol Medicine. 9(2), 215-226. 
 
Russo, J., Robinson, R., and Oldham, M. J. (2008) Effects of cartilage 
rings on airflow and particle deposition in the trachea and main bronchi. 
Medical Engineering and Physics. 30, 581-589. 
 
Sakuma, H., Kusama, M., Yamaguchi, K., Matsuki, T., and Sugawara, S. 
(1984) The distribution of cigarette smoke components between 
  237
mainstream and sidestream smoke.  I. Acidic Components. Beitr. zur 
Tabakforschung. 12(2), 63-71. 
 
Schroeter, J. D., Musante, C. J., Hwang, D. M., Burton, R., Guilmette, R., 
and Martonen, T. B. (2001) Hygroscopic growth and deposition of inhaled 
secondary cigarette smoke in human nasal pathways. Aerosol Science and 
Technology. 34(1), 137-143. 
 
Shi, H., Kleinstreuer, C., and Zhang, Z. (2006) Laminar airflow and 
nanoparticle or vapor deposition in a human nasal cavity model. Journal 
of Biomechanical Engineering. 128, 697-706. 
 
Stahlhofen, W., Rudolf, G., and James, A. C. (1989) Intercomparison of 
experimental regional aerosol deposition data. Journal of Aerosol 
Medicine. 2(3), 285-308. 
 
Talhout, R., Opperhuizen, A., and van Amsterdam, J. G. C. (2007) Role of 
acetaldehyde in tobacco smoke addiction. 
European Neuropsychopharmacology. 17, 627-636. 
 
Taylor, A. B., Borhan, A., and Ultman, J. S. (2007) Three-dimensional 
simulations of reactive gas uptake in single airway bifurcations. Annals of 
Biomedical Engineering. 35(2), 235-249. 
 
Tian, G., and Longest, P. W. (2010a) Development of a CFD boundary 
condition to model transient vapor absorption in the respiratory airways. 
ASME Journal of Biomechanical Engineering. 132, 051003. 
 
Tian, G., and Longest, P. W. (2010b) Transient absorption of inhaled 
vapors into a multilayer mucus-tissue-blood system. Annals of Biomedical 
Engineering. 38(2), 517-536. 
 
US_Department_of_Environmental_Quality. (1994). "DEQ Remediation 
and Redevelopment Operational Memorandum ". 
 
van der Palen, J. (2003) Peak inspiratory flow through Diskus and 
Turbuhaler, measured by means of a peak inspiratory flow meter (In-
Check Dial). Respiratory Medicine. 97, 285-298. 
 
Varghese, S. K., and Gangamma, S. (2009) Particle deposition in human 
respiratory system: Deposition of concentrated hygroscopic aerosols. 
Inhalation Toxicology. 21(7), 619-630. 
 
Vinchurkar, S., and Longest, P. W. (2008) Evaluation of hexahedral, 
prismatic and hybrid mesh styles for simulating respiratory aerosol 
dynamics. Computers and Fluids. 37, 317-331. 
  238
 
Vinchurkar, S., Longest, P. W., and Peart, J. (2009) CFD simulations of 
the Andersen cascade impactor: Model development and effects of aerosol 
charge. Journal of Aerosol Science 40, 807-822. 
 
Weibel, E. R. (1963) Morphometry of the Human Lung, Springer Verlag, 
Berlin. 
 
Wilcox, D. C. (1998) Turbulence Modeling for CFD, 2nd Ed., DCW 
Industries, Inc., California. 
 
Xi, J., and Longest, P. W. (2007a) Effects of improved near-wall modeling 
on micro-particle deposition in oral airway geometries. Proceedings of the 
2007 ASME Summer Bioengineering Conference, Keystone, CO. . Paper 
No. SBC2007-176227. 
 
Xi, J., and Longest, P. W. (2007b) Transport and deposition of micro-
aerosols in realistic and simplified models of the oral airway. Annals of 
Biomedical Engineering. 35(4), 560-581. 
 
Xi, J., and Longest, P. W. (2008a) Effects of oral airway geometry 
characteristics on the diffusional deposition of inhaled nanoparticles. 
ASME Journal of Biomechanical Engineering. 130, 011008. 
 
Xi, J., and Longest, P. W. (2008b) Evaluation of a novel drift flux model 
for simulating submicrometer aerosol dynamics in human upper 
tracheobronchial airways. Annals of Biomedical Engineering. doi:10.1007. 
 
Xi, J., Longest, P. W., and Martonen, T. B. (2008) Effects of the laryngeal 
jet on nano- and microparticle transport and deposition in an approximate 
model of the upper tracheobronchial airways. Journal of Applied 
Physiology. 104, 1761-1777. 
 
Xi, J. X., and Longest, P. W. (2009) Characterization of Submicrometer 
Aerosol Deposition in Extrathoracic Airways during Nasal Exhalation. 
Aerosol Sci. and Technol. 43, 808-827. 
 
Xie, Y., Zeng, P., Siegel, R., Wiedmann, T. S., Hammer, B. E., and 
Longest, P. W. (2010) Magnetic deposition of aerosols composed of 
aggregated superparamagnetic nanoparticles. Pharm. Res. 27(5), 855-865. 
 
Yeates, D. B., Besseris, G. J., and Wong, L. B. (1997) Physicochemical 
properties of mucus and its propulsion. The Lung: Scientific Foundations, 
R. G. Crystal and J. B. West, eds., Lippincott - Raven Publishers, 
Philadelphia, 487-503. 
 
  239
Yeh, H. C., and Schum, G. M. (1980) Models of human lung airways and 
their application to inhaled particle deposition. Bull. Math. Biology. 42, 
461–480. 
 
Yin, Y., Choi, J., Hoffman, E. A., Tawhai, M. H., and Lin, C. L. (2010) 
Simulation of pulmonary air flow with a subject specific boundary 
condition. J. Biomech. 43, 2159-2163. 
 
Zhang, Y., Gilbertson, K., and Finlay, W. H. (2007) In vivo-in vitro 
comparison of deposition in three mouth-throat models with Qvar and 
Turbuhaler inhalers. Journal of Aerosol Medicine. 20(3), 227-235. 
 
Zhang, Z., and Kleinstreuer, C. (2002) Transient airflow structures and 
particle transport in a sequentially branching lung airway model. Physics 
of Fluids. 14(2), 862-880. 
 
Zhang, Z., and Kleinstreuer, C. (2003) Species heat and mass transfer in a 
human upper airway model. International Journal of Heat and Mass 
Transfer. 46(25), 4755-4768. 
 
Zhang, Z., and Kleinstreuer, C. (2004) Airflow structures and nano-
particle deposition in a human upper airway model. Journal of 
Computational Physics. 198(1), 178-210. 
 
Zhang, Z., and Kleinstreuer, C. (2006) Transport and uptake of MTBE and 
ethanol vapors in a human upper airway model. Inhalation Toxicology. 18, 
169-184. 
 
Zhang, Z., Kleinstreuer, C., Donohue, J. F., and Kim, C. S. (2005) 
Comparison of micro- and nano-size particle depositions in a human upper 
airway model. Journal of Aerosol Science. 36(2), 211-233. 
 
Zhang, Z., Kleinstreuer, C., and Kim, C. S. (2006a) Isotonic and 
hypertonic saline droplet deposition in a human upper airway model. 
Journal of Aerosol Medicine. 19(2), 184-198. 
 
Zhang, Z., Kleinstreuer, C., and Kim, C. S. (2006b) Water vapor transport 
and its effects on the deposition of hygroscopic droplets in a human upper 
airway model. Aerosol Science and Technology. 40, 52-67. 
 
Zhang, Z., Kleinstreuer, C., and Kim, C. S. (2009) Comparison of 
analytical and CFD models with regard to micron particle deposition in a 
human 16-generation tracheobronchial airway model. Aerosol Sci. 36(2), 
211-233. 
 
  240
Zhang, Z., Kleinstreuer, C., Kim, C. S., and Cheng, Y. S. (2004) 
Vaporizing microdroplet inhalation, transport, and deposition in a human 
upper airway model. Aerosol Science and Technology. 38(1), 36-49. 
 
Zhao, K., Scherer, P. W., Hajiloo, S. A., and Dalton, P. (2004) Effects of 
anatomy on human nasal air flow and odorant transport patterns: 
Implictions for olfaction. Chem. Senses. 29(5), 365-379. 
 
Zhou, Y., and Cheng, Y. S. (2005) Particle deposition in a cast of human 
tracheobrochial airways. Aerosol Science and Technology. 39, 492-500. 
 
 
  241
 
APPENDIX A 
Transient Analytic Solutions in the Mucus-Tissue-Blood  System 
In this section, the analytic transient solution for time-dependent variables 
Cm(y,t) and Ct(y,t) is developed. Knowing the steady state solution for 
( )mC y% and ( )tC y% , it is appropriate to represent ˆ ( , )mC y t  and ˆ ( , )tC y t  as the 
transient concentration distribution (Powers 1972) 
ˆ ( , ) ( , ) ( )m m mC y t C y t C y= − %    and   ˆ ( , ) ( , ) ( )t t tC y t C y t C y= − %  (A.1) 
By using these expressions, we have the following relations 
ˆ ( , ) ( , ) ( ) ( , )m m m mC y t C y t dC y C y t
t t dt t
∂ ∂ ∂= − =∂ ∂ ∂
%
, (A.2a) 
ˆ ( , ) ( , ) ( ) ( , )t t t tC y t C y t dC y C y t
t t dt t
∂ ∂ ∂= − =∂ ∂ ∂
%
, (A.2b) 
2 2 2 2
2 2 2 2
ˆ ( , ) ( , ) ( ) ( , )m m m mC y t C y t d C y C y t
y y dy y
∂ ∂ ∂= − =∂ ∂ ∂
%
,   and (A.2c) 
2 2 2 2
2 2 2 2
ˆ ( , ) ( , ) ( ) ( , )t t t tC y t C y t d C y C y t
y y dy y
∂ ∂ ∂= − =∂ ∂ ∂
%
. (A.2d) 
Therefore, we get the following Equations for ˆ ( , )mC y t and ˆ ( , )tC y t  
2
2
ˆ ˆ( , ) ( , )m m
m
C y t C y tD
t y
∂ ∂=∂ ∂ , [0, ]my H∈  (A.3a) 
2
2
ˆ ˆ( , ) ( , )t t
t
C y t C y tD
t y
∂ ∂=∂ ∂ , [ , ]m m ty H H H∈ +  (A.3b) 
The initial conditions are 
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m
C C y
C y C y C y y C
H
λ λ=−= − = −
%%  and (A.4a) 
( ) | ( ) |ˆ ( ,0) ( ,0) ( ) ( )m mtm m y H tm m y Ht t t m t
t t
C y C y
C y C y C y y H H
H H
λ λ= == − = − +
% %% . (A.4b) 
The boundary conditions are 
0 0 0
ˆ ( , ) | ( , ) | ( ) | 0m y m y m yC y t C y t C y= = == − =% , (A.5a) 
ˆ ˆ( , ) | ( , ) |
m mt y H tm m y H
C y t C y tλ= == , (A.5b) 
ˆ ˆ( , ) ( , )| |
m m
m t
m y H t y H
C y t C y tD D
y y= =
∂ ∂− = −∂ ∂ ,   and (A.5c) 
ˆ ( , ) | ( , ) | ( , ) | 0
m t m t m tt y H H t y H H t y H H
C y t C y t C y t= + = + = += − =% . (A.5d) 
Introducing a dimensionless variable / my Hξ = , Equations (A.3a) and (A.3b) 
become 
2
2 2
ˆ ˆ( , ) ( , )m m m
m
C t D C t
t H
ξ ξ
ξ
∂ ∂=∂ ∂ , [0,1]ξ ∈  (A.6a) 
2
2 2
ˆ ˆ( , ) ( , )t t t
m
C t D C t
t H
ξ ξ
ξ
∂ ∂=∂ ∂ , [1,1 / ]t mH Hξ ∈ +  (A.6b) 
Substitution of the product ˆ ˆ( , ) ( ) ( )m mC t Y T tξ ξ=  into Equation (A.3a) gives 
2 2
2
2
ˆ1 1
ˆ
m m
mm
d Y H dT
d D T dtY
μξ = = − , 0μ ≠  (A.7a) 
Similarly, substitution of the product ˆ ˆ( , ) ( ) ( )t tC t Y T tξ ξ ′=  into Equation (A.3b) 
after multiplying by /t mD D  gives 
2 2
2
2
ˆ1 1
ˆ
t t m
m mt
D d Y H dT
D d D T dtY
μξ
′= = −′ , 0μ ≠  (A.7b) 
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where 2μ is a separation constant. Equations (A.7a) and (A.7b) immediately result 
in four ordinary differential equations 
2
2
2
ˆ ˆ 0m m
d Y Y
d
μξ + = , (A.8a) 
2
2
m
m
DdT T
dt H
μ= − , (A.8b) 
2 2
2
ˆ ˆ 0t m t
t
d Y D Y
d D
μ
ξ + = ,   and (A.8c) 
2
2
m
m
DdT T
dt H
μ′ ′= − . (A.8d) 
The solutions for the spatially-dependent functions ˆ ( )mY y and ˆ ( )tY y are 
obtained from Equations (A.8a) and (A.8c), and substituting for ξ  gives 
ˆ ( ) cos( ) sin( )m
m m
y yY y A B
H H
μ μ= +    and (A.9a) 
ˆ ( ) cos( ) sin( )m mt
t m t m
D Dy yY y A B
D H D H
μ μ′ ′= + . (A.9b) 
The solutions for the time-variable functions ( )T t  and ( )T t′  are obtained from 
Equations (A.8b) and (A.8d) as 
2
2
( ) ( ) 0
m
m
D t
HT t T t e
μ−′= = > . (A.9c) 
Considering ˆ ˆ(0, ) (0) ( )m mC t Y T t= =0, it follows that ˆ (0) 0mY = , which results in 
0A = . As a result, Equation (A.9a) simplifies to 
ˆ ( ) sin( )m
m
yY y B
H
μ= . (A.10a) 
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Similarly, as ˆ ˆ( , ) | ( ) ( ) 0
m tt y H H t m t
C y t Y H H T t= + = + = , it follows that ˆ ( ) 0t m tY H H+ = , 
and Equation (A.9b) simplifies to (Jeffrey 2002) 
ˆ ( ) sin( )m m tt
t m
D H H yY y P
D H
μ + −= . (A.10b) 
Substituting (A.10a) and (A.10b) into the Equations (A.5b) and (A.5c), the 
boundary conditions become,  
sin( ) sin( )m ttm
t m
D HB P
D H
λ μ μ=  (A.11a) 
 and 
cos( ) cos( )m m tm t
m m t t m
D D HD B D P
H H D D H
μ μμ μ− = . (A.11b) 
Dividing Equation (A.11a) by (A.11b), the eigenvalues, µn, are the sequential 
positive roots of the transcendental equation 
tan( ) tan( ) 0t m ttm
m t m
D D H
D D H
λ μ μ+ = . (A.12) 
The eigenvalues µ can be calculated numerically using Brent’s method which 
combines bisection, secant, and inverse quadratic interpolation methods. The first 
five eigenvalues µ in the series, are provided in Tables A.1 – A.3 at the end of this 
section. 
Constants B and P  come directly from the Equation (A.11a) 
sin( )m t
t m
D HB
D H
μ=    and (A.13a) 
sin( )tmP λ μ= . (A.13b) 
Substituting Equations (A.13a) and (A.13b), Equation (A.11b) becomes  
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1 sin( ) cos( ) sin( )cos( )m m t m t
t tm t m t m
D D H D H
D D H D H
μ μ μ μλ− = . (A.14) 
Substituting Equations (A.13a) and (A.13b), Equations (A.10a) and (A.10b) 
become  
ˆ ( ) sin( )sin( )m tm
t m m
D H yY y
D H H
μμ=    and (A.15a) 
ˆ ( ) sin( )sin( )m m tt tm
t m
D H H yY y
D H
λ μ μ + −= . (A.15b) 
The concentration solutions ˆ ( , )mC y t   and ˆ ( , )tC y t  lead to classical Fourier series 
solutions that take the following form  
2
2
1
ˆ ( , ) sin( )sin( )
m
n
m
D t
Hm t n
m n n
n t m m
D H yC y t W e
D H H
μμμ∞ −
=
=∑ , [0, ]my H∈  (A.16a) 
2
2
1
ˆ ( , ) sin( )sin( )
m
n
m
D t
Hm m t
t tm n n n
n t m
D H H yC y t W e
D H
μλ μ μ∞ −
=
+ −= ∑ , [ , ]m m ty H H H∈ +  (A.16b) 
The coefficient nW (
3/g cm ) can be determined by utilizing the orthogonal 
relation and initial condition of zero mucus and tissue concentration. 
0
2 2
0
ˆ ˆˆ ˆ( ,0) ( ) ( ,0) ( )
ˆ ˆ( ) ( )
m m t
m
m m t
m
H H H
m m t t
H
n H H H
m t
H
C y Y y dy C y Y y dy
W
Y y dy Y y dy
η
η
+
+
+
=
⎡ ⎤ ⎡ ⎤+⎣ ⎦ ⎣ ⎦
∫ ∫
∫ ∫
, (A.16c) 
where η is a weight function that must satisfy 
0
ˆ ˆ ˆ ˆ( ) ( ) ( ) ( ) 0
m m t
m
H H H
mi mj ti tj
H
Y y Y y dy Y y Y y dyη
+
+ =∫ ∫ , i j≠  (A.16d) 
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By a detailed derivation, the eigen functions are orthogonal with 1/ tmη λ=  
over the interval [0, ]m tH H+ . Thus, substituting 1/ tmη λ= into Equation (A.16c), 
the coefficients nW can be determined.  These coefficients were calculated 
numerically and the first five values in the series are tabulated in Tables A.1 – 
A.3. 
The resulting analytic transient solutions for ( , )mC y t  and ( , )tC y t  have the 
following form 
2
2
1
ˆ( , ) ( , ) ( )
( ) |
sin( )sin( ) ,
m
n
mm
m m m
D t
ma air m y HHm t n
n n ma air
n t m m m
C y t C y t C y
C C yD H yW e C y
D H H H
μ λμμ λ∞ − =
=
= +
−= + −∑
%
%  (A.17a) 
2
2
1
ˆ( , ) ( , ) ( )
( ) |
sin( )sin( ) ( ),
m
n
mm
t t t
D t
tm m y HHm m t
tm n n n m t
n t m t
C y t C y t C y
C yD H H yW e H H y
D H H
μ λλ μ μ∞ − =
=
= +
+ −= + + −∑
%
%
 (A.17b) 
The value of ( ) |
mm y H
C y =% is determined from the steady state solution, shown 
previously. 
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Transient Analytic Solutions in the Air-Mucus-Tissue-Blood  System 
In this section, the analytic transient solution for time-dependent variables 
Cm(y,t) and Ct(y,t) is developed. To achieve the desired solution we now construct 
the transient analytic solutions ( , )mC y t  and ( , )tC y t  of the problem by the 
superposition of the solutions of two simpler sub-problems in the form (Ozisik 
1980) 
ˆ( , ) ( , ) ( ) ( )m m mC y t C y t f t C y= + % ,  and ˆ( , ) ( , ) ( ) ( )t t tC y t C y t f t C y= + % , (A.18) 
By using these expressions, we have the following system of equations 
ˆ( , ) ( , ) ( )( )m m m
C y t C y t df tC y
t t dt
∂ ∂= +∂ ∂
% , (A.19a) 
ˆ( , ) ( , ) ( )( )t t t
C y t C y t df tC y
t t dt
∂ ∂= +∂ ∂
% , (A.19b) 
2 2 2 2
2 2 2 2
ˆ ˆ( , ) ( , ) ( ) ( , )( )m m m mC y t C y t d C y C y tf t
y y dy y
∂ ∂ ∂= + =∂ ∂ ∂
%
, (A.19c) 
2 2 2 2
2 2 2 2
ˆ ˆ( , ) ( , ) ( ) ( , )( )t t t tC y t C y t d C y C y tf t
y y dy y
∂ ∂ ∂= + =∂ ∂ ∂
%
, (A.19d) 
where ( )f t is a time-dependent variable that can be defined as 0( ) ( , ) |m yf t C y t == . 
This variable is used to account for an arbitrary concentration on the mucus layer 
at the air-mucus interface. ( , )mC y t% , ( , )tC y t% , ˆ ( )mC y , and ˆ ( )tC y  are the solutions 
of the following sub-problems. 
1. ( , )mC y t%  and ( , )tC y t%  are the steady state solutions with a time constant air 
phase concentration. 
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2
2
( ) 0md C y
dy
=% , [0, ]my H∈  (A.20a) 
2
2
( ) 0td C y
dy
=% , [ , ]m m ty H H H∈ +  (A.20b) 
The boundary conditions from the steady state case are: 
0( ) | 1m yC y = =% , (A.21a) 
( ) | ( ) |
m mt y H tm m y H
C y C yλ= ==% % , (A.21b) 
( ) ( )| |
m m
m t
m y H t y H
dC y dC yD D
dy dy= =
− = −% % , (A.21c) 
( ) | 0
m tt y H H
C y = + =% , (A.21d) 
The analytic solutions of the steady diffusion Equations (A.3a and b) are: 
1 ( ) |
( ) 1 mm y Hm
m
C y
C y y
H
=−= −
%% , [0, ]my H∈  (A.22a) 
( ) |
( ) ( )mtm m y Ht m t
t
C y
C y H H y
H
λ == + −
%% , [ , ]m m ty H H H∈ +  (A.22b) 
The concentration on the mucus side at the mucus-tissue interface ( ) |
mm y H
C y =%  
can be obtained from Equations (A.21c), (A.22a), and (A.22b); the resulting 
expression is 
( ) |
m
t m
m y H
m tm t t m
H DC y
H D H Dλ= = +% , (A.23) 
At steady state, Equation A.18 has the following form by substituting 
0 0( ) ( ) | ( ) |m y ma a yf t C y C yλ= =′→∞ = =% %  ; 
0( ) ( ) | ( )m ma a y mC y C y C yλ =′ ′=% % % ,   and 0( ) ( ) | ( )t ma a y tC y C y C yλ =′ ′=% % % , (A.24) 
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where ( )mC y′% and ( )tC y′% are the steady-state solutions of  Equation 18. 0( ) |a yC y =′%  
is the steady-state concentration on the air side at the air-mucus interface. The 
value can be obtained by solving a steady-state transport equation in the air layer.  
2. ˆ ( )mC y and ˆ ( )tC y  are the solutions of the following time-dependent problem. 
2
2
ˆ ˆ( , ) ( , ) ( )( )m mm m
C y t C y t df tD C y
t y dt
∂ ∂= −∂ ∂
% , [0, ]my H∈  (A.25a) 
2
2
ˆ ˆ( , ) ( , ) ( )( )t tt t
C y t C y t df tD C y
t y dt
∂ ∂= −∂ ∂
% , [ , ]m m ty H H H∈ +  (A.25b) 
The initial conditions are: 
ˆ ( ,0) ( ,0) (0) ( ) 0m m mC y C y f C y= − =% , (A.26a) 
ˆ ( ,0) ( ,0) (0) ( ) 0t t tC y C y f C y= − =% , (A.26b) 
The boundary conditions are: 
0 0 0
ˆ ( , ) | ( , ) | ( ) ( ) | 0m y m y m yC y t C y t f t C y= = == − =% , (A.27a) 
ˆ ˆ( , ) | ( , ) |
m mt y H tm m y H
C y t C y tλ= == , (A.27b) 
ˆ ˆ( , ) ( , )| |
m m
m t
m y H t y H
C y t C y tD D
y y= =
∂ ∂− = −∂ ∂ , (A.27c) 
ˆ ( , ) | ( , ) | ( ) ( , ) | 0
m t m t m tt y H H t y H H t y H H
C y t C y t f t C y t= + = + = += − =% , (A.27d) 
The concentration solutions ˆ ( , )mC y t   and ˆ ( , )tC y t  lead to a Fourier series 
solutions that takes the following form (Ozisik 1980) 
2
2 2
2
1 0
ˆ ˆ( , ) ( , ) ( ) ( , )
( )
m
n mm n
m
D t DtH
H
m m n n n
n n
eC y t Y y F e A d
N
μ
μ τ
τ
μ μ μ τ τμ
−
∞
= =
⎡ ⎤= +⎢ ⎥⎢ ⎥⎣ ⎦
∑ ∫ , [0, ]my H∈  (A.28a) 
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2
2 2
2
1 0
ˆ ˆ( , ) ( , ) ( ) ( , )
( )
m
n mm n
m
D t DtH
H
t t n n n
n n
eC y t Y y F e A d
N
μ
μ τ
τ
μ μ μ τ τμ
−
∞
= =
⎡ ⎤= +⎢ ⎥⎢ ⎥⎣ ⎦
∑ ∫ ,
[ , ]m m ty H H H∈ +  (A.28b) 
where  
2 2
0
ˆ ˆ( ) ( , ) ( , )
m m t
m
H H H
n m n t n
H
N Y y dy Y y dyμ μ η μ
+
⎡ ⎤ ⎡ ⎤= +⎣ ⎦ ⎣ ⎦∫ ∫ , (A.29a) 
0
ˆ ˆˆ ˆ( ) ( ,0) ( , ) ( ,0) ( , ) 0
m m t
m
H H H
n m m n t t n
H
F C y Y y dy C y Y y dyμ μ η μ
+
= + =∫ ∫ , (A.29b) 
0
( ) ˆ ˆ( , ) ( ) ( , ) ( ) ( , )
m m t
m
H H H
n m m n t t n
H
dfA C y Y y dy C y Y y dy
d
τμ τ μ η μτ
+⎛ ⎞= − +⎜ ⎟⎜ ⎟⎝ ⎠∫ ∫
% % . (A.29c) 
By using methods of separating variables and the orthogonal condition, we have 
ˆ ( , ) sin( )sin( )m t nm n n
t m m
D H yY y
D H H
μμ μ= , (A.30a) 
ˆ ( , ) sin( )sin( )m m tt n tm n n
t m
D H H yY y
D H
μ λ μ μ + −= , (A.30b) 
1/ tmη λ= , (A.30c) 
The eigenvalues µn, were determined by solving the transcendental equation: 
tan( ) tan( ) 0t m ttm
m t m
D D H
D D H
λ μ μ+ = , (A.31) 
The eigenvalues µ can be calculated numerically using Brent’s method, which 
combines bisection, secant, and inverse quadratic interpolation methods. The first 
five eigenvalues µ , are provided in Tables A.4 and A.5 at the end of this section. 
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Based on the expressions above, the analytical solutions for ( , )mC y t  and 
( , )tC y t can be obtained by using the Fourier series expansion, which results in 
 
 
2
2 ( ) 0
0
1 0
ˆ( , ) ( , ) ( ) ( )
1 ( ) |( , ) |ˆ ( , ) ( , ) | 1 ,
m
n
mm
m m m
Dt t
m y Hm yH
n m n m y
n m
C y t C y t f t C y
C ydC y
W Y y e d C y t y
d H
μ τ
τ
τμ ττ
∞ − − ==
=
= =
= +
⎛ ⎞−= + −⎜ ⎟⎜ ⎟⎝ ⎠∑ ∫
%
%
 (A.32a) 
2
2 ( ) 0
0
1 0
ˆ( , ) ( , ) ( ) ( )
( ) |( , ) |ˆ ( , ) ( , ) | ( ) ,
m
n
mm
t t t
Dt t
tm m y Hm yH
n t n m y m t
n t
C y t C y t f t C y
C ydC y
W Y y e d C y t H H y
d H
μ τ
τ
λτμ ττ
∞ − − ==
=
= =
= +
⎛ ⎞= + + −⎜ ⎟⎜ ⎟⎝ ⎠∑ ∫
%
%
 (A.32b) 
where 
0
ˆ ˆ( ) ( , ) ( ) ( , )
( )
m m t
m
H H H
m m n t t n
H
n
n
C y Y y dy C y Y y dy
W
N
μ η μ
μ
+
+
= −
∫ ∫% %
, (A.33) 
The coefficients nW   were calculated numerically to 4 decimal places and are 
tabulated in Tables A.4 and A.5. The value of ( ) |
mm y H
C y =% is determined from the 
steady state solution, shown in Eq. (A.23). 
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Table A.1. The first five eigenvalues µ and coefficients W (g/cm3) for the ET2 
 model MTB wall. 
Acetaldehyde Benzene 
µ1= 0.5092 W 1=-8.5258×10-5 µ1=0.4050 W 1=-1.8697×10-8 
µ2=0.9992 W 2=3.3998×10-5 µ2=0.8708 W 2=3.4088×10-9 
µ3=1.4243 W 3=-2.7282×10-5 µ3=1.3677 W 3=-1.4458×10-9 
µ4=1.7934 W 4=2.1203×10-5 µ4=1.8712 W 4=1.1024×10-9 
µ5=2.2359 W 5=-1.5109×10-5 µ5=2.3646 W 5=-1.4375×10-9 
 
Table A.2. The first five eigenvalues µ and coefficients W (g/cm3) for the BB 
 model MTB wall. 
Acetaldehyde Benzene 
µ1=0.3469 W 1=-1.1550×10-4 µ1=0.2903 W 1=-2.7590×10-8 
µ2=0.6905 W 2=3.6056×10-5 µ2=0.6044 W 2=5.3716×10-9 
µ3=1.0244 W 3=-2.3299×10-5 µ3=0.9366 W 3=-2.0081×10-9 
µ4=1.3343 W 4=2.0736×10-5 µ4=1.2772 W 4=1.1003×10-9 
µ5=1.8954 W 5=1.3921×10-5 µ5=1.9639 W 5=7.6020×10-10 
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Table A.3. The first five eigenvalues µ and coefficients W (g/cm3) for the bb 
 model MTB wall. 
Acetaldehyde Benzene 
µ1=0.6625 W 1=-7.2539×10-5 µ1=0.5099 W 1=-1.4215×10-8 
µ2=1.2579 W 2=3.6264×10-5 µ2=1.1278 W 2=2.6088×10-9 
µ3=1.7129 W 3=-2.7475×10-5 µ3=1.7827 W 3=-1.4502×10-9 
µ4=2.2560 W 4=1.9307×10-5 µ4=2.4215 W 4=1.9762×10-9 
µ5=2.9062 W 5=-3.7751×10-5 µ5=2.9732 W 5=-8.2184×10-9 
 
Table A.4: The first five eigenvalues µ and the coefficients W for the ET2 
 model AMTB wall. 
Acetaldehyde Benzene 
µ1= 
0.5092 
W 1=-1.4549 µ1=0.4050 W 1=-1.3355 
µ2=0.9992 W 2=0.5802 µ2=0.8708 W 2=0.2435 
µ3=1.4243 W 3=-0.4656 µ3=1.3677 W 3=-0.1033 
µ4=1.7934 W 4=0.3618 µ4=1.8712 W 4=0.0787 
µ5=2.2359 W 5=-0.2578 µ5=2.3646 W 5=-0.1027 
 
  254
 
Table A.5. The first five eigenvalues µ and coefficients W for the BB model 
AMTB wall. 
Acetaldehyde Benzene 
µ1=0.3469 W 1=-1.9710 µ1=0.2903 W 1=-1.9708 
µ2=0.6905 W 2=0.6153 µ2=0.6044 W 2=0.3837 
µ3=1.0244 W 3=-0.3976 µ3=0.9366 W 3=-0.1434 
µ4=1.3343 W 4=0.3538 µ4=1.2772 W 4=0.0786 
µ5=1.8954 W 5=0.2376 µ5=1.9639 W 5=0.0543 
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